Pharmaceutical Composition
Patent Information
- Application Number
- JP2023519417
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-09-29
- Filing Date
- 2021-09-29
- Publication Date
- 2024-11-01
AI Technical Summary
Nilotinib, a lipophilic compound used to treat chronic myeloid leukemia, has low oral bioavailability, is highly variable with food intake, and can cause QT interval prolongation when taken with certain medications, posing safety risks.
A pharmaceutical composition comprising an amorphous solid dispersion of nilotinib with a hydrophilic polymer and surfactant, which improves oral bioavailability and reduces absorption variability, formulated as tablets or capsules.
The composition enhances oral bioavailability of nilotinib, allowing for lower doses and consistent absorption regardless of food intake, while minimizing QT interval prolongation risks.
Smart Images

Figure 00000129_0000 
Figure 00000129_0001
Abstract
Description
[Technical Field]
[0001] The chemical name of nilotinib free base is 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide. Nilotinib hydrochloride is approved for the treatment of chronic myeloid leukemia (CML) under the trade name TASIGNA. The structure of nilotinib free base is depicted below.
[0002] [ka]
[0003] Nilotinib Nilotinib is a lipophilic compound with a cLogP of 5.8 and is practically insoluble in water. TASIGNA is known to have the potential for increased and highly variable exposure when administered with food. Significant prolongation of the QT interval can occur when nilotinib is inappropriately ingested with food and / or other strong CYP3A4 inhibitors and / or other medications known to have the potential to prolong the QT interval. Therefore, coadministration with food should be avoided, and concomitant use with strong CYP3A4 inhibitors and / or other medications known to have the potential to prolong the QT interval should be avoided. Sudden death was reported in 0.3% of CML patients treated with TASIGNA in a clinical trial of 5,661 patients. The relatively early occurrence of some of these deaths associated with TASIGNA initiation suggests that ventricular repolarization abnormalities may contribute to their occurrence.
[0004] There is a need for nilotinib compositions that have improved oral bioavailability, allow for low-dose administration, reduce the variability in absorption caused by food intake, and reduce the variability in in vitro inter-subject absorption.More generally, there is a need for improved formulations of highly lipophilic active pharmaceutical ingredients that have improved oral bioavailability, allow for low-dose administration, reduce the variability in absorption caused by food intake, and reduce the variability in in vivo inter-subject absorption.
[0005] Incorporation by Reference All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Summary of the Invention
[0006] Disclosed herein is a pharmaceutical composition comprising: (a) an amorphous solid dispersion comprising: i. an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, the active pharmaceutical ingredient being nilotinib free base or a pharmaceutically acceptable salt thereof; ii. one or more surfactants selected from one or more polymeric nonionic surfactants and one or more phospholipids, or any combination thereof; iii. a nonionic hydrophilic polymer; and iv. optionally, an adsorbent; and b) a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition is in the form of a tablet or capsule. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is a salt of nilotinib. In some embodiments, the salt of nilotinib is selected from nilotinib hydrochloride, nilotinib sulfate, nilotinib fumarate, nilotinib 2-chloromandelate, nilotinib succinate, nilotinib adipate, nilotinib l-tartrate, nilotinib glutarate, nilotinib p-toluenesulfonate, nilotinib camphorsulfonate, nilotinib glutamate, nilotinib palmitate, nilotinib quina hydrochloride, nilotinib citrate, nilotinib maleate, nilotinib acetate, nilotinib l-malate, nilotinib l-aspartate, nilotinib formate, nilotinib hydrobromide, nilotinib oxalate, and nilotinib malonate. In some embodiments, the nilotinib salt is nilotinib hydrochloride. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of about 50 mg to about 125 mg of free base, or an equivalent amount of a pharmaceutically acceptable salt of nilotinib. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of about 10% to about 30% by weight. In some embodiments, one or more surfactants are present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the one or more surfactants are present in the pharmaceutical composition in an amount of about 25 mg to about 125 mg.In some embodiments, the one or more surfactants are present in the pharmaceutical composition in an amount of about 10% to 40% by weight. In some embodiments, the one or more surfactants are lecithin. In some embodiments, the one or more surfactants are a block copolymer of polyethylene glycol and polypropylene glycol. In some embodiments, the nonionic hydrophilic polymer is polyvinyl alcohol (PVA), an oligosaccharide, a polysaccharide, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC or hypromellose), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl beta-cyclodextrin (HP-β-CD), hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyethylene glycol (PEG), a polyvinyl acetate and polyvinyl caprolactam-based graft copolymer (PVAc-PVCap-PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (PCL-PVAc-PEG), or a combination thereof. In some embodiments, the non-ionic hydrophilic polymer is present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the non-ionic hydrophilic polymer is present in the pharmaceutical composition in an amount of about 10 mg to about 200 mg. In some embodiments, the non-ionic hydrophilic polymer is present in the amorphous solid dispersion in an amount of about 1% to about 80% by weight. In some embodiments, the amorphous solid dispersion contains silicon dioxide powder in an amount of about 10% to about 35% by weight. In some embodiments, the pharmaceutical composition does not contain an organic acid. In some embodiments, the pharmaceutically acceptable carrier or excipient comprises an external acid. In some embodiments, the external acid is not present in the amorphous solid dispersion. In some embodiments, the external acid is a surface-modified acid comprising acid particles and a neutral salt layer. In some embodiments, the neutral salt layer is formed by reaction between a pharmaceutically acceptable base and a powdered or granular acid. In some embodiments, the surface-modified acid is in powdered or granular form. In some embodiments, the external acid is a surface-modified organic acid.In some embodiments, the external acid is a surface-modifying acid selected from tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, maleic acid, benzenesulfonic acid, and p-toluenesulfonic acid. In some embodiments, the external acid is a surface-modifying acid selected from tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, and maleic acid. In some embodiments, the external acid is a surface-modifying acid selected from tartaric acid and succinic acid. In some embodiments, the pharmaceutically acceptable base is selected from sodium carbonate, potassium carbonate, sodium acetate, potassium acetate, sodium stearate, potassium stearate, lysine, arginine, and histidine. In some embodiments, the pharmaceutically acceptable base is sodium carbonate. In some embodiments, the weight ratio of the pharmaceutically acceptable base to the acid particles is about 2% to about 20%. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 50 mg to about 300 mg. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 5% to about 35% by weight. In some embodiments, the pharmaceutical composition comprises: a) an amorphous solid dispersion comprising: i. nilotinib free base or nilotinib HCl in an amount of about 10 mg to about 200 mg; ii. one or more surfactants in an amount of about 10 mg to about 500 mg, the surfactant comprising lecithin, or a block copolymer of polyethylene glycol and polypropylene glycol, tocopherol polyethylene glycol succinate (TPGS or vitamin E TPGS), or a combination thereof; iii. a non-ionic hydrophilic polymer in an amount of about 10 mg to about 500 mg, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and iv. optionally, silicon dioxide in an amount of about 10 mg to 300 mg; and b) a pharmaceutically acceptable carrier or excipient.In some embodiments, the pharmaceutical composition comprises: a) an amorphous solid dispersion comprising: i. nilotinib free base or nilotinib HCl in an amount of about 50 mg to about 125 mg; ii. one or more surfactants in an amount of about 10 mg to about 500 mg, the surfactant comprising lecithin; iii. a non-ionic hydrophilic polymer in an amount of about 10 mg to about 200 mg, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and iv. optionally, silicon dioxide in an amount of about 50 mg to 150 mg; and b) an external acid in an amount of about 50 mg to about 300 mg, the external acid being a surface-modifying acid. In some embodiments, the pharmaceutical composition comprises: a) an amorphous solid dispersion (ASD) comprising: i. nilotinib free base or nilotinib HCl in an amount between about 5% and about 35% by weight of the ASD; ii. one or more surfactants in an amount between about 5% and about 50% by weight of the ASD, the surfactant comprising one or more phospholipids, one or more non-ionic surfactants, or any combination thereof; iii. a non-ionic hydrophilic polymer in an amount between about 1% and about 80% by weight of the ASD, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and iv. optionally, silicon dioxide in an amount between about 10% and 40% by weight of the ASD; and b) a pharmaceutically acceptable carrier or excipient.In some embodiments, the pharmaceutical composition comprises: a) an amorphous solid dispersion (ASD) comprising: i. nilotinib free base or nilotinib HCl in an amount between about 5% and about 35% by weight of the ASD; ii. one or more surfactants in an amount between about 5% and about 50% by weight of the ASD, the surfactant comprising lecithin, a block copolymer of polyethylene glycol and polypropylene glycol, TPGS, or a combination thereof; iii. a non-ionic hydrophilic polymer in an amount between about 1% and about 80% by weight of the ASD, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and iv. optionally, silicon dioxide in an amount between about 10% and 40% by weight of the ASD; and b) a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises: a) an amorphous solid dispersion comprising: i. nilotinib free base or nilotinib HCl in an amount between about 15% and about 30% by weight of the ASD; ii. one or more surfactants in an amount between about 10% and about 40% by weight of the ASD, the surfactant comprising lecithin, a block copolymer of polyethylene glycol and polypropylene glycol, TPGS, or a combination thereof; iii. a non-ionic hydrophilic polymer in an amount between about 15% and about 60% by weight of the ASD, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and iv. optionally, silicon dioxide in an amount between about 15% and 35% by weight of the ASD; and b) a pharmaceutically acceptable carrier or excipient.In some embodiments, the pharmaceutical composition comprises: a) an amorphous solid dispersion comprising: i. nilotinib free base or nilotinib HCl in an amount between about 15% and about 30% by weight of the ASD; ii. one or more surfactants in an amount between about 10% and about 40% by weight of the ASD, the surfactant comprising lecithin, a block copolymer of polyethylene glycol and polypropylene glycol, TPGS, or a combination thereof; iii. a non-ionic hydrophilic polymer in an amount between about 15% and about 60% by weight of the ASD, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and iv. optionally, silicon dioxide in an amount between about 15% and 35% by weight of the ASD; and an external acid in an amount between about 5% and 35% by weight of the pharmaceutical composition. In some embodiments, the pharmaceutical composition is shelf-stable at 75°C / 75% RH for at least 2 weeks, wherein the shelf-stable pharmaceutical composition has less than 100 ppm of impurity A at the end of the storage period. In some embodiments, the pharmaceutical composition is shelf-stable at 40°C / 75% RH for at least 6 months, wherein the shelf-stable pharmaceutical composition has less than 100 ppm of impurity A at the end of the storage period. In some embodiments, the pharmaceutical composition is shelf-stable at 40°C / 75% RH for at least 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, or 24 months, wherein the shelf-stable pharmaceutical composition has less than 100 ppm of impurity A at the end of the storage period. In some embodiments, the pharmaceutical composition has a total area under the curve (AUC) after oral administration (TAC). AUC) or C after oral administration max In some embodiments, the pharmaceutical composition exhibits a bioavailability, when measured as the total area under the curve (AUC) after oral administration, or a C after oral administration, that is at least two times greater than the bioavailability of a corresponding formulation comprising the crystalline form of nilotinib free base or a pharmaceutically acceptable salt thereof. maxThe bioavailability of the pharmaceutical composition is at least 2-fold higher than the bioavailability of a reference pharmaceutical composition containing nilotinib HCl, wherein the reference pharmaceutical composition does not contain an amorphous solid dispersion. In some embodiments, the bioavailability is measured in a fasted or fed dog model. In some embodiments, the bioavailability of the pharmaceutical composition is measured as the total area under the curve (AUC) after oral administration or as the C after oral administration. max When measured as a function of time, the bioavailability does not change by more than 50% when administered orally in the fed state compared to when administered in the fasted state.
[0007] Disclosed herein is a pharmaceutical composition comprising: (a) an amorphous solid dispersion comprising: i. an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, wherein the active pharmaceutical ingredient has a log P in octanol-water of 2.0 or greater; ii. one or more surfactants selected from a polymeric nonionic surfactant and a phospholipid, or any combination thereof; iii. a nonionic hydrophilic polymer; and iv. optionally, an adsorbent; and b) a pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition is in the form of a tablet or capsule. In some embodiments, the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof is nilotinib, abiraterone acetate, celecoxib, flurazepam, atorvastatin, indomethacin, nortriptyline, loratadine, fluoxetine, diclofenac, clopidogrel, duloxetine, maprotiline, imipramine, amitriptyline, cyproheptadine, sertraline, flufenamic acid, chlorpromazine, miconazole, rimonabant, clofazimine , enzalutamide, lapatinib, pazopanib, erlotinib, dasatinib, gefitinib, sorafenib, axitinib, crizotinib, vemurafenib, telotristat ethyl, ivacaftor, nintedanib, ibrutinib, alectinib, bosutinib, lenvatinib, midostaurin, avapritinib, pexidartinib, alectinib, neratinib, enzalutamide, their corresponding free bases, and pharmaceutically acceptable salts thereof. In some embodiments, the active pharmaceutical ingredient has a log P in octanol-water of 3.0 or greater. In some embodiments, the active pharmaceutical ingredient is a compound of Formula (I), or an N-oxide or pharmaceutically acceptable salt thereof:
[0008] [ka] During the ceremony, R 1 is hydrogen, C1-C6 alkyl, or halogen; R Ais hydrogen, C1-C6 alkyl, C 1-6 Alkoxy-C 1-6 Alkyl, acyloxy-C 1-6 Alkyl, carboxy-C 1-6 Alkyl, C 1-6 Alkoxycarbonyl-C 1-6 Alkyl, or phenyl-C 1-6 is alkyl, R B is hydrogen, optionally and independently, one or more R 10 , C1-C6 alkyl substituted by a cycloalkyl, benzcycloalkyl, heterocyclyl, aryl group, or a mono- or bicyclic heteroaryl group containing 0, 1, 2, or 3 ring nitrogen atoms and 0 or 1 oxygen atom and 0 or 1 sulfur atom, in each case the group is unsubstituted, mono- or polysubstituted; R 10 is hydroxy, C1-C6 alkoxy, acyloxy, carboxy, C 1-6 represents an alkoxycarbonyl, carbamoyl, N-monosubstituted or N,N-disubstituted carbamoyl, amino, monosubstituted or disubstituted amino, cycloalkyl, heterocyclyl, aryl group, or a monocyclic or bicyclic heteroaryl group containing 0, 1, 2, or 3 ring nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom, in each case the group is unsubstituted, monosubstituted, or polysubstituted; or R A and R B together form a C4-C6 alkylene optionally mono- or di-substituted by C1-C6 alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, C1-C6 alkoxy, amino, mono- or di-substituted amino, oxo, pyridyl, pyrazinyl, or pyrimidinyl, a benzalkylene having 4 or 5 carbon atoms, an oxaalkylene having one oxygen and 3 or 4 carbon atoms, or an azaalkylene having one nitrogen and 3 or 4 carbon atoms, wherein the nitrogen is unsubstituted or is selected from the group consisting of C1-C6 alkyl, phenyl-C1-C6 alkyl, C 1-6 Alkoxycarbonyl-C1-6 Alkyl, carboxy-C 1-6 Alkyl, Carbamoyl-C 1-6 Alkyl, N-monosubstituted or N,N-disubstituted carbamoyl-C 1-6 Alkyl, cycloalkyl, C 1-6 Substituted by alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl. In some embodiments, the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof is present in the unit dosage form of the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the one or more surfactants are present in the unit dosage form of the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the one or more surfactants are poloxamer 188, lecithin, TPGS, or a combination thereof. In some embodiments, the non-ionic hydrophilic polymer is polyvinyl alcohol (PVA), an oligosaccharide, a polysaccharide, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC or hypromellose), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl beta-cyclodextrin (HP-β-CD), hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyethylene glycol (PEG), a polyvinyl acetate and polyvinyl caprolactam-based graft copolymer (PVAc-PVCap-PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (PCL-PVAc-PEG), or a combination thereof. In some embodiments, the non-ionic hydrophilic polymer is present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the composition comprises an adsorbent, the adsorbent being selected from silicon dioxide, activated carbon, magnesium aluminum silicate, diatomaceous earth, microcrystalline cellulose (MCC), silicified microcrystalline cellulose (SMCC), talc, cross-linked povidone, sodium carboxymethylcellulose, sodium carboxymethyl starch, and sugars or sugar alcohols, such as sorbitol, mannitol, lactose, cyclodextrin, and maltodextrin. In some embodiments, the adsorbent is silicon dioxide. In some embodiments, the adsorbent is present in the amorphous solid dispersion in an amount of about 10% to about 35% by weight. In some embodiments, the pharmaceutically acceptable carrier or excipient comprises an external acid. In some embodiments, the external acid is a surface-modified acid comprising acid particles and a neutral salt layer. In some embodiments, the neutral salt layer is formed by reaction between a pharmaceutically acceptable base and a powdered or granular acid.In some embodiments, the surface-modified acid is in powder or granular form. In some embodiments, the external acid is a surface-modified organic acid. In some embodiments, the external acid is a surface-modified acid selected from tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, maleic acid, benzenesulfonic acid, and p-toluenesulfonic acid. In some embodiments, the external acid is a surface-modified acid selected from tartaric acid and succinic acid. In some embodiments, the pharmaceutically acceptable base is selected from sodium carbonate, potassium carbonate, sodium acetate, potassium acetate, sodium stearate, potassium stearate, lysine, arginine, and histidine. In some embodiments, the pharmaceutically acceptable base is sodium carbonate. In some embodiments, the weight percent of the external acid is about 2% to about 35%. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 50 mg to about 300 mg. In some embodiments, the pharmaceutical composition exhibits a saturation coefficient of about 0.015, as measured by the total area under the curve (AUC) after oral administration, or a Cmax of about 0.015, as measured by the total area under the curve (AUC) after oral administration. max In some embodiments, the pharmaceutical composition exhibits a bioavailability, measured as the total area under the curve (AUC) after oral administration, or a C after oral administration, that is at least two times greater than the bioavailability of a corresponding formulation comprising the active pharmaceutical ingredient in crystalline form or a pharmaceutically acceptable salt thereof. max The bioavailability of the pharmaceutical composition is at least two-fold higher than the bioavailability of a reference pharmaceutical composition comprising the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, wherein the reference pharmaceutical composition does not comprise an amorphous solid dispersion, when measured as the area under the curve (AUC) after oral administration or the C after oral administration. In some embodiments, the bioavailability is measured in a fasted or fed dog model. In some embodiments, the bioavailability of the pharmaceutical composition is measured as the area under the curve (AUC) after oral administration or the C after oral administration. maxThe bioavailability, measured as a function of time, does not change by more than 50% when administered orally in a fed state compared to when administered in a fasted state. In some embodiments, the amorphous solid dispersion further comprises an inorganic or organic acid. In some embodiments, the acid is selected from the group consisting of tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, methanesulfonic acid, ethanesulfonic acid, isethionic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, sulfuric acid, and phosphoric acid. In some embodiments, the pharmaceutical composition is shelf-stable at 40°C / 75% RH for at least 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, or 24 months, wherein the shelf-stable pharmaceutical composition has less than 100 ppm of degradation products of the active pharmaceutical ingredient.
[0009] Disclosed herein is an amorphous solid dispersion comprising: a) a lipophilic active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, wherein the active pharmaceutical ingredient has a log P in octanol-water of 2.0 or greater; b) one or more surfactants selected from polymeric non-ionic surfactants, phospholipids, TPGS, and any combination thereof; c) a non-ionic hydrophilic polymer; and d) optionally, an adsorbent. Disclosed herein is an amorphous solid dispersion comprising: a) a lipophilic active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, wherein the active pharmaceutical ingredient has a log P in octanol-water of 2.0 or greater; b) one or more surfactants selected from one or more non-ionic surfactants, one or more phospholipids, or any combination thereof; c) a non-ionic hydrophilic polymer; and d) optionally, an adsorbent. In some embodiments, the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof is nilotinib, abiraterone acetate, celecoxib, flurazepam, atorvastatin, indomethacin, nortriptyline, loratadine, fluoxetine, diclofenac, clopidogrel, duloxetine, maprotiline, imipramine, amitriptyline, cyproheptadine, sertraline, flufenamic acid, chlorpromazine, miconazole, rimonabant, clofazimine , enzalutamide, lapatinib, pazopanib, erlotinib, dasatinib, gefitinib, sorafenib, axitinib, crizotinib, vemurafenib, telotristat ethyl, ivacaftor, nintedanib, ibrutinib, alectinib, bosutinib, lenvatinib, midostaurin, avapritinib, pexidartinib, alectinib, neratinib, enzalutamide, their corresponding free bases, and pharmaceutically acceptable salts thereof. In some embodiments, the active pharmaceutical ingredient is a compound of formula (I), or an N-oxide or a pharmaceutically acceptable salt thereof:
[0010] [ka] During the ceremony, R 1 is hydrogen, C1-C6 alkyl, or halogen; R A is hydrogen, C1-C6 alkyl, C 1-6 Alkoxy-C 1-6 Alkyl, acyloxy-C 1-6 Alkyl, carboxy-C 1-6 Alkyl, C 1-6 Alkoxycarbonyl-C 1-6 Alkyl, or phenyl-C 1-6 is alkyl, R B is hydrogen, optionally and independently, one or more R 10 , C1-C6 alkyl substituted by a cycloalkyl, benzcycloalkyl, heterocyclyl, aryl group, or a mono- or bicyclic heteroaryl group containing 0, 1, 2, or 3 ring nitrogen atoms and 0 or 1 oxygen atom and 0 or 1 sulfur atom, in each case the group is unsubstituted, mono- or polysubstituted; R 10 is hydroxy, C1-C6 alkoxy, acyloxy, carboxy, C 1-6 represents an alkoxycarbonyl, carbamoyl, N-monosubstituted or N,N-disubstituted carbamoyl, amino, monosubstituted or disubstituted amino, cycloalkyl, heterocyclyl, aryl group, or a monocyclic or bicyclic heteroaryl group containing 0, 1, 2, or 3 ring nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom, in each case the group is unsubstituted, monosubstituted, or polysubstituted; or R A and R Btogether form a C4-C6 alkylene optionally mono- or di-substituted by C1-C6 alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, C1-C6 alkoxy, amino, mono- or di-substituted amino, oxo, pyridyl, pyrazinyl, or pyrimidinyl, a benzalkylene having 4 or 5 carbon atoms, an oxaalkylene having one oxygen and 3 or 4 carbon atoms, or an azaalkylene having one nitrogen and 3 or 4 carbon atoms, wherein the nitrogen is unsubstituted or is selected from the group consisting of C1-C6 alkyl, phenyl-C1-C6 alkyl, C 1-6 Alkoxycarbonyl-C 1-6 Alkyl, carboxy-C 1-6 Alkyl, Carbamoyl-C 1-6 Alkyl, N-monosubstituted or N,N-disubstituted carbamoyl-C 1-6 Alkyl, cycloalkyl, C 1-6The surfactant may be substituted by alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl. In some embodiments, the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof is nilotinib hydrochloride. In some embodiments, the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof is present in the amorphous solid dispersion in an amount of about 5 wt% to about 70 wt% based on the solids. In some embodiments, the one or more surfactants are polymeric nonionic surfactants. In some embodiments, the polymeric nonionic surfactant comprises a block copolymer of polyethylene glycol and polypropylene glycol. In some embodiments, the polymeric nonionic surfactant is poloxamer 188. In some embodiments, the one or more surfactants comprise one or more phospholipids. In some embodiments, the surfactant comprises lecithin. In some embodiments, the surfactant is present in the amorphous solid dispersion in an amount of about 5 wt% to about 70 wt% based on the solids. In some embodiments, the weight ratio of the active pharmaceutical ingredient or its pharmaceutically acceptable salt to one or more surfactants is about 10:1 to about 1:10. In some embodiments, the nonionic hydrophilic polymer comprises polyvinyl alcohol (PVA), oligosaccharides, polysaccharides, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC or hypromellose), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl beta-cyclodextrin (HP-β-CD), hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyethylene glycol (PEG), polyvinyl acetate and polyvinyl caprolactam-based graft copolymer (PVAc-PVCap-PEG), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (PCL-PVAc-PEG), or a combination thereof. In some embodiments, the nonionic hydrophilic polymer is HPMC, PVP, HP-β-CD, PVA, HPMCAS, or PCL-PVAc-PEG.In some embodiments, the nonionic hydrophilic polymer is present in the amorphous solid dispersion in an amount of about 5 wt% to about 70 wt% based on solids. In some embodiments, the weight ratio of the active pharmaceutical ingredient or its pharmaceutically acceptable salt to the nonionic hydrophilic polymer is about 10:1 to about 1:10. In some embodiments, the adsorbent is selected from silicon dioxide, activated carbon, magnesium aluminum silicate, diatomaceous earth, microcrystalline cellulose (MCC), silicified microcrystalline cellulose (SMCC), talc, cross-linked povidone, sodium carboxymethylcellulose, sodium carboxymethyl starch, and sugars or sugar alcohols, such as sorbitol, mannitol, lactose, cyclodextrin, and maltodextrin. In some embodiments, the adsorbent is silicon dioxide. In some embodiments, the adsorbent is present in the amorphous solid dispersion in an amount of about 10 wt% to about 35 wt%. In some embodiments, the average particle size of the amorphous solid dispersion is 1 μm to 1000 μm. In some embodiments, the amorphous solid dispersion has an average particle size, in terms of particle size, of about 10 μm to about 150 μm. In some embodiments, the amorphous solid dispersion further comprises an inorganic or organic acid. In some embodiments, the acid is selected from the group consisting of tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, methanesulfonic acid, ethanesulfonic acid, isethionic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, sulfuric acid, and phosphoric acid. In some embodiments, the amorphous solid dispersion comprises: a) nilotinib free base or nilotinib HCl in an amount of about 5% to about 35% by weight; b) one or more surfactants in an amount of about 5% to about 50% by weight, the surfactant comprising lecithin, one or more non-ionic surfactants, or a combination thereof; c) a non-ionic hydrophilic polymer in an amount of about 1% to about 80% by weight, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and (d) optionally, an adsorbent in an amount of about 10% to 40% by weight.In some embodiments, the amorphous solid dispersion comprises: a) nilotinib free base or nilotinib HCl in an amount of about 5% to about 35% by weight; b) one or more surfactants in an amount of about 5% to about 50% by weight, the surfactant comprising lecithin, a block copolymer of polyethylene glycol and polypropylene glycol, TPGS, or a combination thereof; c) a non-ionic hydrophilic polymer in an amount of about 1% to about 80% by weight, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and (d) optionally, silicon dioxide in an amount of about 10% to 40% by weight. In some embodiments, the pharmaceutical composition comprises: a) nilotinib free base or nilotinib HCl in an amount of about 15% to about 30% by weight; b) one or more surfactants in an amount of about 10% to about 40% by weight, the surfactant comprising lecithin, a block copolymer of polyethylene glycol and polypropylene glycol, TPGS, or a combination thereof; c) a non-ionic hydrophilic polymer in an amount of about 15% to about 60% by weight, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and d) optionally, silicon dioxide in an amount of about 15% to 35% by weight.In some embodiments, the pharmaceutical composition comprises: a) nilotinib free base or nilotinib HCl in an amount of about 15% to about 30% by weight; b) one or more surfactants in an amount of about 10% to about 40% by weight, the surfactant comprising lecithin, a block copolymer of polyethylene glycol and polypropylene glycol, TPGS, or a combination thereof; c) a non-ionic hydrophilic polymer in an amount of about 15% to about 60% by weight, the non-ionic hydrophilic polymer comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), or hydroxypropyl beta-cyclodextrin (HP-β-CD); and d) optionally, silicon dioxide in an amount of about 15% to 35% by weight.
[0011] Disclosed herein are methods for preparing an amorphous solid dispersion, the method comprising: a) combining (i) an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, (ii) one or more surfactants, including one or more phospholipids, one or more non-ionic surfactants, or any combination thereof, (iii) a non-ionic hydrophilic polymer, (iv) optionally an additive, such as an adsorbent, and (v) a solvent, thereby forming a liquid mixture or solution; and b) removing the solvent from the mixture, thereby forming the amorphous solid dispersion. In some embodiments, the solvent is an organic solvent or a mixture of organic solvents. In some embodiments, the one or more surfactants are selected from a non-ionic surfactant, TPGS, a phospholipid, and any combination thereof. In some embodiments, the solvent is or comprises an alcohol. In some embodiments, the combining step comprises dissolving the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, the one or more surfactants, and the non-ionic hydrophilic polymer in the solvent. In some embodiments, the removing step comprises spray drying or rotor evaporation. In some embodiments, the removing step comprises spraying the adsorbent with a solution and drying in a fluidized bed apparatus.
[0012] Disclosed herein are methods of treating a disease or disorder, the methods comprising administering to a subject in need of treatment a pharmaceutical composition or amorphous solid dispersion disclosed herein.
[0013] Disclosed herein are methods for treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition disclosed herein. In some embodiments, the cancer is a blood cancer. In some embodiments, the blood cancer is chronic myeloid leukemia (CML). In some embodiments, the cancer is a solid tumor.
[0014] Disclosed herein are methods for inhibiting BCR-ABL tyrosine kinase, comprising administering to a subject in need thereof a pharmaceutical composition disclosed herein. In some embodiments, the subject is resistant or intolerant to imatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent. In some embodiments, the method further comprises administering a hematopoietic growth factor, such as erythropoietin or G-CSF. [Brief explanation of the drawings]
[0015] The novel features of the invention are set forth with particularity in the appended claims. For a better understanding of the features and advantages of the present invention, reference should be made to the following detailed description that sets forth illustrative embodiments in which the principles of the invention are utilized, and the accompanying drawings. [Figure 1a] 1 shows X-ray powder diffraction studies for Formulations 1, 2a, 2b, 3a, 3b, 4, 5, 6, 7, 8, 9, and amorphous solid dispersions of crystalline nilotinib hydrochloride. [Figure 1b] 1 shows X-ray powder diffraction studies for Formulations 1, 2a, 2b, 3a, 3b, 4, 5, 6, 7, 8, 9, and amorphous solid dispersions of crystalline nilotinib hydrochloride. DETAILED DESCRIPTION OF THE INVENTION
[0016] The present invention is generally directed to compositions comprising pharmaceutically active agents useful as therapeutic agents for alleviating, alleviating, or eliminating one or more conditions in a subject in need of treatment, as further described herein. In particular, pharmaceutical compositions, their synthesis, and uses are described herein, wherein the pharmaceutical composition comprises a lipophilic API, a hydrophilic polymer, and a surfactant in a combination such that the API has improved bioavailability compared to the API alone. In some embodiments, the lipophilic API, the hydrophilic polymer, and the surfactant are in an amorphous solid dispersion.
[0017] definition Unless otherwise specified or clear from the context, as used herein, the term "about" in connection with a number or range of numbers should be understood to mean the specified number and + / -10% of that number, or up to 10% of the recited lower limit and up to 10% of the recited upper limit for the recited values in a range.
[0018] The singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, a reference to a "surfactant" includes a reference to one or more specific surfactants, and a reference to an "antioxidant" includes a reference to one or more such additives.
[0019] As used herein, the term "subject" refers to a mammal (e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, e.g., a monkey, chimpanzee, or baboon).
[0020] As used herein, "AUC" refers to the area under the plasma drug concentration versus time curve extrapolated from time zero to infinity. max " refers to the maximum drug concentration observed in plasma after extravascular administration of the drug. max " refers to the time after drug administration to reach maximum plasma concentration.
[0021] "Effective amount" and "sufficient amount" can be used interchangeably and refer to an amount of a substance sufficient to achieve an intended purpose or goal.
[0022] A "therapeutically effective amount," when used in connection with the pharmaceutical compositions described herein, refers to an amount of one or more pharmaceutically active agents sufficient to effect a therapeutic result in a subject in need thereof.
[0023] "Therapeutically equivalent" when used in connection with the pharmaceutical compositions described herein refers to the amount or quantity of a pharmaceutically acceptable salt or ester of a pharmaceutically active agent that is equivalent to a therapeutically effective amount of the free base or alcohol of the pharmaceutically active agent.
[0024] Amorphous Solid Dispersions The present disclosure relates to pharmaceutical compositions and methods of administering pharmaceutical compositions, wherein the pharmaceutical compositions comprise an amorphous solid dispersion comprising a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersions described herein further comprise one or more adsorbents. In some embodiments, the amorphous solid dispersions described herein further comprise one or more other additives. In some embodiments, the other additives include an organic acid and an inorganic acid. In some embodiments, the solid dispersion is a solid-state solution in which the API (or API salt) and hydrophilic polymer act as the solute and solvent, respectively. Solid dispersions can form multiple structures depending on the composition and sample processing history. When the API loading is lower than the equilibrium solubility of the API in the hydrophilic polymer, the drug molecularly disperses within the polymer matrix, forming a thermodynamically stable homogeneous solution. Homogeneous solutions are often achievable only at very low API loadings and / or elevated temperatures. At high loadings, the mixture becomes a supersaturated solution, and the drug precipitates. This can result in crystalline API particles dispersed in the hydrophilic polymer matrix, at a temperature at which the drug concentration corresponds to the equilibrium solubility. Alternatively, because crystallization of the API is a slow process, an intermediate metastable structure may form in which amorphous API aggregates are dispersed in a hydrophilic polymer matrix containing the API in a non-crystalline, amorphous state. Such amorphous solid dispersions can offer superior dissolution properties compared to crystalline APIs.
[0025] The amorphous solid dispersions described herein may comprise an API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersions described herein further comprise one or more adsorbents. In some embodiments, the amorphous solid dispersions described herein further comprise one or more other additives. In some embodiments, the other additives include organic acids and inorganic acids. In some embodiments, the other additives include antioxidants. In some embodiments, the amorphous solid dispersions described are homogeneous amorphous solid dispersions. In some embodiments, the components of the amorphous dispersion are mixed and heated in a solvent, and the solvent is removed to form the amorphous solid dispersion. In some embodiments, the solvent is water. In some embodiments, the solvent is a polar organic solvent. In some embodiments, the solvent is a non-polar organic solvent. In some embodiments, the solvent is selected from water, n-butanol, n-propanol, isopropanol, formic acid, nitromethane, ethanol, methanol, acetic acid, N-methylpyrrolidone, tetrahydrofuran, ethyl acetate, methyl acetate, dimethylformamide, acetonitrile, dimethyl sulfoxide, dichloromethane (DCM), acetone, tetrahydrofuran (THF), and any combination thereof. In some embodiments, the solvent is selected from water, n-butanol, n-propanol, isopropanol, formic acid, nitromethane, ethanol, methanol, acetic acid, and any combination thereof. In some embodiments, the solvent is selected from water, methanol, ethanol, and isopropanol. In some embodiments, the solvent is selected from dichloromethane, methanol, THF, and acetone. In some embodiments, the solvent is selected from mixtures of these solvents.
[0026] The amorphous solid dispersions described herein may include an API, a hydrophilic polymer, a surfactant, and, optionally, an adsorbent. In some embodiments, the components of the amorphous dispersion, such as the API, the hydrophilic polymer, and the surfactant, are mixed and solubilized in a solvent with or without heating to form a solution. In some embodiments, an adsorbent is further added to the solution to form a homogeneous suspension, and the solvent is removed to form the amorphous solid dispersion. In some embodiments, the solution is sprayed onto the adsorbent, and the solvent is removed to form the amorphous solid dispersion. In some embodiments, the adsorbent is selected from silicon dioxide (also known as silica), magnesium aluminum metasilicate (Neusilin), microcrystalline cellulose (MCC), silicified microcrystalline cellulose (SMCC), talc, cross-linked povidone, sodium carboxymethylcellulose, sodium carboxymethyl starch, sugars, and sugar alcohols. In some embodiments, the sugars and sugar alcohols include sorbitol, mannitol, lactose, cyclodextrin, and maltodextrin. In some embodiments, the adsorbent is silicon dioxide.
[0027] Active Pharmaceutical Ingredients (API) Various embodiments described herein are directed to compositions comprising an effective amount of an active pharmaceutical agent (API). The terms "active pharmaceutical agent," "API," "drug," "pharmaceutically active agent," "bioactive agent," "therapeutic agent," and "active agent," etc., may be used interchangeably and refer to a substance, such as a chemical compound or complex, that, when administered in an effective amount, has a measurable beneficial physiological effect on the body, such as a therapeutic effect in the treatment of a disease or disorder. Furthermore, when these terms are used, or when a particular active agent is specifically identified by name or category, it is understood that such reference is intended to include the active agent itself, as well as its pharmaceutically acceptable, pharmaceutically active derivatives, or compounds significantly related thereto, including, but not limited to, salts, pharmaceutically acceptable salts, N-oxides, prodrugs, active metabolites, isomers, fragments, analogs, solvates, radioisotopes, etc.
[0028] The partition coefficient (P) referred to herein is the ratio of the concentrations of a compound between two immiscible solvent phases at equilibrium. Most commonly, one of the solvents is water and the other is hydrophobic, typically 1-octanol. The logarithm of this ratio is log P (conventionally, the lipophilic phase is the numerator and the hydrophilic phase is the denominator), as shown below:
[0029]
number
[0030] Log P is a measure of lipophilicity or hydrophobicity. Hydrophobicity affects drug absorption, bioavailability, hydrophobic drug-receptor interactions, molecular metabolism, and toxicity. Hydrophilic compounds are soluble in water ("water-loving") and polar solvents. Lipophilic compounds are poorly soluble in water and polar solvents ("water-hating" or hydrophobic), but are soluble in organic solvents. Thus, Less hydrophilic = more lipophilic = higher log P = less solubility in water = less absorbency. High hydrophilicity = low lipophilicity = low log P = good water solubility = good absorption.
[0031] The partition coefficient can be experimentally measured or calculated. Various methods for calculating (or predicting) log P have been developed, and it is typically calculated by matching calculated log P values with experimentally measured log P values for a training set of thousands of molecules (mainly drug-like). Log P calculations are considered very robust and accurately handle many organic molecules. For example, the log P of more than 50% of molecules is predicted with an error of less than 0.25, and more than 80% is predicted with an error of less than 0.5. Less than 3.5% of structures are predicted with an error of more than 1.0. To distinguish it from measured log P, calculated log P is often referred to as clog P. Unless otherwise specified, "log P" as used herein refers to experimental log P values.
[0032] In some embodiments, the API is lipophilic. An API is considered lipophilic if its log P or calculated log P is 2.0 or greater. A log P of 2.0 or greater indicates that the API is 100 times more soluble in a lipophilic solvent than in water. In some embodiments, the API is insoluble in a polar solvent. In some embodiments, the API is insoluble in an aqueous medium. In some embodiments, the API is insoluble in water.
[0033] In some embodiments, the lipophilic API has a log P of at least 2.0, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7.0. Exemplary small molecule lipophilic APIs include, but are not limited to, those set forth in Table 1.
[0034] [Table 1-1]
[0035] [Table 1-2]
[0036] [Table 1-3]
[0037] The acid dissociation constant Ka (or acidity constant) is a measure of the strength of an acid or base in solution, typically water. It is the equilibrium constant for the chemical dissociation of acids and bases. In aqueous solution, the equilibrium for the dissociation of an acid can be written as:
[0038]
number
[0039]
number
[0040]
number
[0041]
number
[0042] K a pK is the logarithm of a is often used to indicate the strength or weakness of an acid or the conjugate acid of a base.
[0043]
number
[0044] In some embodiments, the API is a weak base.
[0045] In some embodiments, the API comprises a weakly basic functional group.
[0046] In some embodiments, the API has a pKa of 3.0 or greater. In some embodiments, the API has a pKa of 3.5 or greater. In some embodiments, the API has a pKa of 4.0 or greater. In some embodiments, the API has a pKa of 4.5 or greater. In some embodiments, the API has a pKa of 5.0 or greater.
[0047] In some embodiments, the API is present in the form of a free base. In some embodiments, the API is present in the form of a pharmaceutically acceptable salt. As used herein, pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium, potassium, and lithium salts, alkaline earth metal salts, calcium salts, magnesium salts, etc., organic amine salts such as triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, etc., inorganic acid salts such as hydrochloride, hydrobromide salts, sulfate salts, phosphate salts, etc., organic acid salts such as formate salts, acetate salts, trifluoroacetate salts, maleate salts, tartrate salts, etc., sulfonates such as methanesulfonate salts, benzenesulfonate salts, p-toluenesulfonate salts, etc., and amino acid salts such as arginate salts, aspartate salts, glutamate salts, etc. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt or ester thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one listed in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API, hydrophilic polymer, and surfactant are formulated as an amorphous solid dispersion. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0048] Pharmaceutically acceptable salts include bitartrate, bitartrate hydrate, hydrochloride, p-toluenesulfonate, phosphate, sulfate, trifluoroacetate, bitartrate hemipentahydrate, pentafluoropropionate, hydrobromide, mucate, oleate, dibasic phosphate, monobasic phosphate, acetate trihydrate, bis(heptafluorobutyrate), bis(pentafluoropropionate), bis(pyridinecarboxylate), bis(trifluoroacetate), chlorhydrate, and sulfate pentahydrate. Other representative pharmaceutically acceptable salts include, for example, water soluble and water insoluble salts, such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, butyrate, calcium edetate, camphorsulfonate, camsylate, carbonate, citrate, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodine ... salts, including ammonium salts, ammonium salts, ammonium nitrate ...Hydrates are another example of pharmaceutically acceptable salts. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one listed in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0049] In some embodiments, the API has low solubility at a pH of about 6-8. In some embodiments, the API has a solubility of less than 10 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 1.0 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 0.5 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 0.1 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 0.05 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 0.04 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 0.03 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 0.02 mg / ml in a solution having a pH of about 6-8. In some embodiments, the API has a solubility of less than 0.01 mg / ml in a solution having a pH between about 6 and 8. In some embodiments, the API has a solubility of less than 0.001 mg / ml in a solution having a pH between about 6 and 8. In some embodiments, the API has low solubility at a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 10 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 1.0 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.5 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.1 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.05 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.04 mg / ml in a solution having a pH between about 4 and 8.In some embodiments, the API has a solubility of less than 0.03 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.02 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.01 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.001 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has low solubility at a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 10 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 1.0 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 0.5 mg / ml in a solution having a pH between about 4 and 8. In some embodiments, the API has a solubility of less than 0.1 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 0.05 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 0.04 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 0.03 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 0.02 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 0.01 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API has a solubility of less than 0.001 mg / ml in a solution having a pH between about 6 and 10. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater.In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives include organic acids and inorganic acids. In some embodiments, the other additives include antioxidants.
[0050] Disclosed herein are pharmaceutical compositions comprising an API. In some embodiments, the API is present in the pharmaceutical composition in an amount of at least 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, or 200 mg. In some embodiments, the API is present in the pharmaceutical composition in an amount of about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, or 200 mg. In some embodiments, the API is present in the pharmaceutical composition in an amount of less than or equal to 1000 mg, 750 mg, 500 mg, 400 mg, 300 mg, 250 mg, 225 mg, 200 mg, 175 mg, 150 mg, 125 mg, 100 mg, 90 mg, 80 mg, 75 mg, 60 mg, 55 mg, or 50 mg. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0051] Pharmaceutical compositions comprising an API are disclosed herein. In some embodiments, the API is present in the pharmaceutical composition in an amount between 10 mg and 1000 mg. In some embodiments, the API is present in an amount between 20 mg and 500 mg. In some embodiments, the API is present in an amount between 20 mg and 400 mg. In some embodiments, the API is present in an amount between 20 mg and 300 mg. In some embodiments, the API is present in an amount between 25 mg and 250 mg. In some embodiments, the API is present in an amount between 30 mg and 200 mg. In some embodiments, the API is present in an amount of about 50 mg, about 100 mg, or about 150 mg. In some embodiments, the API is present in an amount of 50 mg, 100 mg, or 150 mg. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives include organic acids and inorganic acids. In some embodiments, the other additives include antioxidants.
[0052] In some embodiments, the dose may be about, but not limited to, 1.0 mg, 1.5 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21. 5mg, 22mg, 22.5mg, 23mg, 23.5mg, 24mg, 24.5mg, 25mg, 25.5mg, 26mg, 26.5mg, 27mg, 27.5mg, 28mg, 28.5mg, 29mg, 29.5mg, 30mg, 30.5mg, 31mg, 31.5mg, 32mg, 32.5mg, 33mg, 33.5mg, 36mg, 36.5mg, 37mg, 37.5mg, 38mg, 38.5mg, 39mg, 39.5mg, 40mg, 40.5mg, 41mg, 41.5mg, 42mg, 42.5mg, 43mg, 43.5mg, 44mg , 44.5mg, 45mg, 45.5mg, 46mg, 46.5mg, 47mg, 47.5mg, 48mg, 48.5mg, 49mg, 49.5mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 115mg, 120mg, 125mg, 130mg, 135mg, 140mg, 145mg, 150mg, 155mg, 160mg, 165mg, 170mg, 175mg, 180mg, 185mg, 190mg, 200mg, 205mg, 210m g, 215mg, 220mg, 225mg, 230mg, 235mg, 240mg, 245mg, 250mg, 255mg, 260mg, 265mg, 270mg, 275mg, 280mg, 285mg, 290mg, 295mg, 300mg, 305mg, 310mg, 31 5mg, 320mg, 325mg, 326mg, 326.5mg, 327mg, 327.5mg, 328mg, 328.5mg, 329mg, 329.5mg, 330mg, 330.5mg, 331mg, 331.5mg, 332mg, 332.5mg, 333mg, 333.5mg, 334mg, 334.5mg, 335mg, 335.5mg, 336mg, 336.5mg, 337mg, 337.5mg, 338mg, 338.5mg, 339mg, 339.5mg, 340mg, 340.5mg, 341mg, 341.5 mg、342mg、342.5mg、343mg、343.5mg、344mg、344.5mg、345mg、345.5m g、346mg、346.5mg、347mg、347.5mg、348mg、348.5mg、349mg、349.5mg 、350mg、350.5mg、351mg、351.5mg、352mg、352.5mg、353mg、353.5mg、 354mg、354.5mg、355mg、355.5mg、356mg、356.5mg、357mg、357.5mg、3 58mg、358.5mg、359mg、359.5mg、360mg、360.5mg、361mg、361.5mg、36 2mg、362.5mg、363mg、363.5mg、364mg、364.5mg、365mg、365.5mg、366 mg、366.5mg、367mg、367.5mg、368mg、369.5mg、370mg、370.5mg、371 mg、371.5mg、372mg、372.5mg、373mg、373.5mg、374mg、374.5mg、375m g、375.5mg、376mg、376.5mg、377mg、377.5mg、378mg、378.5mg、379mg 、379.5mg、380mg、380.5mg、381mg、381.5mg、382mg、382.5mg、383mg、 383.5mg、384mg、384.5mg、385mg、385.5mg、386mg、386.5mg、387mg、3 87.5mg、388mg、388.5mg、389mg、389.5mg、390mg、390.5mg、391mg、39 1.5mg, 392mg, 392.5mg, 393mg, 393.5mg, 394mg, 394.5mg, 395mg, 395.5mg, 396mg, 396.5mg, 397mg, 397.5mg, 398mg, 398.5mg, 399mg, 399.5mg, 400mg, 405mg, 410mg, 415mg, 420mg, 425mg, 430mg, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470mg, 47 5mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 535mg, 540mg, 545mg, 550mg, 555 mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635m g, 640mg, 645mg, 650mg, 655mg, 660mg, 665mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705mg, 710mg, 715mg, 720mg , 725mg, 730mg, 735mg, 740mg, 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780mg, 785mg, 790mg, 795mg, 800mg, 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845mg, 850mg, 855mg, 860mg, 865mg, 870mg, 875mg, 880mg, 8 Pharmaceutical compositions are provided that include an active pharmaceutical ingredient present in a dose of about 1.0 mg to about 1000 mg, including 85 mg, 890 mg, 895 mg, 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, or 1000 mg. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API is 2.The amorphous solid dispersion has a log P of 0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0053] In some embodiments, the dose may be about, but not limited to, 1.0 mg, 1.5 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21. 5mg, 22mg, 22.5mg, 23mg, 23.5mg, 24mg, 24.5mg, 25mg, 25.5mg, 26mg, 26.5mg, 27mg, 27.5mg, 28mg, 28.5mg, 29mg, 29.5mg, 30mg, 30.5mg, 31mg, 31.5mg, 32mg, 32.5mg, 33mg, 33.5mg, 36mg, 36.5mg, 37mg, 37.5mg, 38mg, 38.5mg, 39mg, 39.5mg, 40mg, 40.5mg, 41mg, 41.5mg, 42mg, 42.5mg, 43mg, 43.5mg, 44mg , 44.5mg, 45mg, 45.5mg, 46mg, 46.5mg, 47mg, 47.5mg, 48mg, 48.5mg, 49mg, 49.5mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 115mg, 120mg, 125mg, 130mg, 135mg, 140mg, 145mg, 150mg, 155mg, 160mg, 165mg, 170mg, 175mg, 180mg, 185mg, 190mg, 200mg, 205mg, 210m g, 215mg, 220mg, 225mg, 230mg, 235mg, 240mg, 245mg, 250mg, 255mg, 260mg, 265mg, 270mg, 275mg, 280mg, 285mg, 290mg, 295mg, 300mg, 305mg, 310mg, 31 5mg, 320mg, 325mg, 326mg, 326.5mg, 327mg, 327.5mg, 328mg, 328.5mg, 329mg, 329.5mg, 330mg, 330.5mg, 331mg, 331.5mg, 332mg, 332.5mg, 333mg, 333.5mg, 334mg, 334.5mg, 335mg, 335.5mg, 336mg, 336.5mg, 337mg, 337.5mg, 338mg, 338.5mg, 339mg, 339.5mg, 340mg, 340.5mg, 341mg, 341.5 mg、342mg、342.5mg、343mg、343.5mg、344mg、344.5mg、345mg、345.5m g、346mg、346.5mg、347mg、347.5mg、348mg、348.5mg、349mg、349.5mg 、350mg、350.5mg、351mg、351.5mg、352mg、352.5mg、353mg、353.5mg、 354mg、354.5mg、355mg、355.5mg、356mg、356.5mg、357mg、357.5mg、3 58mg、358.5mg、359mg、359.5mg、360mg、360.5mg、361mg、361.5mg、36 2mg、362.5mg、363mg、363.5mg、364mg、364.5mg、365mg、365.5mg、366 mg、366.5mg、367mg、367.5mg、368mg、369.5mg、370mg、370.5mg、371 mg、371.5mg、372mg、372.5mg、373mg、373.5mg、374mg、374.5mg、375m g、375.5mg、376mg、376.5mg、377mg、377.5mg、378mg、378.5mg、379mg 、379.5mg、380mg、380.5mg、381mg、381.5mg、382mg、382.5mg、383mg、 383.5mg、384mg、384.5mg、385mg、385.5mg、386mg、386.5mg、387mg、3 87.5mg、388mg、388.5mg、389mg、389.5mg、390mg、390.5mg、391mg、39 1.5mg, 392mg, 392.5mg, 393mg, 393.5mg, 394mg, 394.5mg, 395mg, 395.5mg, 396mg, 396.5mg, 397mg, 397.5mg, 398mg, 398.5mg, 399mg, 399.5mg, 400mg, 405mg, 410mg, 415mg, 420mg, 425mg, 430mg, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470 mg, 475mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 535mg, 540mg, 545mg , 550mg, 555mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 6 25mg, 630mg, 635mg, 640mg, 645mg, 650mg, 655mg, 660mg, 665mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705 mg, 710mg, 715mg, 720mg, 725mg, 730mg, 735mg, 740mg, 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780m g, 785mg, 790mg, 795mg, 800mg, 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845mg, 850mg, 855mg, Contains 860mg, 865mg, 870mg, 875mg, 880mg, 885mg, 890mg, 895mg, 900mg, 905mg, 910mg, 915mg, 920mg, 925mg, 930mg, 935mg, 940mg, 945mg, 950mg, 955mg, 960mg, 965mg, 970mg, 975mg, 980mg, 985mg, 990mg, 995mg, or 1000mg, approximately 1.Pharmaceutical compositions are provided comprising nilotinib or a pharmaceutically acceptable salt thereof present in a dose of 0 mg to about 1000 mg. In some embodiments, the amorphous solid dispersion comprises nilotinib or a pharmaceutically acceptable salt thereof, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0054] In some embodiments, a pharmaceutical composition is provided comprising about 1 mg to about 500 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 10 mg to about 400 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 25 mg to about 200 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 125 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 100 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 100 mg to about 125 mg of API. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersions described herein further comprise one or more adsorbents. In some embodiments, the amorphous solid dispersions described herein further comprise one or more other additives. In some embodiments, the other additives include organic acids and inorganic acids. In some embodiments, the other additives include antioxidants.
[0055] In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 55 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 60 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 65 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 70 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 75 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 80 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 85 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 90 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 95 mg to about 150 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 100 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 105 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 110 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 115 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 120 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 125 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 130 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 135 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 140 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 145 mg to about 150 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 1 mg to about 50 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 5 mg to about 40 mg of API. In some embodiments, a pharmaceutical composition comprising about 10 mg to about 30 mg of API is provided.In some embodiments, a pharmaceutical composition is provided comprising about 5 mg to about 25 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 25 mg to about 50 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 20 mg to about 40 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 10 mg to about 25 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 5 mg to about 20 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 1 mg to about 10 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 1 mg to about 20 mg of API. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one listed in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersions described herein further comprise one or more adsorbents. In some embodiments, the amorphous solid dispersions described herein further comprise one or more other additives. In some embodiments, the other additives include organic acids and inorganic acids. In some embodiments, the other additives include antioxidants.
[0056] In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 145 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 140 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 135 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 130 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 125 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 120 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 115 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 110 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 105 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 100 mg of API. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 95 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 90 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 85 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 80 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 75 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 70 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 65 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 60 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 50 mg to about 55 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 25 mg to about 50 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 40 mg to about 80 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 75 mg to about 125 mg of API. In some embodiments, pharmaceutical compositions are provided that comprise about 25 mg to about 200 mg of API.In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib HCl. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0057] In some embodiments, the API comprises about 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total weight of the composition. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one listed in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0058] In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 99% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 80% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 60% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 40% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 20% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 10% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 1% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 99% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 80% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 60% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 40% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 99% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 80% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 60% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 40% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 40% to about 99% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 40% to about 80% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 40% to about 60% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 5% to about 70% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 5% to about 35% weight percent of API.In some embodiments, about 5% to about 10%, about 5% to about 15%, about 5% to about 18%, about 5% to about 19%, about 5% to about 20%, about 5% to about 21%, about 5% to about 22%, about 5% to about 24%, about 5% to about 25%, about 5% to about 30%, about 5% to about 35%, about 10% to about 15%, about 10% to about 18%, about 10% to about 19%, about 10% to about 20%, about 10% to about 21%, about 10% to about 22%, about 10% to about 24%, about 10% to about 25%, about 10% to about 30%, about 10% to about 35%, about 15% to about 18%, about 15% to about 19%, about 15% to about 20%, about 15% to about 21%, about 15% to about 22%, about 15% to about 24%, about 15% to about 25%, about 15% to about 30%, about 15% to about 35%, about 18% to about 19%, about 18% to about 20%, about 18% to about 21%, about 18% to about 22%, about 18% ~ about 24%, about 18% to about 25%, about 18% to about 30%, about 18% to about 35%, about 19% to about 20%, about 19% to about 21%, about 19% to about 22%, about 19% to about 24%, about 19% to about 25%, about 19% to about 30%, about 19% to about 35%, about 20% to about 21%, about 20% to about 22%, about 20% to about 24%, about 20% to about 25%, about 20% to about 30%, about 20% to about 35%, about 21% to about Pharmaceutical compositions are provided that comprise 22%, about 21% to about 24%, about 21% to about 25%, about 21% to about 30%, about 21% to about 35%, about 22% to about 24%, about 22% to about 25%, about 22% to about 30%, about 22% to about 35%, about 24% to about 25%, about 24% to about 30%, about 24% to about 35%, about 25% to about 30%, about 25% to about 35%, or about 30% to about 35% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise about 5%, about 10%, about 15%, about 18%, about 19%, about 20%, about 21%, about 22%, about 24%, about 25%, about 30%, or about 35% by weight of API. In some embodiments, pharmaceutical compositions are provided that comprise at least about 5%, about 10%, about 15%, about 18%, about 19%, about 20%, about 21%, about 22%, about 24%, about 25%, or about 30% weight percent of API, hi some embodiments, pharmaceutical compositions are provided that comprise at most about 10%, about 15%, about 18%, about 19%, about 20%, about 21%, about 22%, about 24%, about 25%, about 30%, or about 35% weight percent of API.In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0059] Formation of an amorphous solid dispersion may require a predetermined particle size of the API. In some embodiments, the particle size of the API is from about 1 nm to 1 mm. In some embodiments, the particle size of the API is from about 0.01 to 1000 μm. In some embodiments, the particle size of the API is from about 0.01 μm to about 1000 μm. In some embodiments, the particle size of the API is from at least about 0.01 μm. In some embodiments, the particle size of the API is from at most about 1000 μm. In some embodiments, the particle size of the API is from about 1 μm to about 50 μm. In some embodiments, the particle size of the API is from at least about 1 μm. In some embodiments, the particle size of the API is from at most about 50 μm. In some embodiments, the particle size of the API is from about 1 μm to about 3 μm, from about 1 μm to about 7 μm, from about 1 μm to about 10 μm, from about 1 μm to about 13 μm, from about 1 μm to about 17 μm, from about 1 μm to about 20 μm, from about 1 μm to about 23 μm, from about 1 μm to about 27 μm, from about 1 μm to about 30 μm, from about 1 μm to about 40 μm, from about 1 μm to about 50 μm, from about 10 μm to about 13 μm, from about 10 μm to about 17 μm , about 10 μm to about 20 μm, about 10 μm to about 23 μm, about 10 μm to about 27 μm, about 10 μm to about 30 μm, about 10 μm to about 40 μm, about 10 μm to about 50 μm, about 20 μm to about 27 μm, about 20 μm to about 30 μm, about 20 μm to about 40 μm, about 20 μm to about 50 μm, about 30 μm to about 40 μm, about 30 μm to about 50 μm, or about 40 μm to about 50 μm. In some embodiments, the particle size of the API is about 1 μm to about 100 μm. In some embodiments, the particle size of the API is at least about 1 μm. In some embodiments, the particle size of the API is about 0.1, 1, 3, 5, 7, 10, 13, 17, 20, 23, 25, 27, 30, 33, 35, 37, 40, 43, 45, 47, 50, 60, 70, 80, 90, or 100 μm or less. In some embodiments, the particle size of the API is about 20 μm or less. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof.In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0060] In some embodiments, amorphous solid dispersions comprising an API such as nilotinib free base or a pharmaceutically acceptable salt thereof are described herein. In some embodiments, the amorphous solid dispersion is characterized by providing an amorphous powder X-ray diffraction pattern. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the amorphous solid dispersion in an amount of about 5 wt% to about 70 wt% based on the solid matter. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the amorphous solid dispersion in an amount of about 10 wt% to about 50 wt% based on the solid matter. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the amorphous solid dispersion in an amount of about 20 wt% to about 40 wt% based on the solid matter. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the amorphous solid dispersion in an amount of about 10 wt% to about 30 wt% based on the solid matter.
[0061] In some embodiments, the amorphous solid dispersions described herein comprise a surfactant. In some embodiments, the surfactant is selected from a polymeric nonionic surfactant and a phospholipid. In some embodiments, the surfactant is a polymeric nonionic surfactant. In some embodiments, the polymeric nonionic surfactant comprises a block copolymer of polyethylene glycol and polypropylene glycol. In some embodiments, the polymeric nonionic surfactant has a number average molecular weight of about 7,000 Da to about 10,000 Da. In some embodiments, the amorphous solid dispersions described herein comprise the surfactant poloxamer 188. In some embodiments, the amorphous solid dispersions described herein comprise a surfactant comprising one or more phospholipids. In some embodiments, the surfactant comprises one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, plasmalogen, sphingomyelin, and phosphatidic acid. In some embodiments, the one or more phospholipids comprise more than 50%, 60%, 70%, 80%, or 90% phosphatidylcholine by weight. In some embodiments, the surfactant comprises lecithin. In some embodiments, the surfactant is present in the amorphous solid dispersion in an amount of about 5 wt% to about 70 wt% based on the solids. In some embodiments, the surfactant is present in the amorphous solid dispersion in an amount of about 20 wt% to about 60 wt% based on the solids. In some embodiments, the surfactant is present in the amorphous solid dispersion in an amount of about 10 wt% to about 30 wt% based on the solids. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to surfactant is about 10:1 to about 1:10, or any range therebetween. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to surfactant is about 5:1 to about 1:4. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to surfactant is about 2:1 to about 1:2. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to surfactant is about 1:1 to about 1:2.In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to surfactant is about 1:1 to about 1:1.5. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to surfactant is about 0.5:1 to about 1:3. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to surfactant is about 1:1 to about 1:3.
[0062] In some embodiments, the pharmaceutical compositions described herein comprise an active pharmaceutical ingredient or a salt thereof, such as nilotinib free base or a pharmaceutically acceptable salt thereof, a surfactant, and a non-ionic hydrophilic polymer. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of about 20 mg to about 200 mg. In some embodiments, the nilotinib free base or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of about 25 mg, about 50 mg, about 100 mg, about 150 mg, or about 200 mg. In some embodiments, the surfactant is present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the surfactant is present in the pharmaceutical composition in an amount of about 20 mg to about 200 mg. In some embodiments, the non-ionic hydrophilic polymer is present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg. In some embodiments, the non-ionic hydrophilic polymer is present in the pharmaceutical composition in an amount of about 20 mg to about 200 mg.
[0063] In some embodiments, the amorphous solid dispersions described herein comprise a non-ionic hydrophilic polymer. In some embodiments, the non-ionic hydrophilic polymer comprises polyvinyl alcohol (PVA), oligosaccharides, polysaccharides, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC or hypromellose), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyethylene glycol (PEG), polyvinyl acetate and polyvinyl caprolactam-based graft copolymer (PVAc-PVCap-PEG), or polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (PCL-PVAc-PEG, also known as Soluplus®), polyethylene oxide, hydroxypropyl beta-cyclodextrin (HP-β-CD), or a combination thereof. In some embodiments, the non-ionic hydrophilic polymer is HPMC, PVP, HP-β-CD, or PVA.
[0064] In some embodiments, the nonionic hydrophilic polymer is present in the amorphous solid dispersion in an amount of about 5% to about 70%. In some embodiments, the nonionic hydrophilic polymer is present in an amount of about 5% to about 10%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 35%, about 5% to about 40%, about 5% to about 45%, about 5% to about 50%, about 5% to about 55%, about 5% to about 60%, about 5% to about 70%, about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 35%, about 10% to about 40%, or an amount of about 5% to about 10%. %, about 10% to about 45%, about 10% to about 50%, about 10% to about 55%, about 10% to about 60%, about 10% to about 70%, about 20% to about 25%, about 20% to about 30%, about 20% to about 35%, about 20% to about 40%, about 20% to about 45%, about 20% to about 50%, about 20% to about 55%, about 20% to about 60%, about 20% to about 70%, about 25% to about 30%, about 25% to about 35%, about 25% to about 40%, about 2 5% to about 45%, about 25% to about 50%, about 25% to about 55%, about 25% to about 60%, about 25% to about 70%, about 30% to about 35%, about 30% to about 40%, about 30% to about 45%, about 30% to about 50%, about 30% to about 55%, about 30% to about 60%, about 30% to about 70%, about 35% to about 40%, about 35% to about 45%, about 35% to about 50%, about 35% to about 55%, about 35% to about 60%, about 35% to about The amorphous solid dispersion is present in an amount of about 70%, about 40% to about 45%, about 40% to about 50%, about 40% to about 55%, about 40% to about 60%, about 40% to about 70%, about 45% to about 50%, about 45% to about 55%, about 45% to about 60%, about 45% to about 70%, about 50% to about 55%, about 50% to about 60%, about 50% to about 70%, about 55% to about 60%, about 55% to about 70%, or about 60% to about 70%. In some embodiments, the non-ionic hydrophilic polymer is present in the solid amorphous dispersion in an amount of about 5%, about 10%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, or about 70%. In some embodiments, the non-ionic hydrophilic polymer is present in the solid amorphous dispersion in an amount of at least about 5%, about 10%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60%.In some embodiments, the non-ionic hydrophilic polymer is present in the solid amorphous dispersion in an amount of up to about 10%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, or about 70%.
[0065] In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to the non-ionic hydrophilic polymer is about 1:1 to about 1:10. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to the non-ionic hydrophilic polymer is about 10:1 to about 8:1, about 10:1 to about 6:1, about 10:1 to about 4:1, about 10:1 to about 2:1, about 10:1 to about 1:1, about 10:1 to about 1:2, about 10:1 to about 1:4, about 10:1 to about 1:6, about 10:1 to about 1:8, about 10:1 to about 1:10 ... :1 to about 1:10, about 8:1 to about 6:1, about 8:1 to about 4:1, about 8:1 to about 2:1, about 8:1 to about 1:1, about 8:1 to about 1:2, about 8:1 to about 1:4, about 8:1 to about 1:6, about 8:1 to about 1:8, about 8:1 to about 1:10, about 6:1 to about 4:1, about 6:1 to about 2:1, about 6:1 to about 1:1, about 6:1 to about 1:2, about 6:1 to about 1:4, about 6:1 to about 1: 6, about 6:1 to about 1:8, about 6:1 to about 1:10, about 4:1 to about 2:1, about 4:1 to about 1:1, about 4:1 to about 1:2, about 4:1 to about 1:4, about 4:1 to about 1:6, about 4:1 to about 1:8, about 4:1 to about 1:10, about 2:1 to about 1:1, about 2:1 to about 1:2, about 2:1 to about 1:4, about 2:1 to about 1:6, about 2:1 to about 1:8, about 2:1 to about 1:10, about 1: 1 to about 1:2, about 1:1 to about 1:4, about 1:1 to about 1:6, about 1:1 to about 1:8, about 1:1 to about 1:10, about 1:2 to about 1:4, about 1:2 to about 1:6, about 1:2 to about 1:8, about 1:2 to about 1:10, about 1:4 to about 1:6, about 1:4 to about 1:8, about 1:4 to about 1:10, about 1:6 to about 1:8, about 1:6 to about 1:10, or about 1:8 to about 1:10. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to non-ionic hydrophilic polymer is about 10:1, about 8:1, about 6:1, about 4:1, about 2:1, about 1:1, about 1:2, about 1:4, about 1:6, about 1:8, or about 1:10. In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to non-ionic hydrophilic polymer is at least about 10:1, about 8:1, about 6:1, about 4:1, about 2:1, about 1:1, about 1:2, about 1:4, about 1:6, or about 1:8.In some embodiments, the weight ratio of nilotinib free base or a pharmaceutically acceptable salt thereof to non-ionic hydrophilic polymer is at most about 8:1, about 6:1, about 4:1, about 2:1, about 1:1, about 1:2, about 1:4, about 1:6, about 1:8, or about 1:10.
[0066] In some embodiments, the amorphous solid dispersions and / or pharmaceutical compositions described herein do not include an organic acid, hi some embodiments, the amorphous solid dispersions and / or pharmaceutical compositions do not include any acid.
[0067] The amorphous solid dispersions described herein can have a particle size distribution. In some embodiments, the average particle size of the amorphous solid dispersion, in terms of particle size, is about 1 μm to about 500 μm. In some embodiments, the average particle size of the amorphous solid dispersion, in terms of particle size, is about 1 μm to about 300 μm. In some embodiments, the average particle size of the amorphous solid dispersion, in terms of particle size, is about 1 μm to about 20 μm. In some embodiments, the average particle size of the amorphous solid dispersion, in terms of particle size, is about 5 μm to about 15 μm.
[0068] In some embodiments, the particle size distribution of the amorphous solid dispersion is obtained. In some embodiments, the terms D10, D50, and D90 are used to describe the particle size distribution. The D10 diameter is smaller than 10 percent and larger than 90 percent of the particles. D50 is the median diameter at which 50% of the total mass of particles are larger and 50% are smaller. D90 defines the diameter at which 90% of the distribution has a smaller particle size and 10% has a larger particle size.
[0069] In some embodiments, an error band is included. The term "total error band" is used to identify all causes, including sampling and sample preparation, calculated at a 95% confidence level. An example is a D50 100 μm with a total error band of ±5% for size. Other statistics are often used to describe particle size distributions. The most common calculations are standard deviation and variance. The standard deviation (St Dev.) designation defines a diameter within which approximately 68.27% of the total population falls within ±1 St Dev and 95.45% falls within ±2 St Dev.
[0070] In some embodiments, the particle size distribution of the amorphous solid dispersion is obtained. In some embodiments, the terms D10, D50, and D90 are used to describe the particle size distribution. In some embodiments, the D90 particle size is about 1,000 μm, 950 μm, 900 μm, 800 μm, 700 μm, 600 μm, 500 μm, 400 μm, 300 μm, 200 μm, 100 μm, 75 μm, 65 μm, 50 μm, 25 μm, 20 μm, 15 μm, or 10 μm or less. In some embodiments, the D50 particle size is about 500 μm, 400 μm, 300 μm, 200 μm, 100 μm, 50 μm, 35 μm, 25 μm, 20 μm, 15 μm, 10 μm, or 5 μm or less. In some embodiments, the D10 particle size is less than or equal to about 200 μm, 100 μm, 50 μm, 45 μm, 40 μm, 35 μm, 30 μm, 25 μm, 20 μm, 15 μm, 10 μm, 9 μm, 8 μm, 7 μm, 6 μm, 5 μm, 4 μm, 3 μm, 2 μm, or 1 μm.
[0071] In some embodiments, the particle size distribution of the amorphous solid dispersion is obtained. In some embodiments, the terms D10, D50, and D90 are used to describe the particle size distribution. In some embodiments, the D90 particle size is about 10 μm to about 1000 μm.In some embodiments, the D90 particle size is from about 10 μm to about 20 μm, from about 10 μm to about 30 μm, from about 10 μm to about 50 μm, from about 10 μm to about 100 μm, from about 10 μm to about 150 μm, from about 10 μm to about 200 μm, from about 10 μm to about 300 μm, from about 10 μm to about 400 μm, from about 10 μm to about 500 μm, from about 10 μm to about 750 μm, from about 10 μm to about 1,000 μm, from about 20 μm to about 30 μm, from about 20 μm to about 50 μm, from about 20 μm to about 100 μm, from about 20 μm to about 150 μm, from about 20 μm to about 200 μm, from about 20 μm to about 300μm, about 20μm to about 400μm, about 20μm to about 500μm, about 20μm to about 750μm, about 20μm to about 1,000μm m, about 30 μm to about 50 μm, about 30 μm to about 100 μm, about 30 μm to about 150 μm, about 30 μm to about 200 μm, about 30 μm ~ approx. 300 μm, approx. 30 μm ~ approx. 400 μm, approx. 30 μm ~ approx. 500 μm, approx. 30 μm ~ approx. 750 μm, approx. 0μm to approx. 400μm, approx. 50μm to approx. 500μm, approx. 50μm to approx. 750μm, approx. 50μm to approx. 1,000μm, approx. 100μm ~about 150μm, about 100μm to about 200μm, about 100μm to about 300μm, about 100μm to about 400μm, about 100μm to about 500μm, approximately 100μm to approximately 750μm, approximately 100μm to approximately 1,000μm, approximately 150μm to approximately 200μm, approximately 150μm to approximately 300μm, about 150μm to about 400μm, about 150μm to about 500μm, about 150μm to about 750μm, about 150μm to about 1, 000 μm, about 200 μm to about 300 μm, about 200 μm to about 400 μm, about 200 μm to about 500 μm, about 200 μm to about 750 μm, about 200 μm to about 1,000 μm, about 300 μm to about 400 μm, about 300 μm to about 500 μm, about 300 μm to about 750 μm, about 300 μm to about 1,000 μm, about 400 μm to about 500 μm, about 400 μm to about 750 μm, about 400 μm to about 1,000 μm, about 500 μm to about 750 μm, about 500 μm to about 1,000 μm, or about 750 μm to about 1,000 μm.In some embodiments, the D90 particle size is about 10 μm, about 20 μm, about 30 μm, about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 300 μm, about 400 μm, about 500 μm, about 750 μm, or about 1,000 μm. In some embodiments, the D90 particle size is at least about 10 μm, about 20 μm, about 30 μm, about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 300 μm, about 400 μm, about 500 μm, or about 750 μm. In some embodiments, the D90 particle size is at most about 20 μm, about 30 μm, about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 300 μm, about 400 μm, about 500 μm, about 750 μm, or about 1,000 μm.
[0072] In some embodiments, a particle size distribution of the amorphous solid dispersion is obtained. In some embodiments, the terms D10, D50, and D90 are used to describe the particle size distribution. In some embodiments, the D50 particle size is about 5 μm to about 100 μm. In some embodiments, the D50 particle size is about 5 μm to about 10 μm, about 5 μm to about 15 μm, about 5 μm to about 20 μm, about 5 μm to about 25 μm, about 5 μm to about 30 μm, about 5 μm to about 40 μm, about 5 μm to about 50 μm, about 5 μm to about 60 μm, about 5 μm to about 75 μm, about 5 μm to about 100 μm, about 10 μm to about 15 μm, about 10 μm to about 20 μm, about 10 μm to about 25 μm, about 10 μm ~Approx. 30μm, approx. 10μm ~ approx. 40μm, approx. 10μm ~ approx. 50μm, approx. 10μm ~ approx. 60μm, approx. 10μm ~ approx. 75μm, approx. 10μm ~ approx. 100μm, approx. 15μm ~ approx. 20μm, approx. 15μm ~Approx. 25μm, Approx. 15μm~Approx. 30μm, Approx. 15μm~Approx. 40μm, Approx. 15μm~Approx. 50μm, Approx. 15μm~Approx. 60μm, Approx. 15μm~Approx. 75μm, Approx. Approximately 25μm, approximately 20μm to approximately 30μm, approximately 20μm to approximately 40μm, approximately 20μm to approximately 50μm, approximately 20μm to approximately 60μm, approximately 20μm to approximately 75μm, approximately 20μm to approximately 100μm, approximately 25μm Approximately 30μm, approximately 25μm to approximately 40μm, approximately 25μm to approximately 50μm, approximately 25μm to approximately 60μm, approximately 25μm to approximately 75μm, approximately 25μm to approximately 100μm, approximately 30μm to approximately 40μm, approximately 30μm to approximately 50 μm, about 30 μm to about 60 μm, about 30 μm to about 75 μm, about 30 μm to about 100 μm, about 40 μm to about 50 μm, about 40 μm to about 60 μm, about 40 μm to about 75 μm, about 40 μm to about 100 μm, about 50 μm to about 60 μm, about 50 μm to about 75 μm, about 50 μm to about 100 μm, about 60 μm to about 75 μm, about 60 μm to about 100 μm, or about 75 μm to about 100 μm. In some embodiments, the D50 particle size is about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 75 μm, or about 100 μm. In some embodiments, the D50 particle size is at least about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, or about 75 μm.In some embodiments, the D50 particle size is at most about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 75 μm, or about 100 μm.
[0073] In some embodiments, a particle size distribution of the amorphous solid dispersion is obtained. In some embodiments, the terms D10, D50, and D90 are used to describe the particle size distribution. In some embodiments, the D10 particle size is about 0.1 μm to about 50 μm. In some embodiments, the D10 particle size is about 0.1 μm to about 1 μm, about 0.1 μm to about 2 μm, about 0.1 μm to about 3 μm, about 0.1 μm to about 4 μm, about 0.1 μm to about 5 μm, about 0.1 μm to about 7 μm, about 0.1 μm to about 10 μm, about 0.1 μm to about 20 μm, about 0.1 μm to about 30 μm, about 0.1 μm to about 40 μm, about 0.1 μm to about 50 μm, about 1 μm to about 2 μm, about 1 μm to about 3 μm, about 1 μm to about 4 μm, about 1 μm ~Approx. 5μm, approx. 1μm ~ approx. 7μm, approx. 1μm ~ approx. 10μm, approx. 1μm ~ approx. 20μm, approx. 1μm ~ approx. 30μm, approx. 1μm ~ approx. 40μm, approx. 1μm ~ approx. 50μm, approx. 2μm ~ approx. 3μm, approx. 2μm ~ approx. 4μm, approx. 2μm ~Approx. 5μm, approx. 2μm ~ approx. 7μm, approx. 2μm ~ approx. 10μm, approx. 2μm ~ approx. 20μm, approx. 2μm ~ approx. 30μm, approx. 2μm ~ approx. 40μm, approx. 2μm ~ approx. 50μm, approx. 3μm ~ approx. 4μm, approx. Approximately 7μm, approximately 3μm to approximately 10μm, approximately 3μm to approximately 20μm, approximately 3μm to approximately 30μm, approximately 3μm to approximately 40μm, approximately 3μm to approximately 50μm, approximately 4μm to approximately 5μm, approximately 4μm to approximately 7μm, approximately 4μm to approximately 10μm, approximately 4μm ~about 20μm, about 4μm to about 30μm, about 4μm to about 40μm, about 4μm to about 50μm, about 5μm to about 7μm, about 5μm to about 10μm, about 5μm to about 20μm, about 5μm to about 30μm, about 5μm to about 40μm, about 5 μm to about 50 μm, about 7 μm to about 10 μm, about 7 μm to about 20 μm, about 7 μm to about 30 μm, about 7 μm to about 40 μm, about 7 μm to about 50 μm, about 10 μm to about 20 μm, about 10 μm to about 30 μm, about 10 μm to about 40 μm, about 10 μm to about 50 μm, about 20 μm to about 30 μm, about 20 μm to about 40 μm, about 20 μm to about 50 μm, about 30 μm to about 40 μm, about 30 μm to about 50 μm, or about 40 μm to about 50 μm. In some embodiments, the D10 particle size is about 0.1 μm, about 1 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 7 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, or about 50 μm.In some embodiments, the D10 particle size is at least about 0.1 μm, about 1 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 7 μm, about 10 μm, about 20 μm, about 30 μm, or about 40 μm. In some embodiments, the D10 particle size is at most about 1 μm, about 2 μm, about 3 μm, about 4 μm, about 5 μm, about 7 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, or about 50 μm.
[0074] In some embodiments, a particle size distribution of the amorphous solid dispersion is obtained. In some embodiments, the terms D10, D50, and D90 are used to describe the particle size distribution. In some embodiments, D10 has a particle size range of about 0.1 to about 50 μm, D50 has a particle size range of about 5 to about 100 μm, and D90 has a particle size range of about 10 to about 600 μm. In some embodiments, D10 has a particle size range of about 2 to about 10 μm, D50 has a particle size range of about 5 to about 60 μm, and D90 has a particle size range of about 20 to about 250 μm. In some embodiments, D10 has a particle size range of about 2 to about 4 μm, D50 has a particle size range of about 5 to about 20 μm, and D90 has a particle size range of about 100 to about 300 μm. In some embodiments, D10 has a particle size range of about 2 to about 4 μm, D50 has a particle size range of about 5 to about 20 μm, and D90 has a particle size range of about 20 to about 50 μm. In some embodiments, D10 has a particle size range of about 0.1 to about 5 μm, D50 has a particle size range of about 2 to about 10 μm, and D90 has a particle size range of about 10 to about 35 μm.
[0075] Nilotinib In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib hydrochloride.
[0076] In some embodiments, the pharmaceutical compositions described herein have acceptable shelf life. In some embodiments, the pharmaceutical compositions are shelf stable at 75°C / 75% RH for at least 2 weeks, and the shelf-stable pharmaceutical compositions have less than 100 ppm of impurity A at the end of the shelf life. In some embodiments, the pharmaceutical compositions are shelf stable at 40°C / 75% RH for at least 6 months, and the shelf-stable pharmaceutical compositions have less than 100 ppm of impurity A at the end of the shelf life. In some embodiments, the pharmaceutical compositions are shelf stable at 40°C / 75% RH for at least 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, or 24 months, and the shelf-stable pharmaceutical compositions have less than 100 ppm of impurity A at the end of the shelf life.
[0077] In some embodiments, the pharmaceutical compositions described herein have excellent bioavailability.In some embodiments, the pharmaceutical compositions exhibit a bioavailability that is measured as the total area under the curve (AUC) after oral administration that is at least 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 5.5 times, 6 times, 7 times, 8 times, 9 times, or 10 times higher than the bioavailability of the corresponding formulation containing crystalline nilotinib.In some embodiments, the pharmaceutical compositions exhibit a C maxThe crystalline nilotinib exhibits a bioavailability, measured as a function of time, that is at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater than the bioavailability of the corresponding formulation containing crystalline nilotinib. In some embodiments, the pharmaceutical composition exhibits a bioavailability, measured as the total area under the curve (AUC) after oral administration, that is at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater than the bioavailability of TASIGNA capsules containing nilotinib HCl. In some embodiments, the pharmaceutical composition exhibits a C max In some embodiments, the pharmaceutical composition exhibits a bioavailability, measured as a C after oral administration, that is at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater than the bioavailability of TASIGNA capsules containing nilotinib HCl. maxIn some embodiments, the pharmaceutical composition exhibits a bioavailability that is greater than the bioavailability of TASIGNA when measured as: about 1.1-fold to about 2-fold, about 1.1-fold to about 3-fold, about 1.1-fold to about 4-fold, about 1.1-fold to about 5-fold, about 1.1-fold to about 6-fold, about 1.1-fold to about 7-fold, about 1.1-fold to about 8-fold, about 1.1-fold to about 10-fold, about 1.5-fold to about 2-fold, about 1.5-fold to about 3-fold, about 1.5-fold to about 4-fold, about 1.5-fold to about 5-fold, about 1.5-fold to about 6-fold, about 1.5-fold to about 7-fold, about 1.5-fold to about 8-fold, about 1.5-fold to about 10-fold, about 2-fold to about 4-fold, about 2-fold to about 5-fold, about 2-fold to about 5-fold, or about 2-fold greater than the bioavailability of TASIGNA. about 6-fold, about 2-fold to about 7-fold, about 2-fold to about 8-fold, about 2-fold to about 10-fold, about 3-fold to about 4-fold, about 3-fold to about 5-fold, about 3-fold to about 6-fold, about 3-fold to about 7-fold, about 3-fold to about 8-fold, about 3-fold to about 10-fold, about 4-fold to about 5-fold, about 4-fold to about 6-fold, about 4-fold to about 7-fold, about 4-fold to about 8-fold, about 4-fold to about 10-fold, about 5-fold to about 6-fold, about 5-fold to about 7-fold, about 5-fold to about 8-fold, about 5-fold to about 10-fold, about 6-fold to about 7-fold, about 6-fold to about 8-fold, about 6-fold to about 10-fold, about 7-fold to about 8-fold, about 7-fold to about 10-fold, or about 8-fold to about 10-fold higher bioavailability. In some embodiments, the pharmaceutical composition exhibits a bioavailability that is at least about 1.1-fold, about 1.3-fold, about 1.5-fold, about 1.8-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, or about 8-fold greater than that of TASIGNA. In some embodiments, the pharmaceutical composition exhibits a bioavailability that is at least about 2-fold greater than that of TASIGNA. In some embodiments, the pharmaceutical composition exhibits a bioavailability that is at least about 4-fold greater than that of TASIGNA. In some embodiments, the pharmaceutical composition exhibits a bioavailability that is up to about 1.3-fold, about 1.5-fold, about 1.8-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, or about 10-fold greater than that of TASIGNA. In some embodiments, bioavailability is measured in a fasted dog model. In some embodiments, bioavailability is measured in a fed state dog model.In some embodiments, the bioavailability of the pharmaceutical composition, as measured by the total area under the curve (AUC) after oral administration, does not change by more than 50%, 40%, 30%, 20%, 15%, or 10% when administered in the fed state compared to when administered in the fasted state. In some embodiments, the bioavailability of the pharmaceutical composition, as measured by the total area under the curve (AUC) after oral administration, does not change by more than 50%, 40%, 30%, 20%, 15%, or 10% when administered in the fed state compared to when administered in the fasted state. max When measured as a function of time, the bioavailability of the pharmaceutical composition does not change by more than 50%, 40%, 30%, 20%, 15%, or 10% when administered in a fed state compared to when administered in a fasted state. In some embodiments, the bioavailability of the pharmaceutical composition does not change by more than 50% when administered orally in a fed state compared to when administered in a fasted state. In some embodiments, the bioavailability of the pharmaceutical composition does not change by more than 40% when administered orally in a fed state compared to when administered in a fasted state. In some embodiments, the bioavailability of the pharmaceutical composition does not change by more than 20% when administered orally in a fed state compared to when administered in a fasted state.
[0078] In some embodiments, the pharmaceutical compositions described herein comprise an amorphous solid dispersion. In some embodiments, the amorphous solid dispersion comprises an API. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib hydrochloride. In some embodiments, the API is a compound of Formula (I), or an N-oxide or a pharmaceutically acceptable salt thereof:
[0079] [ka] During the ceremony, R 1 is hydrogen, C1-C6 alkyl, or halogen; R A is hydrogen, C1-C6 alkyl, C 1-6 Alkoxy-C 1-6 Alkyl, acyloxy-C 1-6Alkyl, carboxy-C 1-6 Alkyl, C 1-6 Alkoxycarbonyl-C 1-6 Alkyl, or phenyl-C 1-6 is alkyl, R B is hydrogen, optionally and independently, one or more R 10 , C1-C6 alkyl substituted by a cycloalkyl, benzcycloalkyl, heterocyclyl, aryl group, or a mono- or bicyclic heteroaryl group containing 0, 1, 2, or 3 ring nitrogen atoms and 0 or 1 oxygen atom and 0 or 1 sulfur atom, in each case the group is unsubstituted, mono- or polysubstituted; R 10 is hydroxy, C1-C6 alkoxy, acyloxy, carboxy, C 1-6 represents an alkoxycarbonyl, carbamoyl, N-monosubstituted or N,N-disubstituted carbamoyl, amino, monosubstituted or disubstituted amino, cycloalkyl, heterocyclyl, aryl group, or a monocyclic or bicyclic heteroaryl group containing 0, 1, 2, or 3 ring nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom, in each case the group is unsubstituted, monosubstituted, or polysubstituted; or R A and R B together form a C4-C6 alkylene optionally mono- or di-substituted by C1-C6 alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, C1-C6 alkoxy, amino, mono- or di-substituted amino, oxo, pyridyl, pyrazinyl, or pyrimidinyl, a benzalkylene having 4 or 5 carbon atoms, an oxaalkylene having one oxygen and 3 or 4 carbon atoms, or an azaalkylene having one nitrogen and 3 or 4 carbon atoms, wherein the nitrogen is unsubstituted or is selected from the group consisting of C1-C6 alkyl, phenyl-C1-C6 alkyl, C 1-6 Alkoxycarbonyl-C 1-6 Alkyl, carboxy-C 1-6 Alkyl, Carbamoyl-C 1-6Alkyl, N-monosubstituted or N,N-disubstituted carbamoyl-C 1-6 Alkyl, cycloalkyl, C 1-6 Substituted by alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl.
[0080] In some embodiments, the API is a compound of formula (I), or an N-oxide or a pharmaceutically acceptable salt thereof: R 1 is hydrogen, C1-C6 alkyl, or halogen; R A is hydrogen, C1-C6 alkyl, C 1-6 Alkoxy-C 1-6 alkyl, or benzyl; R B is C1-C6 alkyl, trifluoro-C 1-6 Alkyl, Hydroxy-C 1-6 Alkyl, Amino-C 1-6 Alkyl, C 1-6 Alkylamino-C 1-6 Alkyl, Di-C 1-6 Alkylamino-C 1-6 Alkyl, N-cyclohexyl-N-1-6 alkylamino-C 1-6 Alkyl, C 1-6 Alkoxycarbonylpiperidino-C 1-6 Alkyl, NC 1-6 Alkylpiperazino-C 1-6 Alkyl, C 1-6 Alkoxycarbonyl-C 1-6 Alkyl, hydroxy, C1-C6 alkoxy, trifluoro-C 1-6 Alkoxy, 1H-imidazolyl-C 1-6 Alkoxy, C 1-6 Alkanoyloxy, benzoyloxy, carboxy, C 1-6 Alkoxycarbonyl, carbamoyl, C 1-6 Alkylcarbamoyl, Amino, C 1-6 Alkanoylamino, benzoylamino, C1-C6 alkyl, hydroxy-C 1-6 By alkyl or C1-6 Alkoxy-C 1-6 Amino mono- or disubstituted by alkyl, 1H-imidazolyl, C 1-6 Alkyl-1H-imidazolyl, Carboxy-1H-imidazolyl, C 1-6 Alkyl-ester carboxy-1H-imidazolyl, pyrrolidino, piperidino, piperazino, NC 1-6 Alkylpiperazino, morpholino, sulfamoyl, C 1-6 It is phenyl substituted by one or two substituents selected from the group consisting of alkylsulfonyl, phenyl, pyridyl, halogenyl, or benzoyl.
[0081] In some embodiments, the API is a compound of formula (I) or a pharmaceutically acceptable salt thereof: During the ceremony, R 1 is methyl, R A is hydrogen, R B is trifluoromethyl, and optionally hydroxy-C 1-6 Alkyl, C 1-6 Alkylamino, Hydroxy-C 1-6 Alkylamino, Di-C 1-6 Alkylamino, 1H-imidazolyl, C 1-6 Alkyl-1H-imidazolyl, carbamoyl, C 1-6 Alkylcarbamoyl, pyrrolidino, piperidino, piperazino, C 1-6 Alkylpiperazino, morpholino, C1-C6 alkoxy, trifluoro-C 1-6 and phenyl substituted by a further substituent selected from the group consisting of alkoxy, phenyl, pyridyl, and halogenyl.
[0082] In some embodiments, the API is a compound of formula (I), or an N-oxide or a pharmaceutically acceptable salt thereof: R 1 is methyl, R A is hydrogen, RB is phenyl substituted by 5-trifluoromethyl and optionally further substituents selected from the group consisting of 2-methyl-1H-imidazolyl, 4-methyl-1H-imidazolyl, 2,4-dimethyl-1H-imidazolyl, 5-methyl-1H-imidazolyl, 2-methoxymethylamino, propoxy, ethoxy, methylaminocarbonyl, benzoyl, 4-methoxy-2-methyl, acetylamino, 2,4-dimethyl-1H-imidazolyl, acetic acid ethyl ester, piperidinecarboxylic acid ethyl ester.
[0083] General terms used herein preferably have the following meanings within the context of this disclosure, unless otherwise indicated:
[0084] The prefix "under" denotes a radical containing up to 7, especially up to 4, carbon atoms, the radical being either linear or branched with single or multiple branches.
[0085] Where the plural is used for compounds, salts, etc., this is taken to mean also a single compound, salt, etc.
[0086] Any asymmetric carbon atom can be present in the (R)-, (S)-, or (R,S)-configuration, preferably in the (R)- or (S)-configuration. Thus, the compounds can be present as mixtures of isomers or as pure isomers, preferably as enantiomer-pure diastereomers.
[0087] The present disclosure also relates to possible tautomers of the compounds of formula (I).
[0088] Lower alkyl is preferably alkyl having 1 to a maximum of 6, preferably 1 to 4, straight-chain or branched, preferably lower alkyl is butyl, e.g., n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, e.g., n-propyl or isopropyl, ethyl, or methyl. Preferably, lower alkyl is methyl, propyl, or tert-butyl.
[0089] Lower acyl is preferably formyl or lower alkylcarbonyl, especially acetyl.
[0090] An aryl group is an aromatic radical that is attached to a molecule via a bond located on an aromatic ring carbon atom of the radical. In a preferred embodiment, aryl is an aromatic radical having 6 to 14 carbon atoms, in particular phenyl, naphthyl, tetrahydronaphthyl, fluorenyl, or phenanthrenyl, unsubstituted or substituted with amino, mono- or disubstituted amino, halogen, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, phenyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, benzoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, ureido, mercapto, sulfo, lower alkylthio, phenylthio, phenyl-lower alkylthio, lower substituted by one or more, preferably up to three, in particular one or two, substituents selected from alkylphenylthio, lower alkylsulfinyl, phenylsulfinyl, phenyl-lower alkylsulfinyl, lower alkylphenylsulfinyl, lower alkylsulfonyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, lower alkylphenylsulfonyl, halogen-lower alkylmercapto, halogen-lower alkylsulfonyl, such as, in particular, trifluoromethanesulfonyl, dihydroxyborane (-B(OH)2), heterocyclyl, mono- or bicyclic heteroaryl groups, and lower alkylenedioxy, such as, in particular, methylenedioxy, bonded at adjacent C atoms of the ring.Aryl is more preferably phenyl, naphthyl or tetrahydronaphthyl, which is in each case unsubstituted or etherified by halogen, in particular fluorine, chlorine or bromine, hydroxy, lower alkyl, for example by methyl, halogen-lower alkyl, for example by trifluoromethyl, or by phenyl, lower alkylenedioxy attached to two adjacent C-atoms, for example methylenedioxy, lower alkyl, for example methyl or propyl, halogen-lower alkyl, for example trifluoromethyl, hydroxy-lower alkyl, for example hydroxymethyl or 2-hydroxy-2-propyl, lower alkoxy-lower alkyl, for example methoxymethyl or 2-methoxyethyl, lower alkoxycarbonyl-lower alkyl, for example methoxy-carbonylmethyl, lower alkynyl, for example 1 n-propynyl, esterified carboxy, especially lower alkoxycarbonyl, such as methoxycarbonyl, n-propoxycarbonyl, or iso-propoxycarbonyl, N-monosubstituted carbamoyl, especially carbamoyl monosubstituted by lower alkyl, such as methyl, n-propyl, or iso-propyl, amino, lower alkylamino, such as methylamino, di-lower alkylamino, such as dimethylamino or diethylamino, lower alkyleneamino, such as pyrrolidino or piperidino, lower oxaalkylene-amino, such as morpholino, lower azaalkylene-amino, such as piperazino, acylamino, such as acetylamino or benzoylamino, lower alkylsulfonyl, such as methylsulfonyl, sulfamoyl, or phenylsulfonyl.
[0091] The cycloalkyl group is preferably cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl and may be unsubstituted or substituted by one or more, in particular one or two, substituents selected from the group defined above as substituents for aryl, most preferably by lower alkyl, e.g., methyl, lower alkoxy, e.g., methoxy or ethoxy, or hydroxy, or even oxo, or may be fused to a benzo ring, such as benzcyclopentyl or benzcyclohexyl.
[0092] Substituted alkyl is alkyl as last defined, in particular lower alkyl, preferably methyl, in which one or more, in particular up to three, substituents may be present and may be mainly from the group selected from halogen, in particular fluorine, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, and phenyl-lower alkoxycarbonyl, with trifluoromethyl being particularly preferred.
[0093] Mono- or disubstituted amino especially denotes, independently of one another, lower alkyl, such as methyl, hydroxy-lower alkyl, such as 2-hydroxyethyl, lower alkoxy-lower alkyl, such as methoxyethyl, phenyl-lower alkyl, such as benzyl or 2-phenylethyl, lower alkanoyl, such as acetyl, benzoyl, substituted benzoyl, in which the phenyl radical is substituted by one or more, preferably one or two, substituents selected in particular from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, and carbamoyl, and phenyl-lower alkoxycarbonyl, in which the phenyl radical is unsubstituted or substituted by one or more, preferably one or two, substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, and carbamoyl. and amino substituted by one or two selected radicals, preferably N-lower alkylamino, such as N-methylamino, hydroxy-lower alkyl, such as 2-hydroxyethylamino or 2-hydroxypropyl, lower alkoxy-lower alkyl, such as methoxyethyl, phenyl-lower alkylamino, such as benzylamino, N,N-di-lower alkylamino, N-phenyl-lower alkyl-N-lower alkylamino, N,N-di-lower alkylphenylamino, lower alkanoylamino, such as acetylamino, or alternatively benzoylamino and phenyl-lower alkoxycarbonylamino, where the phenyl radical is in each case unsubstituted or substituted, especially by nitro or amino, or also by halogen, amino, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, carbamoyl, or aminocarbonylamino.
[0094] Disubstituted amino is furthermore lower alkylene-amino, such as pyrrolidino, 2-oxopyrrolidino, or piperidino, lower oxaalkylene-amino, such as morpholino, or lower azaalkylene-amino, such as piperazino, or N-substituted piperazino, such as N-methylpiperazino, or N-methoxycarbonylpiperazino.
[0095] Halogen is in particular fluorine, chlorine, bromine or iodine, especially fluorine, chlorine or bromine.
[0096] Etherified hydroxy is especially C8-C20 alkyloxy, such as n-decyloxy, lower alkoxy (preferred), such as methoxy, ethoxy, isopropyloxy, or tert-butyloxy, phenyl-lower alkoxy, such as benzyloxy, phenyloxy, halogen-lower alkoxy, such as trifluoromethoxy, 2,2,2-trifluoroethoxy, or 1,1,2,2-tetrafluoroethoxy, or lower alkoxy substituted by a mono- or bicyclic heteroaryl containing one or two nitrogen atoms, preferably imidazolyl, such as 1H-imidazol-1-yl, pyrrolyl, benzimidazolyl, such as 1-benzimidazolyl, pyridyl, especially 2-pyridyl, 3-pyridyl, or 4-pyridyl, pyrimidinyl, especially 2-pyrimidinyl, pyrazinyl, isoquinolinyl, especially 3-isoquinolyl, quinolyl, indolyl, or lower alkoxy substituted by thiazolyl.
[0097] Esterified hydroxy is especially lower alkanoyloxy, benzoyloxy, lower alkoxycarbonyloxy, such as tert-butoxycarbonyloxy, or phenyl-lower alkoxycarbonyloxy, such as benzyloxycarbonyloxy.
[0098] Esterified carboxy is especially lower alkoxycarbonyl, for example tert-butoxycarbonyl, iso-propoxycarbonyl, methoxycarbonyl or ethoxycarbonyl, phenyl-lower alkoxycarbonyl, or alternatively phenyloxycarbonyl.
[0099] Alkanoyl is primarily alkylcarbonyl, especially lower alkanoyl, such as acetyl.
[0100] N-monosubstituted- or N,N-disubstituted carbamoyl is in particular substituted by one or two substituents independently selected from lower alkyl, phenyl-lower alkyl, and hydroxy-lower alkyl, or lower alkylene, oxa-lower alkylene, or aza-lower alkylene optionally substituted at the terminal nitrogen atom.
[0101] A monocyclic or bicyclic heteroaryl group containing 0, 1, 2 or 3 ring nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom, in each case unsubstituted or mono- or polysubstituted, refers in formula I to a heterocyclic moiety that is unsaturated in the ring that connects the heteroaryl radical to the rest of the molecule, and is preferably a ring, in which in the connected ring, but optionally also in any annealed ring, at least one carbon atom is replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and in which the connected ring preferably has 5 to 12, more preferably 5 or 6, ring atoms, which may be unsubstituted or substituted by one or more, in particular one or two, substituents selected from the group defined above as substituents for aryl, most preferably by lower alkyl such as methyl, lower alkoxy such as methoxy or ethoxy, or hydroxy. Preferably, the monocyclic or bicyclic heteroaryl group is selected from 2H-pyrrolyl, pyrrolyl, imidazolyl, benzimidazolyl, pyrazolyl, indazolyl, purinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 4H-quinolidinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalyl, quinazolinyl, quinolinyl, pteridinyl, indolizinyl, 3H-indolyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, furazanyl, benzo[d]pyrazolyl, thienyl, and furanyl. More preferably, the monocyclic or bicyclic heteroaryl group is selected from the group consisting of pyrrolyl, imidazolyl, e.g., 1H-imidazol-1-yl, benzimidazolyl, e.g., 1-benzimidazolyl, indazolyl, especially 5-indazolyl, pyridyl, especially 2-pyridyl, 3-pyridyl, or 4-pyridyl, pyrimidinyl, especially 2-pyrimidinyl, pyrazinyl, isoquinolinyl, especially 3-isoquinolinyl, quinolinyl, especially 4-quinolinyl or 8-quinolinyl, indolyl, especially 3-indolyl, thiazolyl, benzo[d]pyrazolyl, thienyl, and furanyl.In one preferred embodiment of the invention, the pyridyl radical is substituted with hydroxy at the ortho position relative to the nitrogen atom and therefore exists, at least in part, in the corresponding tautomeric form, pyridin-(1H)2-one. In another preferred embodiment, the pyrimidinyl radical is substituted with hydroxy at both the 2- and 4-positions and therefore exists in multiple tautomeric forms, for example, as pyrimidine-(1H,3H)2,4-dione.
[0102] Heterocyclyl is in particular a 5-, 6- or 7-membered heterocyclic ring system having one or two heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, which may be unsaturated or fully or partially saturated and is unsubstituted or substituted, in particular by lower alkyl, for example methyl, phenyl-lower alkyl, for example benzyl, oxo, or heteroaryl, for example 2-piperazinyl, heterocyclyl being in particular 2-pyrrolidinyl or 3-pyrrolidinyl, 2-oxo-5-pyrrolidinyl, piperidinyl, N-benzyl-4-piperidinyl, N-lower alkyl-4-piperidinyl, N-lower alkyl-piperazinyl, morpholinyl, for example 2-morpholinyl or 3-morpholinyl, 2-oxo-1H-azepin-3-yl, 2-tetrahydrofuranyl, or 2-methyl-1,3-dioxolan-2-yl.
[0103] In some embodiments, the salt of the compound of Formula (I) is formed between a basic nitrogen atom (e.g., a pharmaceutically acceptable salt) and the compound of Formula (I), for example, as an acid addition salt (e.g., with an organic or inorganic acid). Suitable inorganic acids are, for example, halogen acids such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic acids, phosphonic acids, sulfonic acids, or sulfamic acids, acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, Other organic protic acids such as methanesulfonic acid or ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5-naphthalene-disulfonic acid, 2-methylbenzenesulfonic acid, 3-methylbenzenesulfonic acid, or 4-methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methylsulfamic acid, N-ethylsulfamic acid, or N-propylsulfamic acid, or ascorbic acid.
[0104] In the presence of negatively charged radicals such as carboxy or sulfo, salts may also be formed with bases, for example metal or ammonium salts, for example alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, for example tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'-dimethylpiperazine.
[0105] When a basic group and an acid group are present in the same molecule, the compounds of formula I can also form internal salts.
[0106] For isolation or purification purposes, it is also possible to use pharmaceutically unacceptable salts, such as picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (if applicable in the form of pharmaceutical preparations) and are therefore preferred.
[0107] surfactants In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and one or more surfactants. In some embodiments, the pharmaceutical compositions described herein comprise an amorphous solid dispersion comprising a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the pharmaceutical compositions described herein comprise an amorphous solid dispersion comprising a lipophilic API, a hydrophilic polymer, and one or more surfactants. In some embodiments, the API is an API in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the surfactant is a compound or a mixture of compounds comprising a hydrophobic group (usually a hydrocarbon chain) and a hydrophilic group. A surfactant may fulfill one or more functions, including solubility enhancer, bioavailability enhancer, stability enhancer, antioxidant, and emulsifying agent. Other terms in the art for surfactants include emulsifier, emulsifier, surface-active agent, wetting agent, suspending agent, etc. Examples of surfactants include, but are not limited to, phospholipids, sucrose fatty acid esters, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyl 40 hydrogenated castor oil, macrogolglycerol hydroxystearate oil, PEG-40 castor oil, Kolliphor RH40, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, polysorbate, glyceryl monostearate, sodium lauryl sulfate, sodium dodecyl sulfate, lauromacrogol Arlasolve, poloxamer, Labrafil, Labrasol, Tween 80, tocopherol polyethylene glycol 1000 succinate (simply TPGS or vitamin E TPGS), etc. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof.In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the lipophilic API has a calculated log P of at least 2.0. In some embodiments, the lipophilic API is one listed in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API, hydrophilic polymer, and surfactant are formulated as an amorphous solid dispersion. The surfactant used in the present disclosure can be one or more nonionic surfactants, one or more ionic surfactants, or a mixture thereof. In some embodiments, the nonionic surfactant does not have a charged group at its head. Exemplary nonionic surfactants include, but are not limited to, fatty alcohols, cetyl alcohol, stearyl alcohol, cetostearyl alcohol, and oleyl alcohol. Exemplary nonionic surfactants include, but are not limited to, polyethylene glycol alkyl ethers (such as octaethylene glycol monododecyl ether, pentaethylene glycol monododecyl ether), polypropylene glycol alkyl ethers, glucoside alkyl ethers (such as decyl glucoside, lauryl glucoside, octyl glucoside), polyethylene glycol octylphenyl ether (such as Triton X-100), polyethylene glycol alkylphenyl ethers (such as nonoxynol-9), glycerol alkyl esters (such as glyceryl laurate), polyoxyethylene glycol sorbitan alkyl esters (such as polysorbates), sorbitan alkyl esters (such as Spans), cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene glycol (such as poloxamers), polyethoxylated tallow amine (POEA), and tocopherol polyethylene glycol 1000 succinate (simply TPGS or vitamin E TPGS). In some embodiments, the nonionic surfactant comprises one or more of a fatty alcohol, cetyl alcohol, stearyl alcohol, cetostearyl alcohol, and oleyl alcohol.Exemplary nonionic surfactants include, but are not limited to, polyethylene glycol alkyl ethers (such as octaethylene glycol monododecyl ether, pentaethylene glycol monododecyl ether), polypropylene glycol alkyl ethers, glucoside alkyl ethers (such as decyl glucoside, lauryl glucoside, octyl glucoside), polyethylene glycol octylphenyl ether (such as Triton X-100), polyethylene glycol alkylphenyl ethers (such as nonoxynol-9), glycerol alkyl esters (such as glyceryl laurate), polyoxyethylene glycol sorbitan alkyl esters (such as polysorbates), sorbitan alkyl esters (such as Spans), cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene glycol (such as poloxamers), polyethoxylated tallow amine (POEA), and tocopherol polyethylene glycol 1000 succinate (simply TPGS or vitamin E TPGS). In some embodiments, the nonionic surfactant comprises vitamin E, a block copolymer of polyethylene glycol and polypropylene glycol, or any combination thereof. In some embodiments, the surfactant comprises two or more repeating units, such as polyoxyalkylene units. In some embodiments, the surfactant is a nonionic surfactant comprising polyethylene glycol. In some embodiments, the polymeric nonionic surfactant is a block copolymer of polyethylene glycol and polypropylene glycol. In some embodiments, the pharmaceutical composition or amorphous solid dispersion comprises a polysorbate (e.g., polysorbate 20, polysorbate 80). In some embodiments, the pharmaceutical composition or amorphous solid dispersion comprises tocopheryl polyethylene glycol succinate (TPGS). In some embodiments, the pharmaceutical composition or amorphous solid dispersion comprises polyethylene glycol castor oil, e.g., PEG-40 castor oil. In some embodiments, the pharmaceutical composition or amorphous solid dispersion comprises sorbitan oleate.In some embodiments, the pharmaceutical composition or amorphous solid dispersion comprises two surfactants.
[0108] In some embodiments, the ionic surfactant has a charged group at its head. In some embodiments, the ionic surfactant has an anionic head group or a cationic head group. In some embodiments, exemplary ionic surfactants include sodium lauryl sulfate, sodium dodecyl sulfate, calcium oleate, triethanolamine oleate, sodium doxerate, benzalkonium chloride, and cetylpyridinium chloride. In some embodiments, the surfactant is a mixture of one or more nonionic surfactants and one or more ionic surfactants.
[0109] In some embodiments, the nonionic surfactant has a number average molecular weight of about 1000 to about 100,000 Da, 2000 to about 20,000 Da, about 4000 to about 15,000 Da, about 6000 to about 12,000 Da, or about 7000 to about 10,000 Da. In some embodiments, the nonionic surfactant has a number average molecular weight of about 7,000 to about 10,000 Da. In some embodiments, the nonionic surfactant has an ethylene glycol content of about 30 wt% to about 99 wt%, about 50 wt% to about 95 wt%, about 60 wt% to about 95 wt%, about 75 wt% to about 90 wt%, or about 80 wt% to about 85 wt%. In some embodiments, the nonionic surfactant has an ethylene glycol content of about 80 wt% to about 85 wt%.
[0110] In some embodiments, the surfactant is selected from fatty acids, phospholipids, sphingolipids, glycolipids, polyketides, sterol lipids, prenol lipids, etc. In some embodiments, the phospholipid is composed of glycerol with a phosphate group attached and two fatty acids. Other terms used in the art for phospholipids include glycerophospholipid, phosphoglyceride, diacylglyceride, etc. The phosphate group can be unmodified (i.e., R=H structure below) or modified by attachment to a simple organic molecule such as, but not limited to, choline, ethanolamine, or serine (i.e., R≠H structure below). The phospholipid can be further modified by one or more substitutions on the hydrocarbon chain.
[0111] [ka]
[0112] The pharmaceutical compositions and amorphous solid dispersions described herein may contain phospholipids. In some embodiments, the phospholipids are selected from glycerophospholipids, sphingolipids, and / or phospholipid derivatives. In some embodiments, the glycerophospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, diphosphatidylglycerol, phosphatidylinositol, and mixtures thereof. Phospholipid derivatives of the present invention include, but are not limited to, dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipentadeanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), diarachidonylphosphatidylcholine (DAPC), dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine (DPPE), distearoylphosphatidylethanolamine (DSPE), distearoylphosphatidylglycerol (DSPG), phosphatidylinositol, dipalmitoylphosphatidic acid (DPPA), distearoylphosphatidic acid (DSPA), and the like, and mixtures thereof. In some embodiments, the phospholipids comprise at least 40%, 50%, 60%, 70%, 80%, 90%, or 95% by weight of phosphatidylcholine, hi some embodiments, the phospholipids comprise more than 80% phosphatidylcholine.
[0113] In some embodiments, the phospholipid is present in the pharmaceutical composition in an amount of about 25 mg to about 200 mg. In some embodiments, the phospholipid is present in an amount of about 50 mg to 150 mg. In some embodiments, the phospholipid comprises 2.5% to 20% of the total weight of the pharmaceutical composition. In some embodiments, the phospholipid comprises 5% to 17% of the total weight of the pharmaceutical composition. In some embodiments, the phospholipid comprises greater than 80% phosphatidylcholine.
[0114] In some embodiments, the phosphatidylcholine contains a choline group (MeN + It is a phospholipid in which a phosphate group is attached to the phosphate group.
[0115] [ka]
[0116] The pharmaceutical compositions and amorphous solid dispersions described herein can include phosphatidylcholine. A non-limiting example of a phosphatidylcholine is 1-oleoyl-2-palmitoyl-phosphatidylcholine, as shown below.
[0117] [ka]
[0118] In some embodiments, the surfactant is lecithin. The USP 40 definition of lecithin is "a complex mixture of acetone-insoluble phospholipids, isolated from crude vegetable oil sources, consisting primarily of phosphatidylcholine, phosphatidylethanolamine, phosphatyrinositol, and phosphatidic acid, with varying amounts of other substances, such as triglycerides, fatty acids, and carbohydrates." In some embodiments, the lecithin is a mixture of phospholipids. Lecithin can be isolated from a variety of sources, including, but not limited to, eggs, soybeans, milk, marine sources, rapeseed, cottonseed, and sunflower. In some embodiments, the lecithin used in the disclosed amorphous solid dispersions and / or pharmaceutical compositions is isolated from egg yolk.
[0119] In some embodiments, the surfactant is a phospholipid. In some embodiments, the phospholipid is a phosphatidylcholine. In some embodiments, the phospholipid is a mixture that includes phosphatidylcholine. In some embodiments, the surfactant is lecithin. In some embodiments, the lecithin is a mixture of phospholipids. In some embodiments, the lecithin is composed of phosphatidylcholine. In some embodiments, the lecithin comprises more than 25% phosphatidylcholine. In some embodiments, the lecithin comprises more than 80% phosphatidylcholine. In some embodiments, the phosphatidylcholine is derived from an egg source. In some embodiments, the phosphatidylcholine is derived from a soybean source.
[0120] In some embodiments, the surfactant is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of about 25 mg to about 125 mg. In some embodiments, the surfactant is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of about 50 mg to about 100 mg. In some embodiments, the surfactant is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of about 25 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, or about 125 mg. In some embodiments, the surfactant is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of at least about 25 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, or about 120 mg. In some embodiments, the surfactant is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of up to about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, or about 125 mg. In some embodiments, the lecithin is present in an amount of 50 mg to 500 mg. In some embodiments, the lecithin is present in an amount of 75 mg to 300 mg. In some embodiments, the lecithin is present in an amount of 100 mg to 200 mg. In some embodiments, the lecithin is present in an amount of 125 mg to 175 mg. In some embodiments, the lecithin is present in an amount of about 50, 75, 100, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, or 500 mg. In some embodiments, the surfactant is or comprises a phospholipid. In some embodiments, the phospholipid is or comprises lecithin. In some embodiments, the surfactant is or comprises poloxamer. In some embodiments, the surfactant is or comprises TPGS.In some embodiments, the surfactant is or includes a non-ionic surfactant, such as a polysorbate (e.g., polysorbate 20, polysorbate 80), tocopherol polyethylene glycol succinate (TPGS), polyethylene glycol castor oil (e.g., PEG-40 castor oil), and / or sorbitan oleate.
[0121] In some embodiments, the weight ratio of API to surfactant is about 2:1 to about 1:10. In some embodiments, the weight ratio of API to surfactant is about 1:0.5 to about 1:6. In some embodiments, the weight ratio of API to surfactant is about 1:0.8 to about 1:5. In some embodiments, the weight ratio of API to surfactant is about 1:0.8 to about 1:3. In some embodiments, the weight ratio of API to surfactant is about 1:1 to about 1:3. In some embodiments, the weight ratio of API to surfactant is about 1:0.8 to about 1:2.8. In some embodiments, the weight ratio of API to surfactant is about 1:0.8 to about 1:2.5. In some embodiments, the weight ratio of API to surfactant is about 1:1 to about 1:2. In some embodiments, the weight ratio of API to surfactant is about 1:1 to about 1:1.5. In some embodiments, the weight ratio of API to surfactant is about 1:1 to about 1:4. In some embodiments, the weight ratio of API to surfactant is about 1:1 to about 1:3.5. In some embodiments, the surfactant is a phospholipid. In some embodiments, the phospholipid is lecithin. In some embodiments, the surfactant is a poloxamer. In some embodiments, the surfactant is TPGS.
[0122] In some embodiments, the surfactant is present in the amorphous solid dispersion at about 10% to about 40% weight percent. In some embodiments, the surfactant is present in the amorphous solid dispersion at about 15% to about 30% weight percent. In some embodiments, the surfactant is present in the amorphous solid dispersion at about 10%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 40% weight percent. In some embodiments, the surfactant is present in the amorphous solid dispersion at at least about 10%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 40% weight percent. In some embodiments, the surfactant is present in the solid amorphous dispersion at a weight percent of up to about 10%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, or about 40%. In some embodiments, the surfactant is a phospholipid. In some embodiments, the phospholipid is lecithin. In some embodiments, the surfactant is a poloxamer.
[0123] In some embodiments, lecithin is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 225 mg, or 250 mg or more. In some embodiments, lecithin is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of about 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 225 mg, or 250 mg. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0124] In some embodiments, the phospholipid is present in an amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of 50 mg to 500 mg. In some embodiments, the phospholipid is present in an amount of 75 mg to 300 mg. In some embodiments, the phospholipid is present in an amount of 100 mg to 200 mg. In some embodiments, the phospholipid is present in an amount of 125 mg to 175 mg. In some embodiments, the phospholipid is present in an amount of about 50, 75, 100, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, or 500 mg. In some embodiments, the phospholipid is present in an amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of less than or equal to 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 225 mg, 250 mg, 300 mg, or 500 mg. In some embodiments, the phospholipid is present in the amorphous solid dispersion or pharmaceutical composition disclosed herein in an amount of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 225 mg, 250 mg.
[0125] In some embodiments, the phospholipid comprises 0.1% to 50% of the total weight of the compositions described herein. In some embodiments, the composition is an amorphous solid dispersion. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the phospholipid comprises 1% to 30% of the total weight of the pharmaceutical composition. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the phospholipid comprises 5% to 20% of the total weight of the pharmaceutical composition. In some embodiments, the phospholipid comprises 10% to 17% of the total weight of the pharmaceutical composition. In some embodiments, the phospholipid comprises about 15% of the total weight of the pharmaceutical composition. In some embodiments, the phospholipid comprises about 16% of the total weight of the pharmaceutical composition. In some embodiments, the phospholipid comprises about 17% of the total weight of the pharmaceutical composition. In some embodiments, the weight ratio of hydrophilic polymer to lecithin is greater than 0.75. In some embodiments, the weight ratio of hydrophilic polymer to lecithin is greater than 1.0. In some embodiments, the weight ratio of hydrophilic polymer to lecithin is greater than 1.1. In some embodiments, the weight ratio of hydrophilic polymer to lecithin is greater than 1.2. In some embodiments, the weight ratio of the hydrophilic polymer to the lecithin is greater than 1.3. In some embodiments, the weight ratio of the hydrophilic polymer to the lecithin is greater than 1.4. In some embodiments, the weight ratio of the hydrophilic polymer to the lecithin is greater than 1.5. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a phospholipid or poloxamer. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a lecithin. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a non-ionic hydrophilic polymer, and a lecithin. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API.In some embodiments, the lipophilic API is one set forth in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API has a log P of 2.0 or greater. In some embodiments, the amorphous solid dispersion comprises a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the amorphous solid dispersion described herein further comprises one or more adsorbents. In some embodiments, the amorphous solid dispersion described herein further comprises one or more other additives. In some embodiments, the other additives comprise organic acids and inorganic acids. In some embodiments, the other additives comprise antioxidants.
[0126] hydrophilic polymer In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, a surfactant, and optionally silicon dioxide. In some embodiments, the API is an API in Table 1, or a pharmaceutically acceptable salt thereof.
[0127] In some embodiments, the pharmaceutical compositions described herein include a hydrophilic polymer. In some embodiments, the hydrophilic polymer includes povidone, HPMC, PVP, polyvinylpolypyrrolidone (PVPP), Kollidon VA64 HP-b-CD and PVA, hydropropyl methylcellulose acetate succinate (HPMCAS), and at least one of polyethylene glycol, polyvinyl acetate, and polyvinylcaprolactam-based graft copolymer (PVAc-PVCap-PEG) or polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol (PCL-PVAc-PEG, also known as Soluplus®). In some embodiments, the PVP includes PVP K30. In some embodiments, the HMPC includes HPMC E5 and HMPC E50.
[0128] In some embodiments, the hydrophilic polymer is present in the amorphous solid dispersion or pharmaceutical composition described herein in an amount of at least 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, or 200 mg. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone K30. In certain embodiments, the hydrophilic polymer is cross-linked polyvinylpyrrolidone. In some embodiments, the hydrophilic polymer is present in the amorphous solid dispersion or pharmaceutical composition described herein in an amount of about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 225 mg, or 250 mg. In some embodiments, the hydrophilic polymer is present in the amorphous solid dispersion or pharmaceutical composition described herein in an amount of 1000 mg, 750 mg, 500 mg, 400 mg, 300 mg, 250 mg, 225 mg, 200 mg, 175 mg, 150 mg, 125 mg, 100 mg, 90 mg, 80 mg, 75 mg, 60 mg, 55 mg, or 50 mg or less. In some embodiments, the hydrophilic polymer is polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose HMPC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone K30. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone VA64. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E5. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E50.
[0129] In some embodiments, the hydrophilic polymer is present in the amorphous solid dispersion or pharmaceutical composition described herein in an amount between 10 mg and 1000 mg. In some embodiments, the hydrophilic polymer is present in an amount between 20 mg and 500 mg. In some embodiments, the hydrophilic polymer is present in an amount between 20 mg and 400 mg. In some embodiments, the hydrophilic polymer is present in an amount between 20 mg and 300 mg. In some embodiments, the hydrophilic polymer is present in an amount between 25 mg and 250 mg. In some embodiments, the hydrophilic polymer is present in an amount between 30 mg and 200 mg. In some embodiments, the hydrophilic polymer is present in an amount between about 50 mg, about 100 mg, or about 150 mg. In some embodiments, the hydrophilic polymer is present in an amount between 50 mg, 100 mg, or 150 mg. In some embodiments, the hydrophilic polymer is present in an amount between about 25 mg and about 200 mg. In some embodiments, the hydrophilic polymer is present in an amount between about 10 mg and about 400 mg. In some embodiments, the hydrophilic polymer is polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose HMPC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone K30. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone VA64. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E5. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E50.
[0130] In some embodiments, the dose may be about, but not limited to, 1.0 mg, 1.5 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21. 5mg, 22mg, 22.5mg, 23mg, 23.5mg, 24mg, 24.5mg, 25mg, 25.5mg, 26mg, 26.5mg, 27mg, 27.5mg, 28mg, 28.5mg, 29mg, 29.5mg, 30mg, 30.5mg, 31mg, 31.5mg, 32mg, 32.5mg, 33mg, 33.5mg, 36mg, 36.5mg, 37mg, 37.5mg, 38mg, 38.5mg, 39mg, 39.5mg, 40mg, 40.5mg, 41mg, 41.5mg, 42mg, 42.5mg, 43mg, 43.5mg, 44mg , 44.5mg, 45mg, 45.5mg, 46mg, 46.5mg, 47mg, 47.5mg, 48mg, 48.5mg, 49mg, 49.5mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 115mg, 120mg, 125mg, 130mg, 135mg, 140mg, 145mg, 150mg, 155mg, 160mg, 165mg, 170mg, 175mg, 180mg, 185mg, 190mg, 200mg, 205mg, 210m g, 215mg, 220mg, 225mg, 230mg, 235mg, 240mg, 245mg, 250mg, 255mg, 260mg, 265mg, 270mg, 275mg, 280mg, 285mg, 290mg, 295mg, 300mg, 305mg, 310mg, 31 5mg, 320mg, 325mg, 326mg, 326.5mg, 327mg, 327.5mg, 328mg, 328.5mg, 329mg, 329.5mg, 330mg, 330.5mg, 331mg, 331.5mg, 332mg, 332.5mg, 333mg, 333.5mg, 334mg, 334.5mg, 335mg, 335.5mg, 336mg, 336.5mg, 337mg, 337.5mg, 338mg, 338.5mg, 339mg, 339.5mg, 340mg, 340.5mg, 341mg, 341.5 mg、342mg、342.5mg、343mg、343.5mg、344mg、344.5mg、345mg、345.5m g、346mg、346.5mg、347mg、347.5mg、348mg、348.5mg、349mg、349.5mg 、350mg、350.5mg、351mg、351.5mg、352mg、352.5mg、353mg、353.5mg、 354mg、354.5mg、355mg、355.5mg、356mg、356.5mg、357mg、357.5mg、3 58mg、358.5mg、359mg、359.5mg、360mg、360.5mg、361mg、361.5mg、36 2mg、362.5mg、363mg、363.5mg、364mg、364.5mg、365mg、365.5mg、366 mg、366.5mg、367mg、367.5mg、368mg、369.5mg、370mg、370.5mg、371 mg、371.5mg、372mg、372.5mg、373mg、373.5mg、374mg、374.5mg、375m g、375.5mg、376mg、376.5mg、377mg、377.5mg、378mg、378.5mg、379mg 、379.5mg、380mg、380.5mg、381mg、381.5mg、382mg、382.5mg、383mg、 383.5mg、384mg、384.5mg、385mg、385.5mg、386mg、386.5mg、387mg、3 87.5mg、388mg、388.5mg、389mg、389.5mg、390mg、390.5mg、391mg、39 1.5mg, 392mg, 392.5mg, 393mg, 393.5mg, 394mg, 394.5mg, 395mg, 395.5mg, 396mg, 396.5mg, 397mg, 397.5mg, 398mg, 398.5mg, 399mg, 399.5mg, 400mg, 405mg, 410mg, 415mg, 420mg, 425mg, 430mg, 435mg, 440mg, 445mg, 450mg, 455mg, 460mg, 465mg, 470mg, 47 5mg, 480mg, 485mg, 490mg, 495mg, 500mg, 505mg, 510mg, 515mg, 520mg, 525mg, 530mg, 535mg, 540mg, 545mg, 550mg, 555 mg, 560mg, 565mg, 570mg, 575mg, 580mg, 585mg, 590mg, 595mg, 600mg, 605mg, 610mg, 615mg, 620mg, 625mg, 630mg, 635m g, 640mg, 645mg, 650mg, 655mg, 660mg, 665mg, 675mg, 680mg, 685mg, 690mg, 695mg, 700mg, 705mg, 710mg, 715mg, 720mg , 725mg, 730mg, 735mg, 740mg, 745mg, 750mg, 755mg, 760mg, 765mg, 770mg, 775mg, 780mg, 785mg, 790mg, 795mg, 800mg , 805mg, 810mg, 815mg, 820mg, 825mg, 830mg, 835mg, 840mg, 845mg, 850mg, 855mg, 860mg, 865mg, 870mg, 875mg, 880mg, Pharmaceutical compositions are provided that include a hydrophilic polymer present in an amount of about 1.0 mg to about 1000 mg, including 885 mg, 890 mg, 895 mg, 900 mg, 905 mg, 910 mg, 915 mg, 920 mg, 925 mg, 930 mg, 935 mg, 940 mg, 945 mg, 950 mg, 955 mg, 960 mg, 965 mg, 970 mg, 975 mg, 980 mg, 985 mg, 990 mg, 995 mg, or 1000 mg. In some embodiments, the composition is an amorphous solid dispersion. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone or HPMC. In some embodiments, the hydrophilic polymer is PVP K30, PVP VA64, HMPC E5, or HMC E50.
[0131] In some embodiments, a pharmaceutical composition is provided comprising about 1 mg to about 500 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 10 mg to about 400 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 25 mg to about 200 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 125 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 100 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 100 mg to about 125 mg of a hydrophilic polymer. In some embodiments, the hydrophilic polymer is polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose HMPC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone K30. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone VA64. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E5. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E50. In some embodiments, the composition is an amorphous solid dispersion.
[0132] In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 55 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 60 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 65 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 70 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 80 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 85 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 90 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 95 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 100 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 105 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 110 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 115 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 120 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 125 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 130 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 135 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 140 mg to about 150 mg of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 145 mg to about 150 mg of a hydrophilic polymer.In some embodiments, the hydrophilic polymer is polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose HMPC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone K30. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone VA64. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E5. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E50. In some embodiments, the composition is an amorphous solid dispersion.
[0133] In some embodiments, the hydrophilic polymer comprises about 5% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer comprises about 10% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer comprises about 15% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer comprises about 20% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer comprises about 25% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer comprises about 30% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer comprises about 40% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer comprises about 50% of the total weight of the pharmaceutical composition. In some embodiments, the hydrophilic polymer is polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose HMPC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone K30. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone VA64. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E5. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E50. In some embodiments, the composition is an amorphous solid dispersion.
[0134] In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 99% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 80% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 60% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 40% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 20% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 10% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 1% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 20% to about 99% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 20% to about 80% by weight of a hydrophilic polymer. In some embodiments, pharmaceutical compositions are provided comprising about 20% to about 60% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 20% to about 40% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 99% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 80% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 60% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 40% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 40% to about 99% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 40% to about 80% by weight of a hydrophilic polymer. In some embodiments, a pharmaceutical composition is provided comprising about 40% to about 60% by weight of a hydrophilic polymer. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone. In some embodiments, the composition is an amorphous solid dispersion described herein. In some embodiments, the composition is a pharmaceutical composition described herein.
[0135] Formation of an amorphous solid dispersion may require a predetermined particle size of the hydrophilic polymer. In some embodiments, the particle size of the hydrophilic polymer is from about 1 nm to 1 mm. In some embodiments, the particle size of the hydrophilic polymer is from about 0.01 to 1000 μm. In some embodiments, the particle size of the hydrophilic polymer is from about 0.01 μm to 1000 μm. In some embodiments, the particle size of the hydrophilic polymer is from at least about 0.01 μm. In some embodiments, the particle size of the hydrophilic polymer is from at most about 1000 μm. In some embodiments, the particle size of the hydrophilic polymer is from about 1 μm to 50 μm. In some embodiments, the particle size of the hydrophilic polymer is from at least about 1 μm. In some embodiments, the particle size of the hydrophilic polymer is from at most about 50 μm. In some embodiments, the particle size of the hydrophilic polymer is about 1 μm to about 3 μm, about 1 μm to about 7 μm, about 1 μm to about 10 μm, about 1 μm to about 13 μm, about 1 μm to about 17 μm, about 1 μm to about 20 μm, about 1 μm to about 23 μm, about 1 μm to about 27 μm, about 1 μm to about 30 μm, about 1 μm to about 40 μm, about 1 μm to about 50 μm, about 10 μm to about 13 μm, about 10 μm to about 17 μm, about 10 μm to about 20 μm, about 10 μm to about 23 μm, about 10 μm to about 27 μm, about 10 μm to about 30 μm, about 10 μm to about 40 μm, about 10 μm to about 50 μm, about 20 μm to about 27 μm, about 20 μm to about 30 μm, about 20 μm to about 40 μm, about 20 μm to about 50 μm, about 30 μm to about 40 μm, about 30 μm to about 50 μm, or about 40 μm to about 50 μm. In some embodiments, the size of the hydrophilic polymer particles is about 1 μm to 100 μm. In some embodiments, the size of the hydrophilic polymer particles is at least about 1 μm. In some embodiments, the hydrophilic polymer particles have a size of about 0.1, 1, 3, 5, 7, 10, 13, 17, 20, 23, 25, 27, 30, 33, 35, 37, 40, 43, 45, 47, 50, 60, 70, 80, 90, or 100 μm or less, hi some embodiments, the hydrophilic polymer particles have a size of about 20 μm or less.In some embodiments, the hydrophilic polymer is polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose HMPC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone K30. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone VA64. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E5. In certain embodiments, the hydrophilic polymer is polyvinylpyrrolidone HPMC E50.
[0136] In some embodiments, the pharmaceutical composition comprises an amorphous solid dispersion. In some embodiments, the amorphous solid dispersion comprises about 1% to about 90% weight percent of the hydrophilic polymer. In some embodiments, the amorphous solid dispersion comprises about 1% to about 80% weight percent of the hydrophilic polymer. In some embodiments, the amorphous solid dispersion comprises about 10% to about 60% weight percent of the hydrophilic polymer. In some embodiments, the amorphous solid dispersion comprises about 20% to about 50% weight percent of the hydrophilic polymer. In some embodiments, the amorphous solid dispersion comprises about 1%, about 10%, about 20%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 80%, or about 90% weight percent of the hydrophilic polymer. In some embodiments, the solid amorphous dispersion comprises at least about 1%, about 10%, about 20%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, or about 80% weight percent of the hydrophilic polymer, hi some embodiments, the solid amorphous dispersion comprises at most about 10%, about 20%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 80%, or about 90% weight percent of the hydrophilic polymer.
[0137] Adsorbent In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, a surfactant, and optionally an adsorbent. In some embodiments, the API is an API listed in Table 1 or a pharmaceutically acceptable salt thereof. Many adsorbents are solid, porous, or ultraporous adsorbent materials. Adsorbents have numerous micropores or nanopores within their structure, resulting in very large surface areas, e.g., greater than 500 m / g. Exemplary adsorbents include, but are not limited to, silicon dioxide, activated carbon, magnesium aluminum silicate, diatomaceous earth, microcrystalline cellulose (MCC), silicified microcrystalline cellulose (SMCC), talc, cross-linked povidone, sodium carboxymethylcellulose, sodium carboxymethyl starch, and sugars or sugar alcohols, e.g., sorbitol, mannitol, lactose, cyclodextrin, and maltodextrin. In some embodiments, the adsorbent is silicon dioxide.
[0138] In some embodiments, an adsorbent such as silicon dioxide is present in a pharmaceutical composition described herein in an amount of at least 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, or 200 mg. In some embodiments, the silicon dioxide is present in an amount of about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 225 mg, or 250 mg. In some embodiments, the silicon dioxide is present in an amount of less than or equal to 1000 mg, 750 mg, 500 mg, 400 mg, 300 mg, 250 mg, 225 mg, 200 mg, 175 mg, 150 mg, 125 mg, 100 mg, 90 mg, 80 mg, 75 mg, 60 mg, 55 mg, 50 mg, or 25 mg. In some embodiments, the silicon dioxide is present in an amorphous solid dispersion.
[0139] In some embodiments, the adsorbent, such as silicon dioxide, may be present in an amount of, but not limited to, about 1.0 mg, 1.5 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg g, 19mg, 19.5mg, 20mg, 20.5mg, 21mg, 21.5mg, 22mg, 22.5mg, 23mg, 23.5mg, 24mg, 24.5mg, 25mg, 25.5mg, 26mg, 26.5mg, 27mg, 27.5mg, 28mg , 28.5mg, 29mg, 29.5mg, 30mg, 30.5mg, 31mg, 31.5mg, 32mg, 32.5mg, 33mg, 33.5mg, 36mg, 36.5mg, 37mg, 37.5mg, 38mg, 38.5mg, 39mg, 39.5m g, 40mg, 40.5mg, 41mg, 41.5mg, 42mg, 42.5mg, 43mg, 43.5mg, 44mg, 44.5mg, 45mg, 45.5mg, 46mg, 46.5mg, 47mg, 47.5mg, 48mg, 48.5mg, 49mg , 49.5mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 115mg, 120mg, 125mg, 130mg, 135mg, 140mg, 14 In some embodiments, silicon dioxide is present in the pharmaceutical compositions described herein in an amount of about 1.0 mg to about 1000 mg, including 5 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, or 300 mg. In some embodiments, silicon dioxide is present in an amorphous solid dispersion.
[0140] In some embodiments, a pharmaceutical composition is provided that contains about 1 mg to about 500 mg of an adsorbent, such as silicon dioxide. In some embodiments, a pharmaceutical composition is provided that contains about 10 mg to about 400 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 25 mg to about 200 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 50 mg to about 150 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 75 mg to about 125 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 75 mg to about 100 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 100 mg to about 125 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 1 mg to about 200 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 25 mg to about 200 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided that contains about 50 mg to about 200 mg of an adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 125 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 100 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 100 mg to about 125 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 55 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 60 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 65 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 70 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 80 mg to about 150 mg of adsorbent. In some embodiments, pharmaceutical compositions are provided that include about 85 mg to about 150 mg of adsorbent, and in some embodiments, pharmaceutical compositions are provided that include about 90 mg to about 150 mg of adsorbent.In some embodiments, a pharmaceutical composition is provided comprising about 95 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 100 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 105 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 110 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 115 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 120 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 125 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 130 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 135 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 140 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 145 mg to about 150 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 145 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 140 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 135 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 130 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 125 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 120 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 115 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 110 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 105 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 100 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 95 mg of adsorbent.In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 90 mg of adsorbent.In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 85 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 80 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 75 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 70 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 65 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 60 mg of adsorbent. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 55 mg of adsorbent. In some embodiments, the adsorbent comprises about 5% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent comprises about 10% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent comprises about 15% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent comprises about 20% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent comprises about 25% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent comprises about 30% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent comprises about 40% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent comprises about 50% of the total weight of the pharmaceutical composition. In some embodiments, the adsorbent is present in an amorphous solid dispersion. In some embodiments, the silicon dioxide comprises about 5% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide comprises about 10% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide comprises about 15% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide comprises about 20% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide comprises about 25% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide comprises about 30% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide comprises about 40% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide comprises about 50% of the total weight of the pharmaceutical composition. In some embodiments, the silicon dioxide is present in an amorphous solid dispersion.
[0141] In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 99% by weight of an adsorbent, such as silicon dioxide. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 80% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 60% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 40% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 20% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 10% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 0.1% to about 1% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 99% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 80% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 60% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 40% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 99% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 80% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 60% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 30% to about 40% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 40% to about 99% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 40% to about 80% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 40% to about 60% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 15% to about 45% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 25% to about 40% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 20% to about 35% by weight of an adsorbent, and in some embodiments, pharmaceutical compositions are provided that comprise about 25% to about 40% by weight of an adsorbent.In some embodiments, pharmaceutical compositions are provided that comprise about 15% to about 35% by weight of an adsorbent. In some embodiments, pharmaceutical compositions are provided that comprise about 15% to about 50% by weight of an adsorbent. In some embodiments, the adsorbent is present in an amorphous solid dispersion.
[0142] In some embodiments, a sorbent is present in the pharmaceutical composition. In some embodiments, the sorbent powders described herein have an average diameter of 1 to 1,000 nm. In some embodiments, the sorbent particle size is about 0.01 to 1,000 nanometers. In some embodiments, the sorbent particle size is about 0.01 nanometer to about 1,000 nanometers. In some embodiments, the sorbent particle size is at least about 0.01 nanometer. In some embodiments, the sorbent particle size is at most about 1,000 nanometers. In some embodiments, the sorbent particle size is about 1 nanometer to about 500 nanometers. In some embodiments, the sorbent particle size is at least about 1 nanometer. In some embodiments, the sorbent particle size is at most about 500 nanometers. In some embodiments, the particle size of the adsorbent is between about 1 nanometer and about 300 nanometers, between about 1 nanometer and about 700 nanometers, between about 1 nanometer and about 100 nanometers, between about 1 nanometer and about 130 nanometers, between about 1 nanometer and about 170 nanometers, between about 1 nanometer and about 200 nanometers, between about 1 nanometer and about 230 nanometers, between about 1 nanometer and about 270 nanometers, between about 1 nanometer and about 30 nanometers, between about 1 nanometer and about 400 nanometers, between about 1 nanometer and about 500 nanometers, between about 10 nanometers and about 130 nanometers, between about 10 nanometers and about 170 nanometers, between about 10 nanometers ...00 nanometers, between about 1 nanometer and about 230 nanometers, between about 1 nanometer and about 270 nanometers, 0 nanometers to about 200 nanometers, about 100 nanometers to about 230 nanometers, about 100 nanometers to about 270 nanometers, about 100 nanometers to about 300 nanometers, about 100 nanometers to about 400 nanometers, about 100 nanometers to about 500 nanometers, about 200 nanometers to about 270 nanometers, about 200 nanometers to about 300 nanometers, about 200 nanometers to about 400 nanometers, about 200 nanometers to about 500 nanometers, about 300 nanometers to about 400 nanometers, about 300 nanometers to about 500 nanometers, or about 400 nanometers to about 500 nanometers.In some embodiments, the particle size of the adsorbent is about 1 nanometer to about 100 nanometers. In some embodiments, the particle size of the adsorbent is at least about 1 nanometer. In some embodiments, the particle size of the adsorbent is about 0.1, 1, 30, 50, 70, 100, 130, 170, 200, 230, 250, 270, 300, 330, 350, 370, 400, 430, 450, 470, 500, 600, 700, 800, 900, or 1000 nanometers or less. In some embodiments, the adsorbent is a silicon dioxide powder having an average diameter of 1 to 1000 nm. In some embodiments, the silicon dioxide particle size is about 0.01 to 1000 nanometers. In some embodiments, the silicon dioxide particle size is about 0.01 to 1000 nanometers. In some embodiments, the silicon dioxide particles have a size of at least about 0.01 nanometers. In some embodiments, the silicon dioxide particles have a size of at most about 1,000 nanometers. In some embodiments, the silicon dioxide particles have a size of from about 1 nanometer to about 500 nanometers. In some embodiments, the silicon dioxide particles have a size of at least about 1 nanometer. In some embodiments, the silicon dioxide particles have a size of at most about 500 nanometers.In some embodiments, the size of the silicon dioxide particles is from about 1 nanometer to about 300 nanometers, from about 1 nanometer to about 700 nanometers, from about 1 nanometer to about 100 nanometers, from about 1 nanometer to about 130 nanometers, from about 1 nanometer to about 170 nanometers, from about 1 nanometer to about 200 nanometers, from about 1 nanometer to about 230 nanometers, from about 1 nanometer to about 270 nanometers, from about 1 nanometer to about 30 nanometers, from about 1 nanometer to about 400 nanometers, from about 1 nanometer to about 500 nanometers, from about 10 nanometers to about 130 nanometers, from about 10 nanometers ... In some embodiments, the silicon dioxide particle size is from about 1 nanometer to about 100 nanometers. In some embodiments, the silicon dioxide particle size is from about 1 nanometer to about 100 nanometers. In some embodiments, the silicon dioxide particle size is from at least about 1 nanometer. In some embodiments, the size of the silicon dioxide particles is less than or equal to about 0.1, 1, 30, 50, 70, 100, 130, 170, 200, 230, 250, 270, 300, 330, 350, 370, 400, 430, 450, 470, 500, 600, 700, 800, 900, or 1000 nanometers.
[0143] In some embodiments, silicon dioxide is present in the amorphous solid dispersion. In some embodiments, the amorphous solid dispersion is granulated and incorporated into a pharmaceutical composition with an extra granular additive. In some embodiments, silicon dioxide is present outside the amorphous solid dispersion as an extra granular additive. In some embodiments, silicon dioxide is present in the amorphous solid dispersion and is simultaneously an extra granular additive.
[0144] Other additives In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, a surfactant, optionally an adsorbent, and optionally an additional additive or additives. In some embodiments, the API is an API in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, a pharmaceutically acceptable organic or inorganic acid or acid is included as an internal additive and thus part of the solid dispersion. In some embodiments, a pharmaceutically acceptable organic or inorganic acid or acid is included as an external additive that is not part of the solid dispersion. The pharmaceutically acceptable organic acid is selected from the group consisting of tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, aliphatic sulfonic acids (e.g., methanesulfonic acid, ethanesulfonic acid, isethionic acid, etc.), and aromatic sulfonic acids (e.g., benzenesulfonic acid, p-toluenesulfonic acid, etc.), and the pharmaceutically acceptable inorganic acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, etc.
[0145] In some embodiments, the organic or inorganic acid is present in a pharmaceutical composition described herein in an amount of at least 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, or 200 mg. In some embodiments, the organic or inorganic acid is present in an amount of about 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 175 mg, 180 mg, 190 mg, 200 mg, 225 mg, or 250 mg. In some embodiments, the organic or inorganic acid is present in an amount of less than or equal to 1000 mg, 750 mg, 500 mg, 400 mg, 300 mg, 250 mg, 225 mg, 200 mg, 175 mg, 150 mg, 125 mg, 100 mg, 90 mg, 80 mg, 75 mg, 60 mg, 55 mg, 50 mg, or 25 mg. In some embodiments, the organic or inorganic acid is present in the solid amorphous dispersion.
[0146] In some embodiments, the organic or inorganic acid may be present in an amount, including but not limited to, about 1.0 mg, 1.5 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19mg, 19.5mg, 20mg, 20.5mg, 21mg, 21.5mg, 22mg, 22.5mg, 23mg, 23.5mg, 24mg, 24.5mg, 25mg, 25.5mg, 26mg, 26.5mg, 27mg, 27.5mg, 28mg, 2 8.5mg, 29mg, 29.5mg, 30mg, 30.5mg, 31mg, 31.5mg, 32mg, 32.5mg, 33mg, 33.5mg, 36mg, 36.5mg, 37mg, 37.5mg, 38mg, 38.5mg, 39mg, 39.5mg, 40mg, 40.5mg, 41mg, 41.5mg, 42mg, 42.5mg, 43mg, 43.5mg, 44mg, 44.5mg, 45mg, 45.5mg, 46mg, 46.5mg, 47mg, 47.5mg, 48mg, 48.5mg, 49mg, 49.5mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 115mg, 120mg, 125mg, 130mg, 135mg, 140mg, 145 In some embodiments, the organic or inorganic acid is present in the pharmaceutical compositions described herein in an amount of from about 1.0 mg to about 1000 mg, including 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, or 300 mg. ...
[0147] In some embodiments, a pharmaceutical composition is provided comprising about 1 mg to about 500 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 10 mg to about 400 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 25 mg to about 200 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 150 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 125 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 75 mg to about 100 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 100 mg to about 125 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 1 mg to about 200 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 25 mg to about 200 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 200 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 75 mg to about 125 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 75 mg to about 100 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 100 mg to about 125 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 55 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 60 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 65 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, pharmaceutical compositions are provided that include about 70 mg to about 150 mg of an organic or inorganic acid, and in some embodiments, pharmaceutical compositions are provided that include about 75 mg to about 150 mg of an organic or inorganic acid.In some embodiments, a pharmaceutical composition comprising about 80 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 85 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 90 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 95 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 100 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 105 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 110 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 115 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 120 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 125 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 130 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 135 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 140 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 145 mg to about 150 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 145 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 140 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 135 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 130 mg of an organic or inorganic acid is provided. In some embodiments, pharmaceutical compositions are provided that include about 50 mg to about 125 mg of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided that include about 50 mg to about 120 mg of an organic or inorganic acid.In some embodiments, a pharmaceutical composition comprising about 50 mg to about 115 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 110 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 105 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 100 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 95 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 90 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 85 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 80 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 75 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition comprising about 50 mg to about 70 mg of an organic or inorganic acid is provided. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 65 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 60 mg of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 50 mg to about 55 mg of an organic or inorganic acid. In some embodiments, the organic or inorganic acid comprises about 5% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid comprises about 10% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid comprises about 15% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid comprises about 20% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid comprises about 25% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid comprises about 30% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid comprises about 40% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid comprises about 50% of the total weight of the pharmaceutical composition. In some embodiments, the organic or inorganic acid is present in the solid amorphous dispersion.
[0148] In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 99% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 80% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 60% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 40% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 20% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 10% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 0.1% to about 1% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 20% to about 99% by weight of an organic or inorganic acid. In some embodiments, pharmaceutical compositions are provided comprising about 20% to about 80% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 20% to about 60% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 20% to about 40% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 99% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 80% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 60% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 30% to about 40% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 40% to about 99% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 40% to about 80% by weight of an organic or inorganic acid. In some embodiments, a pharmaceutical composition is provided comprising about 40% to about 60% by weight of an organic or inorganic acid.
[0149] The amorphous solid dispersion compositions or pharmaceutical compositions described herein can include one or more preservatives. Preservatives can include antimicrobial agents, antioxidants, and agents that enhance sterility. Typical preservatives include ascorbic acid, ascorbyl palmitate, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), propyl gallate, citric acid, EDTA and its salts, erythorbic acid, fumaric acid, malic acid, propyl gallate, sodium ascorbate, sodium bisulfate, sodium metabisulfite, sodium sulfite, parabens (such as methylparaben, ethylparaben, propylparaben, butylparaben, and their salts), benzoic acid, sodium benzoate, potassium sorbate, vanillin, and the like. In some embodiments, the amorphous solid dispersion compositions or pharmaceutical compositions described herein include an antioxidant. In some embodiments, antioxidants include alpha tocopherol acetate, acetone sodium bisulfite, acetylcysteine, ascorbic acid, vitamin E, ascorbyl palmitate, BHA, BHT, cysteine, cysteine hydrochloride, d-alpha tocopherol (natural or synthetic), dithiothreitol, monothioglycerol, nordihydroguaiaretic acid, propyl gallate, sodium sulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, thiourea, or tocopherol.
[0150] In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, a surfactant, optionally an adsorbent, and optionally an additional additive or additives. In some embodiments, an antioxidant or a mixture of antioxidants is included as an internal additive and thus as part of the solid dispersion. In some embodiments, an antioxidant or a mixture of antioxidants is included as an external additive. Exemplary antioxidants include, but are not limited to, BHT, BHA, gallic acid, propyl gallate, ascorbic acid, ascorbyl palmitate, 4-hydroxymethyl-2,6-di-tert-butylphenol, and tocopherol.
[0151] In some embodiments, the antioxidant is present in a pharmaceutical composition described herein in an amount of at least 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 7.5 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 12.5 mg, 13 mg, 14 mg, 1.5 mg, 16 mg, 17 mg, 17.5 mg, 18 mg, 19 mg, or 20 mg. In some embodiments, the antioxidant is present in an amount of about 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 7.5 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 12.5 mg, 13 mg, 14 mg, 1.5 mg, 16 mg, 17 mg, 17.5 mg, 18 mg, 19 mg, 20 mg, 22.5 mg, or 2.5 mg. In some embodiments, the antioxidant is present in an amount less than or equal to 100 mg, 7.5 mg, 50 mg, 40 mg, 30 mg, 2.5 mg, 22.5 mg, 20 mg, 17.5 mg, 1.5 mg, 12.5 mg, 10 mg, 9 mg, 8 mg, 7.5 mg, 6 mg, 5.5 mg, 5 mg, or 2.5 mg. In some embodiments, the antioxidant is present in an amorphous solid dispersion.
[0152] In some embodiments, the antioxidant may be present in an amount of, but not limited to, about 1.0 mg, 1.5 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16.0 mg, 16.5 mg, 17.0 mg, 17.5 mg, 18.0 mg, 18.5 mg, 19.0 mg, 19.5 mg, 20.0 mg, 20.5 mg, 21.0 mg, 21.5 mg, 22.0 mg, 22.5 mg, 23.0 mg, 23.5 mg, 24.0 mg, 24.5 mg, 25.0 mg, 25.5 mg, 26.0 mg, 26.5 mg, 27.0 mg, 27.5 mg, 28.0 mg, 28.5 mg, 29.0 mg, 30.0 mg, 30.5 mg, 31.0 mg, 31.5 mg, 32.0 mg, 32.5 mg, 33.0 mg, 33.5 mg, 34.0 mg, 34.5 mg, 35.0 mg, 35.5 mg, 36.0 mg, 36.5 mg, 37.0 mg, 37.5 mg, 38.0 mg, 38.5 mg, 39.0 mg, 40.0 mg, 4 .5mg, 15.0mg, 15.5mg, 16mg, 16.5mg, 17mg, 17.5mg, 18mg, 18.5mg, 19mg, 19.5mg, 20mg, 20.5mg, 21mg, 21.5mg, 22mg, 22.5mg, 23mg, 23.5mg, 24mg, 24.5mg, 25mg, 25.5mg, 26mg, 26.5mg, 27mg, 27.5mg, 28mg, 28.5mg, 29mg, 29.5mg, 30mg, 30.5mg, 31mg, 31.5mg, 32mg, 32.5mg, 33mg, 33.5mg, 36mg, 36.5mg, 37mg , 37.5mg, 38mg, 38.5mg, 39mg, 39.5mg, 40mg, 40.5mg, 41mg, 41.5mg, 42mg, 42.5mg, 43mg, 43.5mg, 44mg In some embodiments, the antioxidant is present in the pharmaceutical compositions described herein in an amount of about 1.0 mg to about 100 mg, including 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg. In some embodiments, the antioxidant is present in an amorphous solid dispersion.
[0153] In some embodiments, a pharmaceutical composition is provided comprising about 0.01 mg to about 100 mg of an antioxidant. In some embodiments, the amount of antioxidant is about 0.01 mg to about 100 mg. In some embodiments, the amount of antioxidant is about 0.01 mg to about 0.1 mg, about 0.01 mg to about 1 mg, about 0.01 mg to about 3 mg, about 0.01 mg to about 5 mg, about 0.01 mg to about 7 mg, about 0.01 mg to about 10 mg, about 0.01 mg to about 15 mg, about 0.01 mg to about 20 mg, about 0.01 mg to about 25 mg, about 0.01 mg to about 50 mg, about 0.01 mg to about 100 mg, about 0.1 mg to about 1 mg, about 0.1 mg to about 3 mg, or about 0.1 mg to about 5mg, about 0.1mg to about 7mg, about 0.1mg to about 10mg, about 0.1mg to about 15mg, about 0.1mg to about 20mg, about 0.1mg to about 25mg, about 0.1mg to about 50mg, about 0.1mg to about 100mg, about 1mg to about 3 mg, about 1mg to about 5mg, about 1mg to about 7mg, about 1mg to about 10mg, about 1mg to about 15mg, about 1mg to about 20mg, about 1mg to about 25mg, about 1mg to about 50mg, about 1mg to about 100mg, about 3mg to about 5mg, about 3m g ~ about 7mg, about 3mg - about 10mg, about 3mg - about 15mg, about 3mg - about 20mg, about 3mg - about 25mg, about 3mg - about 50mg, about 3mg - about 100mg, about 5mg - about 7mg, about 5mg - about 10mg, about 5mg - about 1 5mg, about 5mg to about 20mg, about 5mg to about 25mg, about 5mg to about 50mg, about 5mg to about 100mg, about 7mg to about 10mg, about 7mg to about 15mg, about 7mg to about 20mg, about 7mg to about 25mg, about 7mg to about 50m g, about 7 mg to about 100 mg, about 10 mg to about 15 mg, about 10 mg to about 20 mg, about 10 mg to about 25 mg, about 10 mg to about 50 mg, about 10 mg to about 100 mg, about 15 mg to about 20 mg, about 15 mg to about 25 mg, about 15 mg to about 50 mg, about 15 mg to about 100 mg, about 20 mg to about 25 mg, about 20 mg to about 50 mg, about 20 mg to about 100 mg, about 25 mg to about 50 mg, about 25 mg to about 100 mg, or about 50 mg to about 100 mg. In some embodiments, the amount of antioxidant is from about 0.01 mg, about 0.1 mg, about 1 mg, about 3 mg, about 5 mg, about 7 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, or about 100 mg.In some embodiments, the amount of antioxidant is at least about 0.01 mg, about 0.1 mg, about 1 mg, about 3 mg, about 5 mg, about 7 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, or about 50 mg. In some embodiments, the amount of antioxidant is at most about 0.1 mg, about 1 mg, about 3 mg, about 5 mg, about 7 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, or about 100 mg. In some embodiments, the antioxidant comprises about 0.001% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 0.01% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 0.1% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 1% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 2% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 3% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 4% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 5% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 6% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 7% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 8% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 9% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant comprises about 10% of the total weight of the pharmaceutical composition. In some embodiments, the antioxidant is present in an amorphous solid dispersion.
[0154] In some embodiments, pharmaceutical compositions are provided comprising about 0.001% to about 10% by weight of an antioxidant. In some embodiments, the percent weight of the antioxidant is about 0.001% to about 0.01%, about 0.001% to about 0.1%, about 0.001% to about 1%, about 0.001% to about 2%, about 0.001% to about 3%, about 0.001% to about 4%, about 0.001% to about 5%, about 0.001% to about 6%, about 0.001% to about 7%, about 0.001% to about 8%, about 0.001% to about 10%, or about 0. 0.1% to about 0.1%, about 0.01% to about 1%, about 0.01% to about 2%, about 0.01% to about 3%, about 0.01% to about 4%, about 0.01% to about 5%, about 0.01% to about 6%, about 0.01% to about 7%, about 0.01% to about 8%, about 0.01% to about 10%, about 0.1% to about 1%, about 0.1% to about 2%, about 0.1% to about 3%, about 0.1% to about 4%, about 0.1% to about 5%, about 0.1% to about 6 %, about 0.1% to about 7%, about 0.1% to about 8%, about 0.1% to about 10%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1% to about 6%, about 1% to about 7%, about 1% to about 8%, about 1% to about 10%, about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2% to about 6%, about 2% to about 7%, about 2% to about 8%, about 2% to about 10%, about 3% to about 4%, about 3% to About 5%, about 3% to about 6%, about 3% to about 7%, about 3% to about 8%, about 3% to about 10%, about 4% to about 5%, about 4% to about 6%, about 4% to about 7%, about 4% to about 8%, about 4% to about 10%, about 5% to about 6%, about 5% to about 7%, about 5% to about 8%, about 5% to about 10%, about 6% to about 7%, about 6% to about 8%, about 6% to about 10%, about 7% to about 8%, about 7% to about 10%, or about 8% to about 10%. In some embodiments, the percent weight of antioxidant is from about 0.001%, about 0.01%, about 0.1%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, or about 10%. In some embodiments, the percent weight of antioxidant is from at least about 0.001%, about 0.01%, about 0.1%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, or about 8%, hi some embodiments, the percent weight of antioxidant is from at most about 0.01%, about 0.1%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, or about 10%.
[0155] The various internal additives described above can be used alone or together.
[0156] In some embodiments, the pharmaceutical compositions described herein include a lubricant. In some embodiments, the lubricant is silicon dioxide powder. In some embodiments, the silicon dioxide is present in the amorphous solid dispersion. In some embodiments, the silicon dioxide is not present in the amorphous solid dispersion but is included in the pharmaceutical formulation. In some embodiments, the silicon dioxide is present in the amorphous solid dispersion and is a component of the pharmaceutical composition outside the amorphous solid dispersion.
[0157] In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, a surfactant, optionally an adsorbent, optionally an internal additive, and optionally an external additive. In some embodiments, the lipophilic API has a calculated log P of or at least 2.0. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one listed in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, other external additives routinely mixed with the pharmaceutical composition can be included, and these additives are well known in the art. Such additives include, but are not limited to, anti-adherents (anti-blocking agents, glidants, glidants, lubricants) (e.g., talc, magnesium stearate, fumed silica (Carbosil, Aerosil), micronized silica (Syloid No. FP 244, Grace USA), polyethylene glycol, surfactants, waxes, stearic acid, stearates, stearic acid derivatives, starch, hydrogenated vegetable oils, sodium benzoate, sodium acetate, silicon dioxide, leucine, PEG-4000 and magnesium lauryl sulfate), anticoagulants (e.g., acetylated monoglycerides), antifoaming agents (e.g., long-chain alcohols and silicone derivatives), antioxidants (e.g., BHT, BHA, gallic acid, propyl gallate, ascorbic acid, ascorbyl palmitate, 4-hydroxymethyl-2,6-di-tert-butyl ether, methylphenol, tocopherol, etc.), binders (adhesives), i.e., agents that impart adhesive properties to powder materials through particle-to-particle bonding (e.g., matrix binders (dry starch, dry sugars), film binders (starch paste, cellulose, bentonite, sucrose)), chemical binders (e.g., polymeric cellulose derivatives such as carboxymethyl cellulose, sugar syrup, corn syrup, water-soluble polysaccharides (e.g., acacia, tragacanth, guar, alginic acid, etc.), gelatin, gelatin hydrolysate, agar, sucrose,Dextrose, non-cellulosic binders (e.g., PEG, pregelatinized starch, sorbitol, glucose, etc.), buffers (wherein the acid is a pharmaceutically acceptable acid, (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acid, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acid, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propanol ... and propyl acetic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid), wherein the base is a pharmaceutically acceptable base (e.g., amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium bicarbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrosaltite, magnesium aluminum hydroxide, diisopropyl ethylamine, ethanolamine, amine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, or acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acid, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acid, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, parabromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluene pharmaceutically acceptable salts of benzophenone sulfonic acid, and uric acid), chelating agents (e.g., EDTA and EDTA salts), coagulants (e.g., alginic acid), colorants or opacifying agents (opaquants), (e.g., titanium dioxide, food dyes, lakes, natural vegetable colors, iron oxides, silicic acid, sulfuric acid, magnesium hydroxide, and aluminum hydroxide), coolants (e.g., halogenated hydrocarbons (e.g., trichloroethane, trichloroethylene, dichloromethane, fluorotrichloromethane), diethyl ether, and liquid nitrogen), cryoprotectants (e.g.,trehalose, phosphates, citric acid, tartaric acid, gelatin, dextran, mannitol, etc.), diluents or fillers (e.g., lactose, mannitol, talc, magnesium stearate, sodium chloride, potassium chloride, citric acid, spray-dried lactose, hydrolyzed starch, direct compression starch, microcrystalline cellulose, cellulosics, sorbitol, sucrose, sucrose-based materials, calcium sulfate, calcium hydrogen phosphate, and dextrose), disintegrants or superdisintegrants (e.g., crosalmellose sodium, starch, starch derivatives, clays, gums, cellulose, cellulose derivatives, alginates, sodium starch glycolate, and microcrystalline cellulose), hydrogen bonding agents (e.g., magnesium oxide), flavorants or desensitizers (e.g., spray-dried flavorings, essential oils, and ethyl vanillin), ion exchange resins (e.g., styrene / divinylbenzene copolymers and quaternary ammonium compounds), plasticizers (e.g., polyethylene glycol, citric acid esters (e.g., triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate), acetylated monoglycerides, glycerin, triacetin, propylene glycol, phthalates (e.g., diethyl phthalate, dibutyl phthalate), castor oil, sorbitol, and dibutyl acetate. seccate), preservatives (e.g., ascorbic acid, boric acid, sorbic acid, benzoic acid and its salts, parabens, phenol, benzyl alcohol, quaternary ammonium compounds), solvents (e.g., alcohols, ketones, esters, chlorinated hydrocarbons, and water), sweeteners, including natural sweeteners (e.g., maltose, sucrose, glucose, sorbitol, glycerin, and dextrin) and artificial sweeteners (e.g., aspartame, saccharin, and saccharin salts), and thickeners (viscosity modifiers, thickeners), (e.g., sugars, cellulose derivatives, polymers, and alginates).
[0158] Additives may further include proteins (e.g., collagen, gelatin, zein, gluten, mussel protein, lipoproteins), carbohydrates (e.g., alginic acid, carrageenan, cellulose derivatives, pectin, starch, chitosan), gums (e.g., xanthan gum, gum arabic), spermaceti, natural or synthetic waxes, carnauba wax, fatty acids (e.g., stearic acid, hydroxystearic acid), fatty alcohols, sugars, shellac, e.g., sugars (e.g., lactose, sucrose, dextrose), or starch, polysaccharide-based polymers (e.g., maltodextrin and maltodextrin derivatives, dextrates, cyclodextrin and cyclodextrin derivatives), cellulose-based polymers, The material may be a cellulose acetate, cellulose nitrate, cellulose acetate butyrate, cellulose acetate, trimellitic acid, carboxymethylethylcellulose, hydroxypropylmethylcellulose phthalate, or other suitable materials, such as inorganic celluloses (e.g., dicalcium phosphate, hydroxyapatite, tricalcium phosphate, talc, and titania), polyols (e.g., mannitol, xylitol, and sorbitol polyethylene glycol esters), and polymers (e.g., alginate, poly(lactide-co-glycolide), gelatin, cross-linked gelatin, and agar).
[0159] surface modified acid In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, a surfactant, optionally an adsorbent, optionally an internal additive, and optionally an external additive. In some embodiments, the lipophilic API, the hydrophilic polymer, the surfactant, optionally an adsorbent, and optionally an external additive comprise an amorphous solid dispersion. In some embodiments, the API is an API in Table 1 or a pharmaceutically acceptable salt thereof. The external additive differs from the internal additive in that the external additive is not incorporated into the amorphous solid dispersion. In some embodiments, the external additive is an external acid that is not included in the amorphous solid dispersion. In some embodiments, the external acid is an organic acid or an amino acid. In some embodiments, the organic acid is tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, maleic acid, benzenesulfonic acid, or p-toluenesulfonic acid. In some embodiments, the amino acid is glutamic acid, aspartic acid, or an acid salt of glycine, alanine, or serine. In some embodiments, the external acid is a surface-modified acid. In some embodiments, the surface-modified acid comprises a powdered or granular acid, with a neutral salt layer at least partially coating the exterior of the powdered or granular acid. In some embodiments, the surface-modified acid comprises a powdered or granular acid selected from tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, maleic acid, benzenesulfonic acid, p-toluenesulfonic acid, glutamic acid, aspartic acid, and acid salts of glycine, alanine, or serine. In some embodiments, the surface-modified acid comprises a powdered or granular acid selected from tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, and malic acid. In some embodiments, the surface-modified acid comprises a powdered or granular acid selected from tartaric acid.
[0160] In some embodiments, the neutral salt layer reduces the reactivity of the acid with other components of the formulation, such as the active ingredient. Many active ingredients, such as nilotinib, show improved solubility in the presence of acid (see Tables 39 and 40), but degrade over time to form toxic impurities (see Example 5). In some embodiments, formulations with surface-modified acids provide increased solubility while maintaining the stability of the active ingredient.
[0161] In some embodiments, the surface-modified acid is prepared by reacting a basic solution with acid particles (e.g., powdered or granular acid) to form a neutral salt layer on the surface of the acid. In some embodiments, the neutral salt layer comprises anions from the acid and cations from the base. In some embodiments, the basic solution comprises a pharmaceutically acceptable base. In some embodiments, the pharmaceutically acceptable base is selected from sodium carbonate, potassium carbonate, sodium acetate, potassium acetate, sodium stearate, potassium stearate, lysine, arginine, and histidine. In some embodiments, the pharmaceutically acceptable base is a carbonate base.
[0162] In some embodiments, the surface-modified acid is prepared by reacting a basic solution with powdered or granular acid to form a neutral salt layer on the surface of the acid. In some embodiments, the weight concentration of the basic solution is about 1% to about 30%. In some embodiments, the weight concentration of the basic solution is about 5% to about 15%. In some embodiments, the weight concentration of the basic solution is about 1% to about 2.5%, about 1% to about 5%, about 1% to about 7.5%, about 1% to about 10%, about 1% to about 12.5%, about 1% to about 15%, about 1% to about 20%, about 1% to about 25%, about 1% to about 30%, about 2.5% to about 5%, about 2.5% to about 7.5%, about 2.5% to about 10%, about 2.5% to about 12.5%, about 2.5% to about 15%, about 2.5% to about 20%, about 2.5% to about 25%, about 2.5% to about 30%, about 5% to about 7.5%, about 5% to about 10%, about 5% to about 12.5%, about 5% to about 15%, about 5% to about 20%, or about 5% about 25%, about 5% to about 30%, about 7.5% to about 10%, about 7.5% to about 12.5%, about 7.5% to about 15%, about 7.5% to about 20%, about 7.5% to about 25%, about 7.5% to about 30%, about 10% to about 12.5%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 12.5% to about 15%, about 12.5% to about 20%, about 12.5% to about 25%, about 12.5% to about 30%, about 15% to about 20%, about 15% to about 25%, about 15% to about 30%, about 20% to about 25%, about 20% to about 30%, or about 25% to about 30%. In some embodiments, the weight concentration of the basic solution is about 1%, about 2.5%, about 5%, about 7.5%, about 10%, about 12.5%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, the weight concentration of the basic solution is at least about 1%, about 2.5%, about 5%, about 7.5%, about 10%, about 12.5%, about 15%, about 20%, or about 25%. In some embodiments, the weight concentration of the basic solution is at most about 2.5%, about 5%, about 7.5%, about 10%, about 12.5%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, the weight ratio of base to acid is between about 1% and about 20%.In some embodiments, the weight ratio of base to acid is from about 1% to about 2%, from about 1% to about 3%, from about 1% to about 4%, from about 1% to about 5%, from about 1% to about 6%, from about 1% to about 7%, from about 1% to about 8%, from about 1% to about 9%, from about 1% to about 10%, from about 1% to about 15%, from about 1% to about 20%, from about 2% to about 3%, from about 2% to about 4%, from about 2% to about 5%, from about 2% to about 6%, from about 2% to about 7%, from about 2% to about 8%, from about 2% to about 9%, from about 1% to about 10%, from about 1% to about 15%, from about 1% to about 20%, from about 2% to about 3%, from about 2% to about 4%, from about 2% to about 5%, from about 2% to about 6%, from about 2% to about 7%, from about 2% to about 8%, from about 2% to about 9%, from about 2 ... % to about 7%, about 2% to about 8%, about 2% to about 9%, about 2% to about 10%, about 2% to about 15%, about 2% to about 20%, about 3% to about 4%, about 3% to about 5%, about 3% to about 6%, about 3% to about 7%, about 3% to about 8%, about 3% to about 9%, about 3% to about 10%, about 3% to about 15%, about 3% to about 20%, about 4% to about 5%, about 4% to about 6%, about 4% to about 7% , about 4% to about 8%, about 4% to about 9%, about 4% to about 10%, about 4% to about 15%, about 4% to about 20%, about 5% to about 6%, about 5% to about 7%, about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 6% to about 7%, about 6% to about 8%, about 6% to about 9%, about 6% to about 10%, about 6% to about 15%, about 6 In some embodiments, the weight ratio of base to acid is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 10% to about 20%, about 15% to about 20%, about 10% to about 15%, about 10% to about 20%, or about 15% to about 20%. In some embodiments, the weight ratio of base to acid is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, or about 20%. In some embodiments, the weight ratio of base to acid is at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, or about 15%. In some embodiments, the weight ratio of base to acid is at most about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, or about 20%.
[0163] In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 25 mg to about 500 mg. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 50 mg to about 400 mg. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 100 mg to about 300 mg. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 200 mg to about 400 mg. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 50 mg to about 500 mg.In some embodiments, the external acid is from about 50 mg to about 75 mg, from about 50 mg to about 100 mg, from about 50 mg to about 125 mg, from about 50 mg to about 150 mg, from about 50 mg to about 200 mg, from about 50 mg to about 250 mg, from about 50 mg to about 275 mg, from about 50 mg to about 300 mg, from about 50 mg to about 350 mg, from about 50 mg to about 400 mg, from about 50 mg to about 500 mg, from about 75 mg to about 100 mg, from about 75 mg to about 125 mg, from about 75 mg to about 150 mg, from about 75 mg to about 200 mg, from about 75 mg to about 250 mg, from about 75 mg to about 275 mg mg, approx. 75 mg to approx. 300 mg, approx. 75 mg to approx. 350 mg, approx. 75 mg to approx. 400 mg, approx. 75 mg to approx. 500 mg, approx. 100 mg to approx. 125 mg, approx. 100 mg to approx. ~275mg, 100mg~300mg, 100mg~350mg, 100mg~400mg, 100mg~500mg, 125mg~150mg, 125mg~200mg, 125mg~250mg, 125mg~275 mg, approx. 125 mg to approx. 300 mg, approx. 125 mg to approx. 350 mg, approx. 125 mg to approx. 400 mg, approx. 125 mg to approx. 500 mg, approx. 150 mg to approx. 200 mg, approx. 50mg to about 350mg, about 150mg to about 400mg, about 150mg to about 500mg, about 200mg to about 250mg, about 200mg to about 275mg, about 200mg to about 300mg, about 200mg to about 350mg, about 200mg to about 400mg, about 200mg to about It is present in the pharmaceutical composition in an amount of about 500 mg, about 250 mg to about 275 mg, about 250 mg to about 300 mg, about 250 mg to about 350 mg, about 250 mg to about 400 mg, about 250 mg to about 500 mg, about 275 mg to about 300 mg, about 275 mg to about 350 mg, about 275 mg to about 400 mg, about 275 mg to about 500 mg, about 300 mg to about 350 mg, about 300 mg to about 400 mg, about 300 mg to about 500 mg, about 350 mg to about 400 mg, about 350 mg to about 500 mg, or about 400 mg to about 500 mg.In some embodiments, the external acid is present in the pharmaceutical composition in an amount of about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 200 mg, about 250 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, or about 500 mg. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of at least about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 200 mg, about 250 mg, about 275 mg, about 300 mg, about 350 mg, or about 400 mg. In some embodiments, the external acid is present in the pharmaceutical composition in an amount of at most about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 200 mg, about 250 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, or about 500 mg.
[0164] In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of about 1% to about 50%. In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of about 5% to about 30%. In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of about 10% to about 30%. In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of about 5% to about 15%. In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of about 20% to about 40%. In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of about 10% to about 60%. In some embodiments, the external acid is from about 1% to about 5%, from about 1% to about 10%, from about 1% to about 15%, from about 1% to about 20%, from about 1% to about 25%, from about 1% to about 30%, from about 1% to about 35%, from about 1% to about 40%, from about 1% to about 45%, from about 1% to about 50%, from about 5% to about 10%, from about 5% to about 15%, from about 5% to about 20%, from about 5% to about 25%, or 5% to about 30%, about 5% to about 35%, about 5% to about 40%, about 5% to about 45%, about 5% to about 50%, about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 35%, about 10% to about 40%, about 10% to about 45%, about 10% to about 50%, about 15% to about 20%, about 15% to about 25 %, about 15% to about 30%, about 15% to about 35%, about 15% to about 40%, about 15% to about 45%, about 15% to about 50%, about 20% to about 25%, about 20% to about 30%, about 20% to about 35%, about 20% to about 40%, about 20% to about 45%, about 20% to about 50%, about 25% to about 30%, about 25% to about 35%, about 25% to about 40%, The external acid is present in the pharmaceutical composition at a weight percent of about 25% to about 45%, about 25% to about 50%, about 30% to about 35%, about 30% to about 40%, about 30% to about 45%, about 30% to about 50%, about 35% to about 40%, about 35% to about 45%, about 35% to about 50%, about 40% to about 45%, about 40% to about 50%, or about 45% to about 50%. In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%.In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of at least about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, or about 45%. In some embodiments, the external acid is present in the pharmaceutical composition at a weight percent of at most about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%.
[0165] In an exemplary embodiment, the surface-modified acid is prepared by reacting a basic solution of sodium carbonate with powdered tartaric acid to form a neutral salt layer on the tartaric acid. In some embodiments, the aqueous sodium carbonate solution is formulated at a concentration of about 5-30%. The amount of sodium carbonate is about 1-10% by weight relative to the tartaric acid. The formulated aqueous sodium carbonate solution is then added to tartaric acid powder particles having a particle size of about 40-60 mesh. After stirring, the tartaric acid powder particles are dried in a drying oven or fluidized bed to obtain modified tartaric acid powder particles.
[0166] Oral dosage form The pharmaceutical compositions of the present invention can be in the form of a solution, suspension, emulsion, tablet, pill, pellet, capsule, liquid-containing capsule, powder, suppository, emulsion, suspension, or any other form suitable for use. Preferred pharmaceutical compositions are formulated for oral delivery. In some embodiments, the pharmaceutically acceptable vehicle is a capsule. The capsule can be a hard or soft capsule, a push-type gelatin capsule, or a soft, sealed gelatin capsule, and a plasticizer (e.g., glycerol or sorbitol). In some embodiments, the capsule contains about 1000 mg of the pharmaceutical composition. In some embodiments, the capsule contains less than 1000 mg of the pharmaceutical composition. The capsule can be any size. Examples of standard sizes include, but are not limited to, those listed in Table 2 (#000, #00, #0, #1, #2, #3, #4, and #5). In some embodiments, the pharmaceutical composition is a liquid dosage form filled in a hard capsule. In some embodiments, the pharmaceutical composition is a liquid dosage form filled in a soft capsule. In some embodiments, the pharmaceutical composition is a tablet dosage form. In some embodiments, the pharmaceutical composition comprises an amorphous solid dispersion. In some embodiments, the pharmaceutical composition comprises an amorphous solid dispersion in the form of a tablet. In some embodiments, the pharmaceutical composition is in the form of a multi-layer tablet. In some embodiments, the tablet has one, two, three, four, or more layers. In some embodiments, the tablet has an inner core and an outer core.
[0167] [Table 2] See, e.g., Remingo's Pharmaceutical Sciences, pages 1658-1659 (Alfonso Gennaro ed., Mack Publishing Company, Easton Pa., 18 th ed., 1990). In some embodiments, the capsules used herein are size #00 or #0.
[0168] Administration method The pharmaceutical compositions described herein can be administered for the treatment or prevention of diseases. When used to treat or prevent diseases or disorders, the pharmaceutical compositions can be administered or applied alone or in combination with other agents. The pharmaceutical compositions can be administered or applied alone or in combination with other pharmaceutically active agents. Provided herein are methods of treatment and prevention by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a subject in need of such treatment. The subject may be an animal, e.g., a mammal, such as a human. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a phospholipid or poloxamer. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a lecithin. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a non-ionic hydrophilic polymer, and a lecithin. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API, hydrophilic polymer, and surfactant are formulated as an amorphous solid dispersion.
[0169] In some embodiments, the pharmaceutical composition is administered orally. In some embodiments, the pharmaceutical composition is administered in an oral liquid, semi-liquid, or semi-solid dosage form. In some embodiments, the pharmaceutical composition is administered as a solid oral dosage form. In some embodiments, the pharmaceutical composition is administered as a liquid oral dosage form. In some embodiments, the pharmaceutical composition is administered as a pill, tablet, chewable tablet, special tablet, buccal tablet, sublingual tablet, orally disintegrating tablet, capsule, gel capsule, softgel capsule, hardgel capsule, special capsule, buccal capsule, sublingual capsule, orally disintegrating capsule, powder, granule, crystal, or oral dispersion film. In some embodiments, the pharmaceutical composition is administered as a liquid or capsule. In some embodiments, the pharmaceutical composition is administered as a softgel capsule. In some embodiments, the pharmaceutical composition is administered as a hardgel capsule.
[0170] In some embodiments, the pharmaceutical composition is formulated for oral administration. In some embodiments, the pharmaceutical composition is formulated for once-daily administration. In some embodiments, the pharmaceutical composition is formulated for twice-daily administration.
[0171] disease In some embodiments, the pharmaceutical compositions may be used to inhibit Bcr-Abl tyrosine kinase / in a subject in need of inhibiting Bcr-Abl tyrosine kinase. In some embodiments, the subject has a disease or disorder associated with tyrosine kinase. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API, hydrophilic polymer, and surfactant are formulated as an amorphous solid dispersion.
[0172] In one aspect, methods of treating a disease or condition in a subject are described herein. The disease or condition can be cancer. In some embodiments, the pharmaceutical compositions described herein can be used to treat or prevent cancer. In some embodiments, the pharmaceutical compositions can be used to treat or prevent prostate cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, liver cancer, salivary gland cancer, hair loss, acne, hirsutism, ovarian cysts, polycystic ovarian disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration. In some embodiments, the pharmaceutical compositions can be used to treat or prevent prostate cancer. In some embodiments, the pharmaceutical compositions can be used to treat or prevent one or more of leukemia, Philadelphia chromosome (Ph+) positive chronic myeloid leukemia, gastrointestinal stromal tumor, Parkinson's disease, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, castration-recurrent prostate cancer, high-risk castration-sensitive prostate cancer, metastatic high-risk castration-sensitive prostate cancer, hormone-resistant prostate cancer, hormone-resistant prostate cancer, androgen-independent prostate cancer, androgen deprivation-resistant prostate cancer, androgen ablation-resistant prostate cancer, androgen-ablation-independent prostate cancer, antiandrogen-recurrent prostate cancer, metastatic castration-resistant prostate cancer in patients who have previously received chemotherapy including docetaxel, newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer in asymptomatic, mildly affected patients after androgen deprivation therapy failure where chemotherapy is not yet clinically necessary, and metastatic castration-resistant prostate cancer in patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen. In some embodiments, the pharmaceutical compositions are used to treat newly diagnosed adult patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). In some embodiments, the pharmaceutical compositions are used to treat newly diagnosed children with chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). In some embodiments, the pharmaceutical compositions are used to treat chronic phase (CP) and accelerated phase (AP) Ph+ CML in adult patients who are resistant or intolerant to prior therapy, including imatinib.In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a phospholipid or poloxamer. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a lecithin. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a non-ionic hydrophilic polymer, and a lecithin. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one listed in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API, hydrophilic polymer, and surfactant are formulated as an amorphous solid dispersion. In some embodiments, the subject is an adult. In some embodiments, the subject is a child. In some embodiments, the subject is at least 1 year old. In some embodiments, the subject is less than 1 year old. In some embodiments, the subject is 1 to 12 years old. In some embodiments, the subject is 1 to 18 years old. In some embodiments, the subject is 12 to 18 years old. In some embodiments, the subject is at least 18 years old. In some embodiments, the subject is at least 24 years old. In some embodiments, the subject is 1 to 90 years old. In one aspect, described herein are methods of inhibiting tyrosine kinases that target BCR-ABL. In some embodiments, the method comprises administering a pharmaceutical composition or amorphous solid dispersion comprising nilotinib or a salt thereof.
[0173] In some embodiments, the pharmaceutical composition is used to treat a cancer selected from the group consisting of breast cancer, acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancer, AIDS-related lymphoma, anal cancer, appendiceal cancer, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumors, e.g., cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumor, glioma of the visual pathway and hypothalamus, bronchial adenoma, Burkitt's lymphoma, cancer of unknown primary, central nervous system lymphoma, cerebellar astrocytoma, uterine cervical cancer, childhood cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, germ cell tumors, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, pancreatic islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, lip and oral cancer, liposarcoma, liver cancer, lung cancer, e.g., non-small cell lung cancer and small cell lung cancer Lung cancer, lymphoma, leukemia, macroglobulinemia, malignant fibrous histiocytoma / osteosarcoma of bone, medulloblastoma, melanoma, mesothelioma, metastatic squamous cell carcinoma of the neck of unknown primary, oral cancer, multiple endocrine neoplasia syndrome, myelodysplastic syndrome, myeloid leukemia, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma / malignant fibrous histiocytoma of bone, ovarian germ cell tumor, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer, islet cell carcinoma, cancer of the paranasal sinuses and nasal cavity, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal gland In some embodiments, the disease or condition is selected from the group consisting of astrocytoma, pineal germinoma, pituitary adenoma, pleuropulmonary blastoma, plasma cell neoplasm, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureter transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland carcinoma, sarcoma, skin cancer, skin cancer Merkel cell, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, gastric cancer, T-cell lymphoma, pharyngeal cancer, thymoma, thymic carcinoma, thyroid cancer, trophoblastic tumor (gestational), cancer of unknown primary site, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's hypergammaglobulinemia, and Wilms' tumor. In some embodiments, the disease or condition is associated with a tyrosine kinase.
[0174] In some embodiments, the pharmaceutical compositions described herein can be used in combination with at least one other therapeutic agent. The pharmaceutical composition and the therapeutic agent can act additively or, more preferably, synergistically. In some embodiments, the pharmaceutical composition is administered simultaneously with another therapeutic agent. In some embodiments, the pharmaceutical composition is administered before or after the administration of another therapeutic agent. In some embodiments, the pharmaceutical composition is administered in combination with omacetaxine, imatinib, selumetinib, ruxolitinib, aciminib, pegylated interferon alpha-2B, cetuximab, paclitaxel, or dasatinib. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a surfactant. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a phospholipid or poloxamer. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a hydrophilic polymer, and a lecithin. In some embodiments, the pharmaceutical compositions described herein comprise a lipophilic API, a non-ionic hydrophilic polymer, and a lecithin. In some embodiments, the API is nilotinib or a pharmaceutically acceptable salt thereof. In some embodiments, the API is nilotinib. In some embodiments, the API is a pharmaceutically acceptable salt of nilotinib. In some embodiments, the API is a lipophilic API. In some embodiments, the lipophilic API is one set forth in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the lipophilic API, hydrophilic polymer, and surfactant are formulated as an amorphous solid dispersion.
[0175] Manufacturing method Disclosed herein are methods for preparing an amorphous solid dispersion, the methods comprising: (a) combining (i) an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, (ii) one or more surfactants (e.g., polymeric nonionic surfactants and phospholipids), (iii) a hydrophilic polymer (e.g., a nonionic hydrophilic polymer), (iv) optionally an adsorbent or adsorbents, (v) optionally other additional additives, and (vi) a solvent or solvent mixture, thereby forming a liquid mixture (solution or suspension); and (b) removing all or part of the solvent from the mixture, thereby forming an amorphous solid dispersion. In some embodiments, the solvent is selected from an organic solvent and water. In some embodiments, the organic solvent is ethyl acetate, ethanol, isopropanol, or methanol, n-butanol, n-propanol, isopropanol, formic acid, nitromethane, ethanol, acetic acid, N-methylpyrrolidone, tetrahydrofuran (THF), methyl acetate, dimethylformamide, acetonitrile, dimethyl sulfoxide, dichloromethane (DCM), acetone, and any combination thereof. In some embodiments, the solvent is an alcohol. In some embodiments, the alcohol is ethanol. In some embodiments, the solvent is selected from dichloromethane, methanol, tetrahydrofuran, and acetone. In some embodiments, the solvent is selected from mixtures of these solvents. In some embodiments, the combining step comprises dissolving the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, the surfactant, the non-ionic hydrophilic polymer, and optionally, the adsorbent and / or additional additives in the solvent. In some embodiments, the adsorbent is suspended in the solvent. In some embodiments, the solvent removal step comprises spray drying or rotor evaporation. In some embodiments, the API is an API of Table 1, or a pharmaceutically acceptable salt thereof.
[0176] In some embodiments, a method for preparing an amorphous solid dispersion includes: (a) combining (i) an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, (ii) one or more surfactants (e.g., a polymeric nonionic surfactant and a phospholipid), (iii) a hydrophilic polymer (e.g., a nonionic hydrophilic polymer), (iv) optionally other additional additives, and (v) a solvent or solvent mixture to form a liquid mixture or solution; (b) spraying the liquid mixture or solution onto an adsorbent or adsorbents; and (c) removing all or part of the solvent from the liquid mixture or solution to form an amorphous solid dispersion. In some embodiments, the solvent is selected from an organic solvent and water. In some embodiments, the organic solvent is ethyl acetate, ethanol, isopropanol, or methanol, n-butanol, n-propanol, isopropanol, formic acid, nitromethane, ethanol, acetic acid, N-methylpyrrolidone, tetrahydrofuran, methyl acetate, dimethylformamide, acetonitrile, dimethyl sulfoxide, dichloromethane (DCM), acetone, and any combination thereof. In some embodiments, the solvent is an alcohol. In some embodiments, the alcohol is ethanol. In some embodiments, the solvent is selected from dichloromethane, tetrahydrofuran, methanol, and acetone. In some embodiments, the solvent is selected from mixtures of these solvents. In some embodiments, the combining step comprises dissolving the active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, the surfactant, the non-ionic hydrophilic polymer, and optionally additional additives in the solvent. In some embodiments, the amorphous solid dispersion is produced by a fluidized bed spray and drying process. In some embodiments, the amorphous solid dispersion is produced by rotor evaporation.
[0177] In an exemplary manufacturing workflow, an amorphous solid dispersion is first formed by the API, hydrophilic polymer, surfactant, and optionally an additive or additives in a solvent or water at room temperature or with heating to form a clear solution. This clear solution is then spray-dried to form the amorphous solid dispersion. Furthermore, an amorphous solid dispersion is first formed by the API, hydrophilic polymer, surfactant, and optionally an additive or additives in a solvent or water at room temperature or with heating to form a clear solution. An adsorbent or adsorbent mixture is further added at room temperature or with heating to form a homogeneous suspension. This homogeneous suspension is then spray-dried to form the amorphous solid dispersion. After the amorphous solid dispersion is formed, it is mixed with other additives and excipients used in the formulation. This mixture is then compressed into tablets or filled into capsules.
[0178] A typical spray dryer contains three chambers: a drying chamber, a cyclone chamber, and a sample collection chamber. During the spray drying process, the spray-dried dispersed solids are collected in the sample collection chamber. However, solids may also be present on the surfaces of the drying chamber and the cyclone chamber, resulting in low production yields (low amounts of solids in the sample collection chamber). In some embodiments, amorphous solid dispersions containing an API, a hydrophilic polymer, and a surfactant have low production yields. When an adsorbent is incorporated into these amorphous solid dispersions, the production yield can be significantly improved. In some embodiments, the production yield of an amorphous solid dispersion with an adsorbent is increased by at least 10% compared to a solid dispersion without an adsorbent. For clarity, the percentage term refers to the absolute difference in yield. For example, if the production yield of an amorphous solid dispersion without an adsorbent is 10% and the production yield of an amorphous solid dispersion with an adsorbent is 20%, the increase in yield is the difference between these two yields, i.e., 10%. In some embodiments, the production yield of the amorphous solid dispersion with the adsorbent is increased by at least 20% compared to the solid dispersion without the adsorbent. In some embodiments, the production yield of the amorphous solid dispersion with the adsorbent is increased by at least 30% compared to the solid dispersion without the adsorbent. In some embodiments, the production yield of the amorphous solid dispersion with the adsorbent is increased by at least 40% compared to the solid dispersion without the adsorbent. In some embodiments, the production yield of the amorphous solid dispersion with the adsorbent is increased by at least 50% compared to the solid dispersion without the adsorbent. In some embodiments, the production yield of the amorphous solid dispersion with the adsorbent is increased by at least 60% compared to the solid dispersion without the adsorbent. In some embodiments, the production yield of the amorphous solid dispersion with the adsorbent is increased by at least 70% compared to the solid dispersion without the adsorbent. In some embodiments, the production yield of the amorphous solid dispersion with the adsorbent is increased by at least 80% compared to the solid dispersion without the adsorbent.In some embodiments, the production yield of the solid amorphous dispersion with the adsorbent is increased by at least 90% compared to the solid dispersion without the adsorbent. [Example]
[0179] Example 1: Composition and preparation procedure of an amorphous solid dispersion formulation of a lipophilic API produced by spray drying
[0180] Composition of spray-dried amorphous solid dispersions of lipophilic APIs The following tables, Tables 3 to 13, list the compositions of some of the amorphous solid dispersions prepared by spray drying.
[0181] [Table 3]
[0182] [Table 4]
[0183] [Table 5]
[0184] [Table 6]
[0185] [Table 7]
[0186] [Table 8]
[0187] [Table 9]
[0188] [Table 10]
[0189] [Table 11]
[0190] [Table 12]
[0191] [Table 13]
[0192] [Table 14]
[0193] [Table 15]
[0194] General preparation of amorphous solid dispersions by spray drying The active pharmaceutical ingredient, polymer, and optional surfactants and / or additives were dissolved in a solvent or solvent mixture at room temperature and up to 80°C to form a clear solution. The total amount of solids added to the solution was approximately 5% to 15%. When an adsorbent was added, a homogenized suspension was formed. A benchtop spray dryer was preheated to steady state. The solution was then introduced into the spray dryer by flash atomization at a feed rate of approximately 3 to 5 rpm, an inlet drying gas temperature of approximately 50 to 150°C, an outlet temperature of approximately 40 to 45°C, and a pressure of approximately 2 to 3 bar. After recovery, the particles were placed in a convection tray dryer operated at 30°C or higher.
[0195] Specifically, the processing parameters for the spray drying process for the formulations in Tables 3 to 8 are listed in Tables 16 and 17.
[0196] [Table 16]
[0197] [Table 17]
[0198] The particle size distribution of these amorphous solid dispersions was measured by a Malvern Particle Size Analyzer 3000 using the dry powder method at a dispersion pressure of 2 bar, and the results are shown in Tables 18 and 19.
[0199] [Table 18]
[0200] [Table 19]
[0201] XRPD showed that these formulations were amorphous with no detectable crystallinity (Figures 1a and 1b).
[0202] Example 2: Difference in production yield between amorphous solid dispersions with and without adsorbents
[0203] The production yields of these ASDs for amorphous solid dispersions with and without silicon dioxide (as an adsorbent) are shown in Table 20 below.
[0204] [Table 20]
[0205] The results in Table 20 show that for some solid amorphous dispersions with adsorbents, the production yield of the spray drying process can be significantly improved.
[0206] Example 3: Composition and preparation procedure of tablets or capsules of amorphous solid dispersion formulations of lipophilic API
[0207] Capsule formulation For Formulations 1 to 3b, a single dose of amorphous solid dispersion powder was filled into size 0 or size 00 gelatin capsules for further testing, as shown in Table 21.
[0208] [Table 21]
[0209] Formulations 4, 5, and 6 were prepared according to Table 22 and filled into capsules.
[0210] [Table 22]
[0211] The formulations were prepared by dry granulating the relative amounts of the amorphous solid dispersion with other excipients. The dry granulation was carried out by slugging, milling, and screening to form dry granules. Additional excipients were mixed with the dry granules and filled into size 0 capsules.
[0212] Tablet formulation Formulations 8a and 8b were prepared according to the table below and compressed into tablets.
[0213] [Table 23]
[0214] The formulations were prepared by dry granulating the relative amounts of the amorphous solid dispersion with other excipients. The dry granulation was performed by slugging, milling, and screening to form dry granules. Additional excipients were mixed with the dry granules and compressed into tablets.
[0215] For Formulation 8b, surface-modified tartaric acid was prepared by spraying 300 g of 10% aqueous sodium carbonate solution (30 g Na2CO3 in 270 g aqueous solution) onto 500 g of tartaric acid in a powder bed, followed by drying in a fluidized bed apparatus. Approximately 6% by weight of sodium carbonate based on tartaric acid was sprayed onto the surface of the tartaric acid. The sodium carbonate solution reacted with the tartaric acid powder to form a neutral salt layer, producing the surface-modified acid. The surface-modified acid differs from the unmodified acid in the presence of a protective neutral layer that at least partially insulates the acid and reduces its interaction with other compounds in the formulation, such as active ingredients.
[0216] Formulation 10 was prepared by mixing the ASD of Formulation 10 (shown in Table 8) with additional excipients and then compressed into tablets according to Table 24.
[0217] [Table 24]
[0218] The tablet formulations shown in Tables 25 to 31 were prepared by mixing the ASD compositions of Formulations 11 to 23 (shown in Tables 9 to 15) with additional excipients and then compressed into tablets.
[0219] [Table 25]
[0220] [Table 26]
[0221] [Table 27]
[0222] In Tables 26 and 27, 2% surface-modified tartaric acid in formulations 12b, 13, and 14 was prepared by spraying 400 g of 10% aqueous sodium carbonate solution (40 g Na2CO3 in 360 g aqueous solution) onto 2000 g of tartaric acid powder bed, followed by drying in a fluidized bed apparatus. Approximately 2 wt% sodium carbonate was sprayed onto the surface of the tartaric acid. In Table 26, 6% surface-modified tartaric acid in formulation 12c was prepared based on formulation 8b shown in Table 23.
[0223] [Table 28]
[0224] [Table 29]
[0225] [Table 30]
[0226] [Table 31]
[0227] [Table 32]
[0228] Similar to formulations 12b, 13, and 14 shown in Tables 26 and 27, the 2% surface-modified tartaric acid used in formulations 20a, 20b, 21, 22, and 23 shown in Tables 31 and 32 was prepared by spraying approximately 2% by weight of sodium carbonate onto the surface of the tartaric acid.
[0229] While specific embodiments described herein have been shown and described herein, such embodiments are provided by way of example only. Numerous modifications, changes, and substitutions will occur to those skilled in the art without departing from the invention. It is understood that various alternatives to the embodiments described herein may be utilized in practicing the invention. The following claims define the scope, and it is intended that methods and structures within the scope of these claims and their equivalents be covered thereby.
[0230] Example 4: Oral bioavailability of ASD formulations in dogs
[0231] In vivo pharmacokinetic properties of nilotinib compositions (T max , C max , AUC) was investigated by administering such compositions to beagle dogs as described below.
[0232] Comparison of bioavailability of ASD formulations with that of TASIGNA in dogs Beagle dogs (3 males and 3 females) were fasted for 12 hours before administration. The test formulation was orally administered to each dog with 50 mL of water at the time of administration. Blood samples were collected at 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours after administration, and plasma nilotinib concentrations were measured. From these measurements, C max , T max , and AUC were calculated and are presented in Tables 33 to 35 below.
[0233] Table 33 compares pharmaceutical formulations with various physical states. Formulation 1 is an amorphous solid dispersion (ASD) formulation without surfactant and with acid. Nilotinib HCl is present in a 55 mg dose (equivalent to 50 mg of nilotinib, with a nilotinib HCl to nilotinib ratio of 1.1), but the bioavailability is comparable to that of the listed drug, TASIGNA, at a 220 mg dose (equivalent to 200 mg of nilotinib, with a nilotinib HCl to nilotinib ratio of 1.1). Canine studies were conducted using a crossover design for the formulations listed in Table 33. The drug "TASIGNA" is marketed with three dosage forms of nilotinib HCl at equivalent doses of 50 mg, 150 mg, and 200 mg of nilotinib free base. The dosage form is formulated as a hard capsule and contains the following excipients: lactose monohydrate, crospovidone, poloxamer, colloidal silica, anhydrous / colloidal silicon dioxide, and magnesium stearate. The nilotinib hydrochloride in the TASIGNA formulation is not known to be incorporated into an amorphous solid dispersion. The API in the TASIGNA formulation is in a crystalline state, while the API in Formulation 1 is part of an amorphous solid dispersion (ASD).
[0234] Table 33 shows the advantages of using an amorphous solid dispersion to deliver an API. max and AUC ∞ is similar to that of TASIGNA, even though TASIGNA has four times the amount of API.
[0235] [Table 33]
[0236] Table 34 compares formulations (Formulations 2a and 2b) containing 55 mg of nilotinib HCl (equivalent to 50 mg of nilotinib free base) and amorphous solid dispersions containing various polymers, surfactants, and acids with a 220 mg dose (equivalent to 200 mg of nilotinib) of the listed drug product, TASIGNA. The canine study was conducted using a crossover design. Table 34 highlights the unexpected benefits of incorporating lecithin or polaxamer 188 into amorphous solid dispersions containing nilotinib HCl and polymers. Despite using only one-quarter the amount of nilotinib HCl, the bioavailability of the API is twice that of the marketed drug product. Reducing the API burden while maintaining bioavailability can lead to a reduction in undesirable side effects.
[0237] [Table 34]
[0238] Table 35 compares 55 mg of nilotinib HCl (equivalent to 50 mg of nilotinib) and acid-free amorphous solid dispersions containing various polymers, surfactants, and acids (Formulations 3a and 3b) with a 220 mg dose (equivalent to 200 mg of nilotinib) of the listed drug product, TASIGNA.
[0239] In the crossover dog study, formulations 3a and 3b were particularly noteworthy for two reasons. First, the doses of formulations 3a and 3b were approximately 1 / 4 of the dose of the listed drug, TASIGNA, yet the bioavailability results were comparable. Second, no unmodified organic acids were used in formulations 3a or 3b, preventing the formation of toxic impurities during storage (see Example 5 below). In addition, the C of formulation 3a max It is observed that the and AUC results are slightly better than those of formulation 3b.
[0240] [Table 35]
[0241] Comparison of bioavailability of ASD formulations in fed and fasted dogs Beagle dogs (3 males, 3 females) were randomly divided into three groups. A three-period crossover experimental design was used. The dogs were fasted for 12 hours before the experiment. Group 1 received Formulation 3a under fasting conditions. Group 2 received Formulation 3a under fed conditions. For the fed condition, dogs were fed dog food (Shoobree, China) mixed with butter (Anchor, New Zealand) in a 100g:16.4g ratio, 500 calories. Group 3 received TASIGNA under fasting conditions. The test formulation was orally administered to each dog with 50 mL of water at the time of administration. Blood samples were collected at 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours after administration, and plasma nilotinib concentrations were measured. From these measurements, C max , T max The parameters of , and AUC were calculated and are presented in Table 36 below.
[0242] One limitation of the commercially available drug, TASIGNA, is the need for administration under fasting conditions. Groups 1 and 2 had similar C values in both fed and fasted states. max and AUC are shown. Formulation 3a represents an improvement over current technology by eliminating the requirement for administration in the fasted state only. Formulation 3a is more bioavailable than the marketed drug administered to Group 3, despite being one-quarter the dose of the marketed drug.
[0243] [Table 36]
[0244] The oral absorption of Formulation 4 in dogs was investigated under fasted and fed conditions. Beagle dogs (3 males, 3 females) were randomly assigned to three groups. Similar to the study conducted for Formulation 3a above, a three-period crossover experimental design was employed. max , T max The pharmacokinetic parameters of , and AUC were calculated and are presented in Table 37 below.
[0245] [Table 37]
[0246] Formulation 4 is shown in Table 37 above to be effective in both the fed and fasted states. This constitutes an improvement over the current art by eliminating the need for dosing in the fasted state only. Groups 1 and 2 had similar C values in both the fed and fasted states. max and AUC are shown. Despite the lower dose of Formulation 4, the bioavailability is higher than that of the commercial product administered to Group 3. The oral absorption of tablet formulations of ASD in dogs was also evaluated using a study design similar to that described for Tables 36 and 37, with the only difference being the use of different diets in the feeding conditions. In these studies, dogs were given a diet consisting of 25 grams of dog food, 150 mL of full-fat milk, and 60 grams of bacon by oral gavage.
[0247] Table 38 shows the in vivo exposure in dogs of TASIGNA tablets under three different dosing conditions. In this study, dogs dosed under fasting conditions also receive an IM injection of 6 μg / kg of pentagastrin. When the product was administered after a high-fat meal, exposure was C max There is a three-fold increase in AUC and a four-fold increase in AUC. In addition, coadministration with an acid-blocking drug (ranitidine 50 mg per dog by IM injection) significantly reduces exposure.
[0248] [Table 38]
[0249] Tables 39 and 40 show the in vivo exposure in dogs for tablet formulations Formulation 11a and Formulation 11b (see Table 25 for composition). Formulations 11a and 11b differ in that 11b contains an additional 100 mg of tartaric acid in the outer granule material. The results in Tables 39 and 40 demonstrate two findings. First, the results suggest that the feeding effect is significantly reduced and the dose can be reduced by a factor of four, i.e., the in vivo exposure of a 50 mg dose of Formulations 11a and 11b is roughly equivalent to a 200 mg dose of TASIGNA. Second, the results suggest that the inclusion of additional acid in the outer granule material significantly reduces the C max The results show that the AUC increases with increasing
[0250] [Table 39]
[0251] [Table 40]
[0252] Tables 41-43 show the in vivo exposure in dogs of tablet formulations Formulations 12-14 administered with and without food. The food effect increases slightly with increasing API to surfactant component ratio, but is still significantly less than that of TASIGNA, suggesting that the amorphous solid dispersion formulation reduces the food effect across the dose range.
[0253] [Table 41]
[0254] [Table 42]
[0255] [Table 43]
[0256] The oral absorption of tablet formulations of ASD in dogs was also evaluated using a study design similar to that described for Tables 36 and 37, with the only difference being the use of different diets in the feeding conditions. In these studies, dogs were given a diet consisting of 25 grams of dog food, 150 mL of full-fat milk, and 60 grams of bacon by oral gavage.
[0257] Comparative bioavailability of ASD formulations in fasted dogs with controlled gastric pH. Beagle dogs (3 males, 3 females) were randomly divided into three groups. A three-period crossover experimental design was used. The dogs were fasted for 12 hours before the experiment. All three groups received Formulation 3a under fasting conditions. The test formulation was administered orally to each dog with 50 mL of water at the time of administration. In Group 1, each dog received an intramuscular injection of 6 μg / kg of pentapeptide gastrin 45 minutes before oral administration. In Group 2, ranitidine 50 mg was injected intravenously 1 hour before oral administration. Group 3 was the control group. Blood samples were collected at 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours after administration, and plasma nilotinib concentrations were measured. From these measurements, C max , T max The pharmacokinetic parameters of , and AUC were calculated and are presented in Table 44 below.
[0258] The study measured the efficacy of Formulation 3a in dogs with high and low gastric pH. The pentapeptide gastrin can stimulate gastric acid release, and ranitidine can inhibit gastric acid release. This model simulates a patient's stomach under the influence of acid-suppressing drugs. The commercially available product, TASIGNA, is known to reduce in vivo absorption in patients taking acid-suppressing drugs, such as proton pump inhibitors (PPIs).
[0259] [Table 44]
[0260] As can be seen in Table 44, the C between groups 1 and 2 max Although the pharmacokinetic parameters of ATP and AUC differ by only about 30%, with minimal differences in parameters between Groups 2 and 3, TASIGNA has a significant reduction in in vivo exposure following co-administration of an acid-blocking drug (ranitidine 50 mg per dog via IM injection), as shown in Table 38. These data suggest that the formulations described herein can be administered to patients taking acid-blocking drugs.
[0261] Example 5: Formation of genotoxic impurities in amorphous solid dispersions of nilotinib and acid
[0262] Formulations 2a and 2b in Example 4 demonstrate that amorphous solid dispersions of nilotinib with acidic excipients can result in overwhelmingly superior bioavailability (see Tables 39 and 40). However, nilotinib HCl often produces a genotoxic impurity in amorphous solid dispersions with acidic excipients. Under acidic conditions, nilotinib hydrolyzes to form 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline (hereinafter referred to as "Impurity A"), as shown below.
[0263] [ka]
[0264] To compare the stability of different compositions, dissolution studies were conducted using amorphous solid dispersion formulations, Formulations A, B, and C. Formulation A was formulated as an amorphous solid dispersion of 55 mg of nilotinib HCl, 100 mg of citric acid, 100 mg of lecithin, and 100 mg of PVP K30. Formulation B was formulated as an amorphous solid dispersion of 55 mg of nilotinib HCl, 100 mg of lecithin, and 100 mg of PVP K30. Formulation C was formulated as an amorphous solid dispersion of 55 mg of nilotinib HCl, 75 mg of citric acid, and 100 mg of PVP K30. The formulated powders were stored at 40°C / 75% RH and 75°C / 75% RH for 2 weeks. Formulation C was formulated as an amorphous solid dispersion of 55 mg of nilotinib HCl, 75 mg of citric acid, and 100 mg of PVP K30. The formulated powder was stored at 40°C / 75% RH and 75°C / 75% RH for 2 weeks. Genotoxic impurity A was measured by HPLC-MS, and the results are shown below in Table 45. The concentration of genotoxic impurity A was found to be high in Formulations A and C and low in Formulation B. The degradation test parameters were in accordance with the European Pharmacopoeia 9.8;07 / 2019:2993, which provides detailed parameters for assessing the purity of nilotinib hydrochloride monohydrate samples.
[0265] [Table 45]
[0266] Additionally, tablets of Formulation 12a and Formulation 12c were placed in HDPE bottles with 2 grams of desiccant and then stored at 40°C / 75%RH for up to 6 months. ASD powder of Formulation 12 (shown in Table 9) was also placed in sealed aluminum pouches and then stored under the same storage conditions (40°C / 75%RH).
[0267] The level of impurity A was measured by HPLC-MS method, and the results are shown in Table 46 below. Note that the ASD of formulation 12 has no acid component and has the lowest level of impurity A. Formulation 12c, which has the ASD of formulation 12 and 6% surface-modified tartaric acid, has a similar level of impurity A. However, formulation 12a, which has the ASD of formulation 12 and a non-surface-modified tartaric acid component, has a significantly increased level of impurity A. This result suggests that surface modification can reduce impurity formation and improve the storage stability of APIs.
[0268] [Table 46]
[0269] Example 6: In vivo exposure of ASD tablet formulations in humans
[0270] A tablet formulation (Formulation 11a) was tested for in vivo exposure in humans. The study was conducted in 18 healthy volunteers using a three-way crossover design. Formulation 11a was administered within 30 minutes after a high-fat, high-calorie meal (approximately 800-1000 kcal, with 150, 250, and 500-600 kcal from protein, carbohydrate, and fat, respectively) under overnight fasting conditions. In addition, a TASIGNA tablet formulation administered under overnight fasting conditions was also tested for comparison. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose, and plasma nilotinib concentrations were measured by HPLC. From these measurements, C max , T max The parameters of , and AUC were calculated using Winnonlin 8.3.1 and are presented in Table 47 below.
[0271] [Table 47]
[0272] This result, compared with the results in Table 39, suggests that the amorphous solid dispersion technology applied to this tablet formulation significantly reduced the food effect. The in vivo exposure of the formulation at 50 mg strength is slightly lower than that of TASIGNA (200 mg strength). However, considering the results of animal studies, Formulation 11a is expected to be higher than TASIGNA when compared at the same dosage strength (200 mg). The in vivo exposure in humans is also expected to be increased by adding acid to the outer granule material.
[0273] Tablet formulations containing acid in the outer granule material (e.g., Formulations 11b, 12a, 12b, 12c, 13, 14, 20a, 20b, 21, 22, and 23) will be tested for in vivo exposure in dogs and humans. The study will be conducted in healthy volunteers using a three-way crossover design. The formulations will be administered within 30 minutes of a high-fat, high-calorie meal (approximately 800-1000 kcal, with 150, 250, and 500-600 kcal from protein, carbohydrate, and fat, respectively) under overnight fasting conditions. Additionally, a TASIGNA tablet formulation will be administered under overnight fasting conditions for comparison. Blood samples will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose, and plasma nilotinib concentrations will be measured by HPLC. For these measurements, C max , T max The parameters of , and AUC are calculated using Winnonlin 8.3.1.
[0274] Example 7: Further compositions
[0275] Pharmaceutical compositions containing amorphous solid dispersions having APIs disclosed in Table 1 are prepared and evaluated according to the procedures of Examples 1-6 by substituting the APIs used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions containing chlordiazepoxide are prepared and evaluated according to the procedures of Examples 1-6 by substituting the APIs used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions containing naringenin are prepared and evaluated according to the procedures of Examples 1-6 by substituting the APIs used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions containing clofibric acid are prepared and evaluated according to the procedures of Examples 1-6 by substituting the APIs used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions containing hesperetin are prepared and evaluated according to the procedures of Examples 1-6 by substituting the APIs used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions containing cinchonidine are prepared and evaluated according to the procedures of Examples 1-6 by substituting the APIs used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing quinine are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing tramadol are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing lormetazepam are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing trazodone are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing diltiazem are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing brompheniramine are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6.Pharmaceutical compositions comprising amorphous solid dispersions containing alprenolol are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing propranolol are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing diazepam are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing apigenin are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing venlafaxine are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions comprising amorphous solid dispersions containing rosiglitazone are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions of pyrilamine are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions of quetiapine are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions of ketoprofen (Ketopren) are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions of chlorphenamine are prepared and evaluated according to the procedures of Examples 1-6 by substituting the API used in Examples 1-6. Pharmaceutical compositions containing amorphous solid dispersions of fenbufen are prepared a...
Claims
1. A pharmaceutical composition, comprising: a) an amorphous solid dispersion, i. an active pharmaceutical ingredient or a pharma- ceutically acceptable salt thereof, wherein said active pharmaceutical ingredient has a log P in octanol-water of 2.0 or greater; ii. one or more surfactants, including a non-ionic surfactant, a phospholipid, or any combination thereof; iii. a hydrophilic polymer, and iv. optionally, an adsorbent; and an amorphous solid dispersion comprising: b) a pharma- ceutically acceptable carrier or excipient; and 13. A pharmaceutical composition comprising:
2. An amorphous solid dispersion, the amorphous solid dispersion comprising: a) a lipophilic active pharmaceutical ingredient or a pharma- ceutically acceptable salt thereof, said active pharmaceutical ingredient having a log P in octanol-water of 2.0 or greater; b) one or more surfactants, including a non-ionic surfactant, a phospholipid, or any combination thereof; c) a hydrophilic polymer, and d) optionally an adsorbent; 1. The amorphous solid dispersion comprising:
3. A pharmaceutical composition, comprising: a) an amorphous solid dispersion, i. an active pharmaceutical ingredient, which is nilotinib free base or nilotinib hydrochloride, or a pharma- ceutically acceptable salt thereof; ii. one or more surfactants, including one or more non-ionic surfactants, one or more phospholipids, or any combination thereof; iii. a hydrophilic polymer, and iv. optionally, an adsorbent; an amorphous solid dispersion comprising: b) a pharma- ceutically acceptable carrier or excipient; and 13. A pharmaceutical composition comprising:
4. The pharmaceutical composition of claim 1 or 3, wherein the pharmaceutical composition is in the form of a tablet or capsule.
5. 5. The pharmaceutical composition of claim 3 or 4, wherein the nilotinib free base or nilotinib hydrochloride is present in the pharmaceutical composition in an amount of about 10 mg to about 500 mg.
6. The pharmaceutical composition of any one of claims 3 to 5, wherein the nilotinib free base or nilotinib hydrochloride is present in the pharmaceutical composition in an amount of about 10% to 35% by weight.
7. 7. The pharmaceutical composition of any one of claims 1 or 3-6, wherein the one or more surfactants are present in the pharmaceutical composition in an amount of about 5% to 50% by weight.
8. 8. The pharmaceutical composition of claim 1, wherein the one or more surfactants comprises lecithin.
9. 9. The pharmaceutical composition of any one of claims 1 or 3 to 8, wherein the amorphous solid dispersion comprises a non-ionic hydrophilic polymer, the non-ionic hydrophilic polymer being polyvinyl alcohol (PVA), an oligosaccharide, a polysaccharide, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC or hypromellose), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl beta cyclodextrin (HP-β-CD), hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyethylene glycol (PEG), polyvinyl acetate and polyvinylcaprolactam based graft copolymer (PVAc-PVCap-PEG), polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol (PCL-PVAc-PEG), or a combination thereof.
10. 9. The pharmaceutical composition of any one of claims 1 or 3-8, wherein the hydrophilic polymer comprises povidone, HPMC, polyvinylpyrrolidone VA64, HP-β-CD, or hydropropyl methylcellulose acetate succinate (HPMCAS).
11. 9. The pharmaceutical composition of any one of claims 1 or 3-8, wherein the hydrophilic polymer is present in the amorphous solid dispersion in an amount of about 1% to about 80% by weight.
12. 12. The pharmaceutical composition of any one of claims 1 or 3-11, wherein the amorphous solid dispersion comprises silicon dioxide powder in an amount of about 0.1% to about 20% by weight.
13. The pharmaceutical composition of any one of claims 1 or 3-12, wherein the pharmaceutical composition does not contain an organic acid.
14. 13. The pharmaceutical composition of any one of claims 1 or 3-12, wherein the pharma- ceutically acceptable carrier or excipient comprises an external acid, the external acid being absent in an amorphous solid dispersion, and the external acid is a surface-modified acid comprising acid particles and a neutral salt layer.
15. A pharmaceutical composition, comprising: a) an amorphous solid dispersion (ASD), i. nilotinib free base or nilotinib hydrochloride in an amount of about 5% to about 35% by weight of the ASD; ii. one or more surfactants in an amount of about 5% to about 50% by weight of the ASD, the surfactant comprising lecithin, a block copolymer of polyethylene glycol and polypropylene glycol, TPGS, or a combination thereof; iii. a non-ionic hydrophilic polymer in an amount of about 5% to about 70% by weight of the ASD, comprising polyvinylpyrrolidone (PVP), polyvinylpyrrolidone VA64, hydroxypropyl methylcellulose (HPMC or hypromellose), hydroxypropyl cellulose (HPC), hydroxypropyl beta cyclodextrin (HP-β-CD), hydropropyl methylcellulose acetate succinate (HPMCAS), or a combination thereof; and iv. silicon dioxide in an amount of about 0.1% to 40% by weight of the ASD; an amorphous solid dispersion comprising: b) a pharma- ceutically acceptable carrier or excipient; and 13. A pharmaceutical composition comprising:
16. 16. The pharmaceutical composition of any one of claims 1 or 3-15, wherein the pharmaceutical composition is storage-stable at 40°C / 75% RH for at least 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, or 24 months, wherein a storage-stable pharmaceutical composition has less than 100 ppm of Impurity A at the end of the storage period.
17. 17. The pharmaceutical composition of any one of claims 1 or 3-16, wherein the pharmaceutical composition exhibits a bioavailability, measured as total area under the curve (AUC) after oral administration or as Cmax after oral administration, that is at least 1.5-fold higher than the bioavailability of a corresponding formulation comprising a crystalline form of nilotinib free base or nilotinib hydrochloride.
18. 18. A pharmaceutical composition according to any one of claims 1 or 3 to 17 or an amorphous solid dispersion according to claim 2 for use in the treatment of cancer.
19. 20. The pharmaceutical composition or amorphous solid dispersion of claim 18, wherein the cancer is a hematological cancer.
